Substrate Identification of an Oncogenic Kinase: Elucidating the Pathogenesis of a Rare Liver Cancer by Jarmel, Melissa
Rockefeller University 
Digital Commons @ RU 
Student Theses and Dissertations 
2019 
Substrate Identification of an Oncogenic Kinase: Elucidating the 
Pathogenesis of a Rare Liver Cancer 
Melissa Jarmel 
Follow this and additional works at: https://digitalcommons.rockefeller.edu/
student_theses_and_dissertations 
 Part of the Life Sciences Commons 
SUBSTRATE IDENTIFICATION OF AN ONCOGENIC KINASE:  
ELUCIDATING THE PATHOGENESIS OF A RARE LIVER CANCER 
A Thesis Presented to the Faculty of 
The Rockefeller University 
in Partial Fulfillment of the Requirements for 




ã Copyright by Melissa Jarmel 2019
SUBSTRATE IDENTIFICATION OF AN ONCOGENIC KINASE:  
ELUCIDATING THE PATHOGENESIS OF A RARE LIVER CANCER 
Melissa Jarmel, Ph.D. 
The Rockefeller University 2019 
Fibrolamellar Hepatocellular Carcinoma (FLC) is a rare liver cancer with limited 
treatment options. This cancer primarily affects adolescents and young adults. Our 
lab has identified a new fusion gene in this cancer called DNAJB1-PRKACA that 
results from a break and re-fusion in chromosome 19. This chimeric gene results in a 
fusion kinase that acts as the driver of this cancer.  While we have shown that the 
kinase activity of the fusion protein is essential for transformation, it is not currently 
known whether the oncogenic kinase that results from this fusion event, DNAJB1-
PRKACA, phosphorylates the same substrates as PRKACA, the protein product of 
PRKACA. While the total phosphoproteome of a cancer can implicate critical pathway 
changes in the tumor versus healthy tissue, it cannot provide sufficient information on 
what kinase is directly responsible for the phosphorylations. Knowing which proteins 
DNAJB1-PRKACA is directly phosphorylating in the liver could help elucidate a step-
wise mechanism for understanding the pathogenesis. Furthermore, it could provide 
new potential therapeutic options by targeting the downstream pathways of this 
oncogenic kinase.  
In this thesis, I will first describe my work to determine a method of directly 
identifying proteins that are substrates of DNAJB1-PRKACA and PRKACA. I first 
tested an approach developed by the Shokat Lab that uses an analog-sensitive (AS) 
kinase in combination with a selective adenosine triphosphate (ATP) analog to identify 
unique substrates of a kinase.  However, serious concerns of substrate specificity of 
the AS-kinases were raised as I developed AS versions of DNAJB1-PRKACA and 
PRKACA. I pivoted to a method that kills the endogenous kinase activity of a lysate 
using 5’-(4-Fluorosulfonylbenzoyl)adenosine (FSBA); kinase reactions are performed 
using this kinase-inactive lysate with the purified active kinase of interest and an ATP 
analog that has a tag on the γ-phosphate. This results in substrates with a specific 
thiol tag. The ATP-γ-S analog I initially used for this method was effective in visualizing 
kinase activity changes via western blots, but the thiol-tags were not reliably identified 
using MS. With the improvement of phosphopeptide enrichment methods and 
encouragement from the Proteomics Resource Center, a pilot experiment was 
designed to enrich phosphopeptides from a kinase reaction using regular ATP, FSBA-
treated mouse liver lysate, and either PRKACA or DNAJB1-PRKACA. The results of 
this pilot experiment showed promising differences in substrate specificity between 
PRKACA and DNAJB1-PRKACA so I moved forward with this assay using human 
hepatocyte lysate instead of mouse liver lysate.  
In the third chapter, I will discuss the results of the assay using kinase-inactive 
human hepatocyte lysate in kinase reactions to determine substrate differences 
between three kinases: DNAJB1-PRKACA, PRKACA, and PRKACA (L206R). 
PRKACA (L206R) is a PRKACA variant found in adrenal tumors of patients with 
Cushing’s disease. The L206R mutation is thought to block interaction with the 
regulatory subunit and pathogenesis of the adrenal tumors has been accepted to be 
the result of constitutive activity of this mutant catalytic subunit. Recently, two papers 
have suggested that there is an alteration in substrate specificity between PRKACA 
and PRKACA (L206R). My results demonstrate that there are differences in substrates 
that are directly phosphorylated by each of the three catalytic subunits:  PRKACA, J- 
PRKACA, and PRKACA (L206R).  
Finally, I will discuss how the results of a total phosphome study of FLC patient 
tumor and normal samples compared against my in vitro substrate identification 
assay. This comparison created a more patient-relevant and focused list of direct 
substrates of DNAJB1-PRKACA for further study. The thesis will conclude with 
discussion of the implications for the pathogenesis of FLC based on the direct 
substrates of interest found in these experiments and future experiments. 
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CHAPTER I: INTRODUCTION 
Rationale for Thesis Work 
In just the last fifty years, our understanding of what causes cancer and how to 
study and treat it has dramatically changed. One of the paradigm shifts in cancer 
research came with the discovery of oncogenes, genes that have the potential to 
transform healthy cells into cancer cells (Stehelin et al. 1976; Shih et al. 1979; Wang et 
al. 1976; Tabin et al. 1982). Oncogenes can arise because of misregulation of gene 
expression, mutations within a gene, or chromosomal abnormalities like gene 
duplications or gene fusions (Esquela-Kerscher and Slack 2006; Croce 2009; 
Bargmann et al. 1986; Herter-Sprie et al. 2013; Clark et al. 2002; Rowley 1973; Yu et al. 
2019; Giam and Rancati 2015).   
Since DNA damage increases with age (Freitas and de Magalhães 2011; Soares 
et al. 2014), it is difficult to find a specific oncogenic driver responsible for an adult 
cancer because it is likely caused by multiple mutations (Vogelstein et al. 1988; 
Vogelstein and Kinzler 1993).  However, cancers that affect young people, while rarer in 
occurrence, also have fewer mutations in their DNA due to age. Thus, when a specific 
genetic driver can be identified in a cancer of a young person, it becomes possible to 
identify the process of pathogenesis of this cancer due to a more defined genetic event. 
While each cancer is unique in its pathogenesis, cancers share hallmarks that take 
advantage of similar pathways to maximize growth and metastasis (Hanahan and 
Weinberg 2000; Hanahan and Weinberg 2011). By better understanding the players in 
the pathways that contribute to these hallmarks of cancer, more effective therapeutic 
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options could be developed that could apply across multiple cancer types that share 
pathway similarities. In this way, studying a rare cancer that affects young people that 
has a specific genetic driver provides a unique opportunity to probe at the pathogenesis 
of not only the rare cancer but also the biology of common pathways critical for the 
development of other cancers. Fibrolamellar Hepatocellular Carcinoma (FLC) is one of 
these rare cancers.  
FLC is a rare liver cancer that primarily affects adolescents and young adults; 
there is a single common genetic alteration found in more than 350 confirmed FLC 
tumors to date since the discovery of this gene fusion in this cancer in 2014 (Honeyman 
et al. 2014).  The fusion event results from a break in chromosome 19. This event links 
the first exon of a heat shock protein, DNAJB1, to exons 2-10 of the catalytic subunit of 
Protein Kinase A, PRKACA. This break occurs in the absence of any other recurrent 
alterations in the DNA (Darcy et al. 2015). In collaboration with Scott Lowe’s lab, we 
found that FLC-like tumors formed after CRISPR-Cas9 genome editing was used to 
recreate the fusion event in mice, with similar results found by others in different mouse 
strains (Engelholm et al. 2017). This indicates that the deletion is sufficient to produce 
the tumor, but it does not distinguish if this occurs because of the formation of the fusion 
gene or the loss of genes on the chromosome that results from the fusion event. To 
address this, DNAJB1-PRKACA was overexpressed using transposon-mediated 
somatic gene transfer. Tumors did not form when PRKACA was overexpressed nor 
when DNAJB1-PRKACA was expressed with a point mutation to kill its kinase activity 
(Kastenhuber et al. 2017), leading us to confidently say that DNAJB1-PRKACA is the 
oncogenic driver for FLC.  
3 
It is not currently known whether the resulting oncogenic kinase, DNAJB1-
PRKACA, phosphorylates the same substrates as PRKACA, the protein product of 
PRKACA. Total phosphoproteome studies of FLC could implicate critical pathway 
changes in the tumor versus healthy tissue, but they could not provide sufficient 
information to determine what is being directly phosphorylated by a particular kinase. 
The changes seen could be the result of downstream effects from the primary changes 
made by DNAJB1-PRKACA. Knowing what DNAJB1-PRKACA is directly 
phosphorylating in the liver could help elucidate a step-wise mechanism for how the 
presence of DNAJB1-PRKACA leads to the development of FLC, as well as provide 
new potential therapeutic options by targeting the downstream pathways of this 
oncogenic kinase. Our lab has many modes to study FLC, including a repository of over 
a hundred patient samples, various cell lines expressing the oncogene, relevant 
genetically-engineered mice, Patient Derived Xenografts (PDX), FLC cells derived from 
PDX, and organoids; this provides a robust system to further investigate any targets of 
the oncogenic kinase that are identified. Additionally, identifying specific 
phosphorylation sites of many substrates is now possible with advancements in 
molecular biology and mass spectrometry (Dephoure et al. 2013).  This thesis describes 
an effort to identify the direct substrates of DNAJB1-PRKACA that are relevant to the 
pathogenesis of FLC.  
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A Brief History of Cancer Biology 
Cancer is an umbrella term for a group of diseases linked by the characterization 
of out of control growth of a cell in one part of the body that can metastasize to 
surrounding tissues. It is currently the second leading cause of death in the United 
States, and more than 1.7 million new cancer diagnoses and 600,000 cancer deaths are 
projected to occur in 2019 in the United States alone (Siegel et al. 2019). While these 
numbers indicate a still pressing need for further research and treatments, the cancer 
death rate has dropped 27% between 1991 and 2016 due to improvements in 
prevention and treatment methods, resulting in more than 2.6 million fewer deaths by 
cancer than would have been predicted by the death rate at its peak (Siegel et al. 
2019). 
Our understanding of what causes cancer has solidified considerably since the 
start of the twentieth century. The first case reported of a possible environmental cancer 
was by Percival Pott in 1775 who observed scrotal skin cancer in chimney sweeps 
(Brown and Thornton 1957). However, it was not until 1933 that the chemical 
responsible for this cancer, benzo(a)pyrene, was identified as the first known 
carcinogen, or cancer-causing substance. This is also the carcinogen found in cigarette 
smoke which is clearly linked to lung cancer (Doll and Hill 1950; Wynder and Graham 
1950; Cornfield et al. 2009). Public health education campaigns have increased 
awareness of this established link and likely contributed to the downward trend of new 
lung cancer cases today (Rodu and Cole 2002; Siegel et al. 2019).  
In 1910 and 1911, Rockefeller scientist Peyton Rous published consecutive 
papers about the results of an experiment where he was able to transmit cancer from a 
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hen with a tumor to a healthy chicken, hypothesizing that a virus from the cancer in the 
hen was responsible for the transmission (Rous 1910; Rous 1911). Despite other 
independent research in Denmark by Ellerman and Bang and in Japan by Fujinami and 
Inamoto showing cell-free filtrates with transforming capabilities in chickens at the time, 
the scientific community did not accept this theory for a few decades since Rous’ 
attempts to repeat his results in mammals were unsuccessful (Weiss and Vogt 2011). 
However, a strain of this Rous Sarcoma Virus (RSV) was shown to be able to produce 
tumors in rats in the late 1950s (Svet-Moldavsky 1957; Svet-Moldavsky 1958). Soon 
after, Howard Temin identified the first transformation mutants of RSV and noted that 
RSV with different mutations determined the various shapes of the cells they infected; 
this led him to state, “Thus, the virus becomes equivalent to a cellular gene controlling 
cell morphology” (Temin 1960). Peyton Rous received the Nobel Prize in Physiology or 
Medicine fifty-six years after his publication for his discovery of tumor-inducing viruses.  
Another cause for cancer was suggested in an epidemiological study in the 
1960s by Li and Fraumeni on the families of rhabdomyosarcoma patients with siblings 
or cousins that also had a sarcoma early in life; they hypothesized that cancer could be 
inherited (Li and Fraumeni 1969). We now know that this syndrome is due to an 
inheritance of an autosomal dominant mutation in a tumor suppressor known as TP53 
(Malkin et al. 1990).  While hereditary cancers are rarer, we are aware of more of them 
now which allows for better monitoring and preventative options for people at risk 
(Parkes et al. 2017; Willoughby et al. 2019; Lahiri Batra 2019).  
The discovery of oncogenes in the 1970s connected these three theories of what 
causes cancer (Stehelin et al. 1976; Shih et al. 1979; Wang et al. 1976; Tabin et al. 
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1982): a gene that has the capability to transform a healthy cell into a tumor cell. Even 
the oncogenic RSV was found to have a gene of cellular origin that the virus had 
previously acquired that had the potential to become an oncogene: Src (Stehelin et al. 
1977; Ottenhoff-Kalff et al. 1992; Aligayer et al. 2002; Wheeler et al. 2009). We now 
know that mutations with a gene, faulty gene expression, or chromosomal abnormalities 
can give rise to oncogenes (Esquela-Kerscher and Slack 2006; Croce 2009; Bargmann 
et al. 1986; Herter-Sprie et al. 2013; Clark et al. 2002; Rowley 1973; Yu et al. 2019; 
Giam and Rancati 2015).  
We also know that for most adult cancers, multiple genetic changes need to 
occur for a cancer to develop (Vogelstein et al. 1988; Vogelstein and Kinzler 1993), and 
that cancers develop more mutations over time, or evolve, which contributes to drug-
resistance (Lipinski et al. 2016). The 1990s saw an explosion of cancer research 
leading to the seminal review of the hallmarks of cancer by Hanahan and Weinberg 
(Hanahan and Weinberg 2000), which has since been updated (Hanahan and Weinberg 
2011). A figure from their latest review is represented here in my thesis as Figure 1 and 
shows that there are now different treatment options based on each of these hallmarks 
of cancer. The more detailed our understanding of the pathways involved in these 
hallmarks becomes, the more we can develop better targeted therapies for cancer. This 
is particularly important for cancer as it continues to evolve in a patient’s lifetime. 
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Figure 1. Hallmarks of Cancer with Therapeutic Targets.  
This figure appears in the latest version of Hanahan and Weinberg’s Hallmarks of 
Cancer review (Hanahan and Weinberg 2011). Each hallmark of cancer 
represents an acquired capability that a cancer needs for growth and 
progression. Drugs have been developed to address each of these hallmarks; 
some are in clinical trials and some are already approved for use in the clinic to 
treat cancer. This is by no means a comprehensive list of the many candidate 
drugs in existence or development.  
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One of the hallmarks of cancer is genome instability and mutation, a feature that 
increases in cells with age (Freitas and de Magalhães 2011; Soares et al. 2014).  As 
stated before, adult cancers usually require multiple mutations to develop (Vogelstein et 
al. 1988; Vogelstein and Kinzler 1993).  Cancers that affect young people (the World 
Health Organization defines young people as aged 10-24) are rarer in occurrence, likely 
due to fewer mutations in the genome due to age (Siegel et al. 2019). Many of these 
cancers have oncogenic fusion-genes (Pritchard-Jones 1996), and the defined genetic 
nature allows for more focused study and treatment.   There is extraordinary value in 
studying these rare cancers, not only for the primary benefit of improving the health of 
these young people, but to have a simpler model for cancer to study specific pathways 
that contribute to a hallmark of all cancers.   Fibrolamellar Hepatocellular Carcinoma 
(FLC) is one of these rare cancers and will be the next focus in this chapter.  
Fibrolamellar Hepatocellular Carcinoma 
Fibrolamellar Hepatocellular Carcinoma (FLC) was first described in 1956 but 
was not referenced as fibrolamellar carcinoma until 1980 (Edmondson 1956; Craig et al. 
1980). The 1980 study was the first to characterize the histology of FLC as showing 
deeply eosinophilic abnormal hepatocytes with pale bodies surrounded by fibrosis 
arranged in a lamellar fashion, and it also noted the prevalence of this cancer to affect 
young people (Craig et al. 1980). The World Health Organization (WHO) only assigned 
FLC its own WHO classification number distinct from hepatocellular carcinoma (HCC) in 
2010 (Bosman FT, World Health Organization, International Agency for Research on 
Cancer 2010), and prior to 2014 the vast majority of FLC literature was of a clinical and 
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epidemiological nature. A 2003 epidemiological study looked retrospectively at a cohort 
of liver cancer patients in the United States from 1986 to 1999 using the Surveillance, 
Epidemiology, and End Results (SEER) program and determined that only 68 cases 
were histologically confirmed cases of FLC compared to the 7896 cases of HCC, 
meaning that FLC only represented 0.85% of all primary liver cancer cases in the United 
States (El-Serag and Davila 2004).  
Based on 275 cases of FLC, the median age of onset for this cancer is 22 years 
of age, and eighty percent of cases occur between the ages of 10 and 35 with no 
preference for gender (Torbenson 2012). There is some literature reporting cases in 
people as young as four months old and as old as 60 years of age, but some of these 
diagnoses are strongly suspect of truly being FLC (Torbenson 2012; Edmondson 1956; 
Craig et al. 1980; Katzenstein et al. 2003; Cruz et al. 2008; Lack et al. 1983; Maitra et 
al. 2000). Patients do not have underlying liver disease, viral infection, or cirrhosis of the 
liver and often present with nonspecific and vague symptoms like abdominal pain, 
malaise, and weight loss, making diagnosis difficult until a large abdominal mass is 
palpable (Craig et al. 1980; El-Gazzaz et al. 2000; Saab and Yao 1996; Berman et al. 
1988; El-Serag and Davila 2004; Hemming et al. 1997).  The overall 5-year survival rate 
of FLC is only 30-45%, and treatment options are still limited, with surgery being the 
mainstay (Katzenstein et al. 2003; Torbenson et al. 2002; Weeda et al. 2013; El-Serag 
and Davila 2004; Kakar et al. 2005; Mavros et al. 2012). In fact, a leading pathologist in 
the FLC field stated that the “most important prognostic feature is whether the tumor is 
resectable” since systemic therapy is not currently an option (Torbenson 2012). The 
published 5-year survival rate is 100% for FLC patients with resectable tumors restricted 
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to the liver compared to patients with lymph node involvement, vascular invasion, or 
multiple tumors (Hemming et al. 1997; Torbenson 2012; Graham and Torbenson 2017). 
These patients with more advanced disease usually die within five years since most 
patients do not respond to conventional chemotherapy and have not favored well in 
clinical trials of current targeted therapies (Hemming et al. 1997; Torbenson 2012; 
Mavros et al. 2012; Mayo et al. 2014; Chaudhari et al. 2018; Abou-Alfa et al. 2015).  
Little was known about the molecular pathogenesis of FLC until the discovery of 
a new fusion gene present in this cancer in 2014 by our lab (Honeyman et al. 2014). 
This gene fusion is the result of a single ~400kb deletion on chromosome 19 that fuses 
the first exon of DNAJB1, which codes for a heat shock protein, and exons 2-10 of 
PRKACA, which codes for the catalytic subunit of cAMP-dependent protein kinase A; 
this new fusion gene yields a functional chimeric kinase present in 15 of 15 of FLC 
tumors in this study and over 350 more to date (Honeyman et al. 2014). 
Our lab also followed up with further genomic and transcriptomic studies that 
showed there are no other consistent detectable genetic changes common among FLC 
patients and that the transcriptome of FLC is distinct from normal liver tissue and HCC 
tissue (Honeyman et al. 2014; Darcy et al. 2015; Simon et al. 2015). Others have 
confirmed these results (Graham et al. 2015; Malouf et al. 2014; Xu et al. 2015; 
Cornella et al. 2015; Griffith et al. 2016; Sorenson et al. 2017; Dinh et al. 2017). Our 
transcriptomic studies implicated several known oncogenes including ErbB2, members 
of the Wnt signaling pathway, and Aurora Kinase A since their transcripts were 
increased in FLC tumors compared to normal liver tissue and further validated with 
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qPCR, western blots, and mass spectrometry (Simon et al. 2015). Unpublished results 
from our lab also notably show that expression of DNAJB1-PRKACA is sufficient to 
produce transcriptomic changes in human hepatoma or HeLa cell lines similar to the 
changes observed in FLC tumor tissue.  
As discussed earlier, our collaboration with the Lowe lab supports that this 
chimeric kinase drives tumorigenesis in mice and is clearly playing some role in the 
pathogenesis of FLC (Kastenhuber et al. 2017), and work with different mouse models 
of FLC supports this same conclusion (Engelholm et al. 2017). However, there is no 
current data on what this chimeric kinase, DNAJB1-PRKACA, could be directly acting 
on in FLC. 
 Another publication from our lab on molecular dynamics simulations (Tomasini 
et al. 2018) suggested the possibility for differential substrate binding and consequently 
differential phosphorylation due to different motions seen near the active site in the 
chimeric kinase that were not observed in PRKACA. Determining whether the chimeric 
kinase has different substrates from the wild type kinase would inform future directions 
of study and treatment of this cancer. The total phosphoproteome from an FLC tumor 
alone would not provide sufficient information to discern the direct substrates of the 
chimeric kinase in FLC and neither would the phosphome of cell lines or mice 
expressing this kinase since the phosphoproteomic changes could be the result of 
secondary changes initially caused by the direct action of DNAJB1-PRKACA. To truly 
understand the pathogenesis of FLC, we need to understand what DNAJB1-PRKACA is 
directly acting on in the cells of FLC. It is possible that the main changes between 
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normal liver tissue and FLC are due to a difference of localization of DNAJB1-PRKACA 
to PRKACA or that DNAJB1-PRKACA has crucial scaffolding properties inside the cell. 
Since DNAJB1-PRKACA is a kinase, it warrants further study to determine if its kinase 
activity differs from PRKACA. 
The Biology of DNAJB1, PRKACA, and DNAJB1-PRKACA 
The NMR (nuclear magnetic resonance) solution structure of the human DNAJB1 
was solved in 1996 and is depicted in Figure 2a (Qian et al. 1996). The NMR structure 
of the characteristic J-domain and glycine/phenylalanine domains of the bacterial DnaJ 
was solved in the same year (Pellecchia et al. 1996). This co-chaperone is one of forty-
one known members of the DnaJ, or Hsp40, family of heat shock proteins (Kampinga 
and Craig 2010; Wawrzynow et al. 2018).  This family of molecular chaperones contains 
a highly conserved amino acid stretch known as the J-domain that is encoded in the first 
exon. The J-domain is known to stimulate the ATPase activity of Hsp70 heat shock 
proteins to promote proper protein folding and to prevent the aggregation of misfolded 
proteins (Liberek et al. 1991; Hennessy et al. 2005; Kampinga and Craig 2010; Kityk et 
al. 2018). The J-domain is comprised of 4 alpha helices and a loop with three conserved 
amino acids: histidine, proline, and aspartic acid; a point mutation in this loop to a 
dissimilar amino acid like glutamine abrogates the ability to bind to Hsp70 (Pellecchia et 
al. 1996; Hennessy et al. 2005). These co-chaperones also have their own intrinsic 
chaperone activity (Langer et al. 1992).  
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Since the biochemical activity of their binding partner, Hsp70, itself is highly 
specific and the number of Hsp70 proteins in a cell is limited, the functional versatility of 
Hsp70 in the cell is thought to be conferred by the J-domains of the many Hsp40 family 
members (Hageman and Kampinga 2009; Kampinga and Craig 2010; Hennessy et al. 
2005; Caplan 2003). The variety of Hsp40 co-chaperones outnumber Hsp70 proteins 
four to one in the mitochondria and six to one in the endoplasmic reticulum, though 
DNAJB1 is thought to operate in the cytosol and nucleus (Kampinga and Craig 2010). 
Heat shock proteins have been heavily implicated in cancer biology and some 
inhibitors are already in clinical trials. Potential anti-cancer therapies for HSP90, another 
family of heat shock proteins, look promising, while recent Hsp70 clinical trials have 
been halted due to limited anti-tumor effects and mild nephrotoxicity (Neckers and 
Workman 2012; Hernández et al. 2002; Karagöz and Rüdiger 2015; Lianos et al. 2015; 
Murphy 2013; Chatterjee and Burns 2017; Kanazawa et al. 2003; Calderwood and 
Gong 2016; Wu et al. 2017; Sidera and Patsavoudi 2014; Chunta et al. 2012; Propper 
et al. 1999).  
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Figure 2. Protein Data Bank (PDB) Structures. 
A. J-Domain of DNAJB1; PDB ID 1HDJ. 
B. PRKACA; PDB ID 2F7X. 
C. DNAJB1-PRKACA; PDB ID 4WB7. 
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Heat shock proteins have been shown to play a specific role in the sequestering 
of the well-known tumor suppressor p53. More recent work shows that chaperones may 
play different roles with this tumor suppressor depending on the context. Because these 
heat shock proteins cannot distinguish mutant p53 from the wild-type, these chaperones 
can stabilize the mutant and aid in its aggregation in the cell instead of targeting the 
mutant protein for degradation (Tracz-Gaszewska et al. 2017; Wawrzynow et al. 2018).  
For DNAJB1, the C-terminal end has been implicated to stabilize MDM2, a 
protein that regulates p53, which inhibits its ability to ubiquitinate and degrade p53. 
Additionally, it was shown that depletion of DNAJB1 in cancer cells inhibited the activity 
of p53, leading to cancer cell growth (Qi et al. 2014). This could be relevant to FLC 
since the C-terminal component of DNAJB1 is lost as a result of the gene fusion. 
DNAJB1 was also implicated in interacting with another p53 regulator, PDCD5, that 
promotes p53 mediated apoptosis (Cui et al. 2015). The Cui et al. paper claims that in 
various cancers DNAJB1 promotes the ubiquitin-dependent proteasomal degradation of 
PDCD5 which inhibits apoptosis. However, the DNAJB1 domain implicated in this 
function is not in exon 1, so may not be directly relevant in FLC. DNAJB1 has also been 
implicated in negatively regulating another tumor suppressor, Mitogen-inducible gene 6 
(MIG6). DNAJB1 stabilizes MIG6 and leads to its ubiquitination and proteasomal 
degradation which leads to the activation of epidermal growth factor receptors (EGFR) 
(Park et al. 2015). Of course, DNAJB1 is also implicated in FLC since the J-domain is 
present on the driver, DNAJB1-PRKACA (Honeyman et al. 2014).  
The literature on Protein Kinase A (PKA) is even more extensive as it has been 
studied for over sixty years. Its road to discovery began in the 1950s when Fischer and 
16 
Krebs demonstrated that not only was ATP required to activate the protein they were 
studying, phosphorylase, but that a phosphate group from ATP was being incorporated 
into a serine in phosphorylase by a phosphorylase kinase that was mediated by cyclic 
adenosine 3’,5’-monophosphate (cAMP) (Krebs and Fischer 1955; Fischer and Krebs 
1955; Fischer et al. 1959; Krebs et al. 1959). They next demonstrated that the cAMP 
effect was mediated by a second kinase leading to the idea of a kinase cascade and the 
purification of what we now know as cAMP-dependent protein kinase A (PKA) (Walsh et 
al. 1968).  
PKA exists in a tetrameric holoenzyme that is comprised of two catalytic subunits 
(either PRKACA, PRKACB, or PRKACG) and two regulatory subunits (either RIβ, RIIβ, 
RIα, or RIIα). The regulatory subunits interact with a highly conserved hydrophobic cleft 
found in the catalytic subunits (Berthon et al. 2015). The catalytic subunit remains 
inactive in the holoenzyme until cAMP stimulates the regulatory subunits to release it 
(Gill and Garren 1970; Tao et al. 1970; Brostrom et al. 1971; Hofmann et al. 1975; 
Rosen et al. 1975; Brandon et al. 1997). The mechanistic details of this allosteric 
activation are still an active topic of study (Zhang et al. 2015; Cao et al. 2019). The 
crystal structure of the PRKACA catalytic subunit revealed the bi-lobe structure of the 
kinase core, which provided structural insight for studying other kinases (Knighton et al. 
1991). 
The various isoforms of PKA are involved in a broad range of signaling 
processes including, but not limited to, protein synthesis, gluconeogenesis, lipogenesis, 
insulin secretion, cell differentiation, excitation-contraction coupling in the heart, ethanol 
consumption, and synaptic transmission and memory formation (Colledge and Scott 
17 
1999; Wand et al. 2001; Layland et al. 2005; Horiuchi et al. 2008; Smith and Scott 
2018). Part of this specificity of function is conferred by the binding of A-kinase-
anchoring proteins (AKAPs) to the regulatory subunits of the holoenzyme. These 
AKAPs compartmentalize PKA in different parts of the cell (Colledge and Scott 1999; 
Torres-Quesada et al. 2017). Phosphatases and phosphodiesterases also play a critical 
role in conferring specificity of PKA phosphorylation in the cell (DeSouza et al. 2002; 
Ahn et al. 2007; Burdyga et al. 2018; Leslie and Nairn 2019; Eiringhaus et al. 2019; Li et 
al. 2006; Stratakis 2012; Epstein 2017). Additionally, substrates of this kinase have an 
amino acid motif at the site of serine or threonine phosphorylation that is preferentially 
recognized by PRKACA (RRxS/T) (Rust and Thompson 2011), as well as a preference 
for hydrophobic residues. 
It should not be surprising that when the activity of a crucial kinase with broad 
functions in the cell is altered disease states would arise. Impaired or altered PKA 
activity has been implicated in diabetes, heart disease, neurodegenerative disorders, 
Carney complex, Cushing’s disease, and cancer (Gold et al. 2013; Bockus and 
Humphries 2015; Dagda and Das Banerjee 2015; Burgers et al. 2016; Caretta and 
Mucignat-Caretta 2011; Shaikh et al. 2012; Sapio et al. 2014; Honeyman et al. 2014; 
Berthon et al. 2015; Cheung et al. 2015; Palorini et al. 2016; Patra et al. 2018; Espiard 
and Bertherat 2015; Beuschlein et al. 2014). Since PKA has been implicated in tumor 
growth, it has been suggested as a molecular target for cancer therapy. However, 
because of the highly conserved region of the ATP binding site, exploiting the more 
specific interaction between PKA and a particular substrate may be a more effective 
approach (Naviglio et al. 2009; Sapio et al. 2014; de Oliveira et al. 2016). 
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Our lab studies the PRKACA variant found FLC. The fusion gene found in FLC, 
DNAJB1-PRKACA, yields the fusion kinase: DNAJB1-PRKACA. This kinase has only 
been identified in FLC tumors and is the driver of this cancer (Honeyman et al. 2014; 
Darcy et al. 2015; Xu et al. 2015; Cornella et al. 2015; Sorenson et al. 2017; Dinh et al. 
2017; Kastenhuber et al. 2017; Engelholm et al. 2017). DNAJB1-PRKACA is comprised 
of the first exon of DNAJB1, which contains the characteristic J-domain, and exons 2-10 
of PRKACA, which preserves the majority of the structure of this kinase, including the 
active site.  
A crystal structure of DNAJB1-PRKACA was published in 2015 (Cheung et al. 
2015), and is depicted in Figure 2c. Our lab used molecular dynamics simulations to 
show that DNAJB1-PRKACA can exist as a structure somewhat similar to the crystal 
structure with the J-domain tucked under the large lobe of the kinase, but the J-domain 
can also swing free, away from the core of the kinase. These predictions were 
confirmed by NMR with a collaborator (Tomasini et al. 2018).  
Modeling from our lab has shown that there are no obvious steric interactions of 
the J-domain with the holoenzyme containing the RIIβ regulatory subunit (Cao et al. 
2019). Further collaborations have also determined the crystal structures of DNAJB1-
PRKACA in complex with the RIα regulatory subunit, as well as the crystal structure of 
PRKACA in complex with RIα (Cao et al. 2019). These quaternary holoenzyme 
structures with RIα differ from the previously reported holoenzyme structures published 
for PRKACA in complex with RIβ and RIIβ. While DNAJB1-PRKACA and PRKACA 
showed the same configuration as a holoenzyme when in complex with RIα, a distinct 
second conformation was identified for DNAJB1-PRKACA. When in complex with RIα, 
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the J-domains of the chimeric kinase are positioned away from the center of the 
holoenzyme and are highly dynamic. Despite great advances in the understanding of 
the structural biology of this kinase, it is not yet known if DNAJB1-PRKACA can 
phosphorylate different substrates compared to PRKACA. Since DNAJB1-PRKACA is 
the driver of FLC and kinases have been thoroughly implicated to play a crucial role in 
cancer biology (citations), determining the phosphorylation pattern of DNAJB1-PRKACA 
in FLC is critical to understanding the nature of this kinase. 
Substrate Identification of Kinases 
It is challenging to identify the direct substrates of a particular kinase in a cell 
since all kinases transfer the gamma-phosphate of ATP to their substrates. Biochemical 
methods are needed to be able to distinguish between the substrates of the kinase of 
interest and the substrates of other kinases in the experiment. Most substrate 
identification methods do not distinguish between direct substrates and substrates that 
are either phosphorylated by another unrelated kinase or phosphorylated as the 
consequence of the relevant direct phosphorylations by the kinase of interest. Below, I 
will highlight five established methods of direct substrate identification.  
Kinase substrate tracking and elucidation (KESTREL) is a method that depletes 
cell lysates of ATP, then introduces an abundance of purified kinase of interest and 
radiolabeled ATP to favor the kinase reactions of the kinase of interest. Because of the 
radiolabel, proteins can be separated on a gel and excised to be identified by MS. The 
substrates are then validated in vivo as part of the published protocol for this method 
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(Cohen and Knebel 2006; Knebel et al. 2001). While the need for in vivo validation is 
acknowledged, it is also worth repeating that all of the kinases in the lysate are still 
active and can confound the list of proteins that need to be validated as true substrates. 
This method would also allow for the identification of specific phosphosites of the 
substrates.  
Substrates of a kinase can also be directly identified by creating a peptide array 
of immobilized substrates and incubating it with the purified kinase of interest and an 
ATP-analog with a radioactive tag on the gamma phosphate (Ptacek et al. 2005; Boyle 
et al. 2007). While this method allows for a high throughput screening of potential 
substrates, it is limited to only identifying substrates in the array, and the dynamics of 
protein interaction could be altered because of the immobilization of the substrates; 
these arrays can also be very expensive in time and resources to develop and use. The 
in vitro nature of this experiment also means that spatial and temporal specificity of an 
interaction is lost so additional in vivo work would be required to know if a substrate 
identified by this method is relevant in a cell.  
The Shokat lab developed a chemical genetic approach to identify substrates of 
kinases by covalent capture of thiophosphopeptides and analysis by mass 
spectrometry. Kinases have a large gatekeeper residue, like methionine, to help block 
the hydrophobic region inside the ATP binding pocket. By mutating this gatekeeper 
reside to a small amino acid, like glycine or alanine, the active site can now utilize a 
bulky ATP analog. This bulky ATP-analog also has a thiol group on the gamma-
phosphate that results in the transfer of a thiophosphate group to the substrate. 
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Substrates can then be purified and identified by the thiophosphate tag. The 
thiophosphorylated substrates exist in a population of phosphorylated and unlabeled 
proteins, but the thiophosphorylated proteins can be specifically alkylated with p-
Nitrobenzyl mesylate (PNBM) to generate a bio-orthogonal thiophosphate ester that is 
recognized by a specific thiophosphate ester specific antibody via western blot. The 
labeled lysate can also be digested with trypsin to generate peptides to use for mass 
spectrometry to identify putative substrates. The sample used for mass spectrometry is 
enriched for the thiol containing peptides. These peptides are then pulled out with 
iodoacetyl agarose beads and treated with Oxone to release the thiosphosphate ester 
linked peptides by spontaneous hydrolysis (Hertz et al. 2010; Allen et al. 2007). This 
method would allow for direct identification of the specific phosphosites of target 
substrates in vitro with minimal background phosphorylation. There is also the 
possibility of designing in vivo experiments with the analog-sensitive kinase and cell-
permeable ATP analogs. However, the creation of the analog-sensitive kinases requires 
mutating the active site of a kinase which could affect the reliability of true substrate 
identification so in vivo validation is still required.  
Kinase-Interacting Substrate Screening (KISS) is a more recently developed 
substrate identification method that washes cell lysate over a glutathione-sepharose 
affinity column (GST) column coated with a GST-tagged version of the kinase of 
interest. Kinase-substrate complexes that form on the column are then incubated with 
ATP to stimulate the phosphorylation of the substrates. The peptides are then digested, 
subjected to phosphopeptide enrichment, and mass spectrometry for analysis (Amano 
et al. 2015). This method allows for the identification of specific phosphorylation sites 
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and enriches for strong substrate-kinase interactions, but more transient 
phosphorylations of substrates cannot be detected by this method. This method also 
requires in vivo validation.  
      Kinase-catalyzed Biotinylation with Inactivated Lysates for Discovery of 
Substrates (K-BILDS) is an even more recently developed method that takes advantage 
of a nucleotide known as 5’-(4-fluorosulfonylbenzoyl) adenosine hydrochloride (FSBA) 
that irreversibly inhibits the majority of kinase activity in cell lysates by reacting with the 
catalytic lysine in the kinase active site. Treating cell lysates with FSBA to knockdown 
endogenous kinase activity then allows for a more controlled kinase reaction with the 
addition of the kinase of interest. This method uses an ATP-analog with the gamma-
phosphate biotinylated so that putative substrates can be purified using streptavidin 
beads and analyzed by mass spectrometry (Embogama and Pflum 2017). This method 
would also allow for direct identification of specific phosphosites of target substrates in 
vitro. However, FSBA does not kill all kinase activity in the cell lysate, so some 
background biotin-phosphorylation will occur. This method also requires in vivo 
validation.  
           While all of these methods have their benefits and caveats, one caveat they all 
share is the requirement of in vivo validation of putative substrates. This emphasizes 
the non-trivial nature of identifying direct substrates of kinases.  
           Despite decades of research, not all of the substrates of PKA are yet known. 
There have been a few recent efforts to identify a more encompassing list of PKA 
substrates (Hu et al. 2014; Hamaguchi et al. 2015; Embogama and Pflum 2017; 
Imamura et al. 2017; Isobe et al. 2017).  
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PhosphoNetworks is an online database based on experimentally determined 
kinase-substrate relationships from a bioinformatics and protein microarray-based 
strategy that screened 289 human kinases against protein microarrays containing 4,191 
different full-length human proteins (Hu et al. 2014); this approach yielded 301 direct 
putative PRKACA substrates.  
           Another approach used a PKA-motif antibody to enrich PKA substrates from cells 
that were treated with chemicals to activate or inhibit PKA; the phosphopeptides that 
were more enriched when PKA was activated, but not when PKA was inhibited, in the 
cell were considered putative PKA substrates upon analysis by mass spectrometry 
(Hamaguchi et al. 2015). This method yielded 45 putative PKA substrates.  
           A third effort was the K-BILDS method described earlier (Embogama and Pflum 
2017); this approach resulted in 279 direct putative PRKACA substrates in HeLa cells, 
17 of which they claim are true direct interactors.  
           Another approach also used drugs to affect PKA activity and quantified the 
change of the phosphoproteome in HeLa cells. That approach also included a 
computational model based on known kinase-substrate relationships to characterize the 
specificity of the kinase sequences and exclude indirect targets (Imamura et al. 2017). 
The computational model narrowed down the list of reliable PKA candidates to 29, eight 
of which were previously known substrates. However, for the purpose of comparison, 
the list of putative substrates identified by their mass spectrometry analysis yielded 
1132 potential candidates.  
    The last approach reviewed here used CRISPR-Cas9 gene editing in 
vasopressin-responsive mouse epithelial cells to knockout PRKACA and PRKACB. The 
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phospho-occupancy of these cells were then compared to cells without gene editing 
which yielded a list of 197 putative direct and indirect PKA substrates (Isobe et al. 
2017). 
           I compared a list of the gene names of the putative substrates from each of these 
methods using a Venn diagram web tool developed by the Bioinformatics and 
Evolutionary Genomics group at the Tech Lane Ghent Science Park in Belgium 
(http://bioinformatics.psb.ugent.be/webtools/Venn/). These lists do not take into account 
whether these methods identified the exact same phosphosite on the putative substrate, 
just that the putative substrate was identified in the screen. The resulting Venn diagram 
and table clearly show that while there is overlap between the putative substrates 
identified in the different approaches, none of them reveal a single common putative 
substrate (Table 1 and Figure 3).  The specific overlaps seen in Table 1 and Figure 3 
demonstrate that the identification of certain putative substrates is favored by different 
methods. However, each could be identifying a true direct substrate of PRKACA that is 
not able to be identified by any other and is worthy of study. This comparison 
emphasizes that each method of substrate identification is limited and definitely requires 
in vivo validation of some kind before moving forward with any experiments or 
treatments based on a potential specific substrate of the kinase of interest.  
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Figure 3. Putative PRKACA Substrate Comparison from Published PKA Substrate 
Identification Methods. 
These substrates were curated from five different sources with various substrate 
identification methods described above (Hu et al. 2014; Hamaguchi et al. 2015; 
Embogama and Pflum 2017; Imamura et al. 2017; Isobe et al. 2017). The Venn 
Diagram was generated by inputting the gene names of the putative substrates from 
each source into the Bioinformatics and Evolutionary Genomics Venn diagram web tool 
(http://bioinformatics.psb.ugent.be/webtools/Venn/). 
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Table 1. Overlap of Putative PRKACA Substrates from Published PKA Substrate 
Identification Methods. 




Total Number of Overlapping 
Putative PRKACA Substrates 
Total Number of Putative 
PRKACA Substrates 
Embogama, et al. 75 279 
Hamaguchi, et al. 22 45 
Hu, et al. 80 301 
Imamura, et al. 186 1132 
Isobe, et al. 87 197 








Overlaps Overlap of Putative PRKACA Substrates 
Hamaguchi, et al. 
Hu, et al. 
Imamura, et al. 
Isobe, et al. 
1 CAD 
Embogama, et al. 
Hu, et al. 
Imamura, et al. 
Isobe, et al. 
1 SPTBN1 
Embogama, et al. 
Hamaguchi, et al. 
Hu, et al. 
Imamura, et al. 
1 PDE3A 
Hu, et al. 
Imamura, et al. 
Isobe, et al. 
2 PCM1 SMARCAD1 
Hamaguchi, et al. 
Imamura, et al. 
Isobe, et al. 
6 SPECC1L SIK2 LIMCH1 TNKS1BP1 REPS1 DENND4C 
Embogama, et al. 
Imamura, et al. 
Isobe, et al. 
1 LMNA 
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Hamaguchi, et al. 
Hu, et al. 
Imamura, et al. 
1 RAF1 
Embogama, et al. 
Hu, et al. 
Imamura, et al. 
9 SMARCC2 NASP ACACA YWHAE YWHAZ ZYX GFPT1 
FLNA CTTN 
Embogama, et al. 
Hamaguchi, et al. 
Imamura, et al. 
1 RPLP2 
Hu, et al. 
Isobe, et al. 
10 NUP133 CTNNB1 BAD LRRFIP1 MAP2 SRC SUFU LSR 
ZHX1 NFKB1 
Hamaguchi, et al. 
Isobe, et al. 
6 KIAA1522 ARHGEF7 NF1 RPL18A NHSL1 PITPNM3 
Imamura, et al. 
Isobe, et al. 
65 COBLL1 MEF2D MYO9B IRF2BP2 TNS3 PI4KB ATG2B 
ARHGAP17 ARHGAP21 SQSTM1 DCP1A PRKAR2A 
XRN2 BNIP2 DYNC1H1 ENAH OSBP SORBS2 FAM83H 
LIMA1 PXN WWC1 PLEKHG3 ARPP19 ARFGEF2 
SIPA1L1 IRS2 TJP1 EIF4B RIN1 PKN2 EIF5B PUM2 
HECTD1 OPTN CTNNA1 TXLNG AKAP1 RBM14 
PRKD2 MAP3K2 MARK2 NCOR1 MICAL3 C2CD2L FBL 
FKBP15 NSFL1C PRRC2A RAB11FIP1 OSBPL11 
CTNND1 TJP2 YBX3 YAP1 HPS5 ABCC1 ARHGAP35 
WNK1 DOCK7 LARP4B PARD3 ABLIM1 PUM1 ITPR3 
Embogama, et al. 
Isobe, et al. 
1 AGPS 
Hamaguchi, et al. 
Hu, et al. 
2 CAMKK1 C19ORF21 
Hu, et al. 
Imamura, et al. 
43 ANKS1A CD44 HSPB1 MATR3 PTPN12 LUZP1 
TERF2IP SMC3 DNAJC5 NPM1 CDCA7L STUB1 
NCOA3 NEDD4L FYN LARP1 VIM PRKAR1A SAFB2 
HIRIP3 PYGO2 ARFGAP2 LASP1 TRIP10 STMN1 
HSP90AA1 FOXP4 SP100 NDRG1 EMD ATRIP 
EIF4ENIF1 LIG1 TRIM28 LAS1L TBC1D10B AKAP13 
CHAF1B LARP4 DNM1L UHRF1 CEBPB PDE3B 
Embogama, et al. 
Hu, et al. 
10 MSN TGM2 YWHAH HLA-A PTBP1 YWHAG XPO1 
PSMC5 PRKACA PSMA8 
Hamaguchi, et al. 
Imamura, et al. 
4 ZNF318 C2CD5 ACIN1 SAFB 
Embogama, et al. 
Imamura, et al. 
51 MAP4 PDHA1 CLUH DPYSL2 PSMA3 ACTL6A PALLD 
KDM5C YWHAQ SLC1A5 SLC9A3R1 RCC2 INF2 EPRS 
SPAG9 RANBP1 CAP1 HNRNPK BAG3 FLNB NACA 
TP53BP1 EIF4G1 LRRC47 MYO1E TK1 HNRNPD 
SF3A1 EFHD2 EGFR BOD1L1 SSB SLC4A1AP 
SLC16A3 EDC4 KHSRP PPP6R3 PDIA6 MARCKSL1 
PAICS GORASP2 HDAC1 IGF2R SUPT6H MAGED2 
MCMBP SERBP1 SRRM2 EIF3G TCOF1 PAK2 
Hamaguchi, et al. 23 KLC4 CDC25B CRY2 OFD1 MARK3 PCNX DAPK2 
CASP11 PITPNM2 CEP72 KIAA0556 CDK18 PHACTR2 
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TMCC1 GLI2 HSPC075 CAMKK2 SIK3 C2ORF55 
PDE8B LRCH3 BAT2 EVL 
Isobe, et al. 104 CHD9 PDLIM2 CASP6 VEPH1 MAP3K5 TBC1D12 
SPIRE2 NEK4 MIB2 PI4KA MYO5B TOMM34 SEC23IP 
CAMK2D IRS1 ZZEF1 ARHGEF2 CASP8 ITSN2 HSPA4 
TIAM1 NULL VILL PSMF1 MTOR OSBPL10 PPM1H 
PEAK1 EPS8L1 LYST TAB2 HBP1 ATP6V0A2 MAP4K3 
MTCH1 CLIP2 WDR4 SLC7A6OS SNX2 MRPS9 
PTPN14 CLMN GOLGA5 KLC3 SAYSD1 BLOC1S5 
TMEM259 IGSF5 PLEKHF2 MAP4K5 PCYT1B MRPL37 
KARS ZNF608 KIAA1109 DOCK1 EIF2AK2 UHRF1BP1L 
WDTC1 CGNL1 SCYL2 CCS SRP14 KLHDC7A 
AFAP1L2 WDFY3 TIAM2 ERBB3 SSH1 SLAIN2 
ARHGAP29 BORCS6 PURG SHROOM3 ERBIN AP3D1 
NFATC2 MPDZ JUP COBL PBXIP1 HERC4 NCK1 
CHCHD6 SNX1 ARHGEF17 RTKN FGD3 SNX12 MIA3 
CGN VIPAS39 SKT DOPEY1 MAP4K4 RAB18 PHLDB2 
KAZN PTPN13 BAIAP2 TNS2 ARHGAP27 PARD6B ZAK 
Embogama, et al. 204 TBCB ECHS1 TKT PFKP DECR1 CSPG4 HSD17B10 
LMAN1 NT5DC1 DDB1 TLN1 PAIP1 DDX5 USP47 GDA 
SDHB IPO9 DDOST PUF60 PSMA1 RPL29 RPL35 
IMPDH2 PTPN11 DDX47 RTF1 EXOSC2 CYFIP1 
USP14 ATP1B1 HYOU1 USP7 NUCB1 SARS UFD1L 
PRDX4 ARF1 SPG20 NUP88 NOMO1 SMC1A DHX15 
HSPA4L FKBP4 SF3A3 FUBP1 AHCYL1 ACO2 UBQLN2 
HEXIM1 OXCT1 ETFA MTHFD1 MTHFD2 TPT1 AP2M1 
RDX UMPS EHBP1L1 MYOF STOM GPKOW LDLR 
ITGB1 FKBP10 RPN1 PSMC4 WARS MPI CASP1 
CECR5 PSMD12 FKBP5 PRMT1 TYMS MCM5 SFN 
CSE1L TXNDC5 PFKM ELP3 TES ACAA2 PLS3 PLOD3 
PLOD2 RPS24 SH3GL1 PSMC1 ACADS MCCC2 IVD 
PSME1 PSMD14 SF1 WIBG YWHAB PARP1 DHX9 
ANXA2 PSMA4 DUSP12 PRKCSH BUB3 CNN2 WDR61 
SERPINH1 CAPZA1 ACY1 PRMT5 RPS10 CLIC4 
NHLRC2 FTO PTPRF SEC24C RAB6A SERPINB4 
SERPINB1 POLDIP2 POFUT TUBB6 MINPP1 AKAP12 
CLU PRPF8 RPL28 IARS ARFIP1 UBE2O MRPL2 
PPP2R2A GNB2L1 SF3B1 CKMT1A TUBA1C HMGCL 
ACAA1 PAAF1 SLC3A2 ASNS PC COPS3 DNM2 VARS 
CHD4 CDC73 GOLIM4 PSMD4 GDI2 RRM1 PRDX2 
DDX17 SBDS TIPRL RNH1 DAK KLC1 GALE DRAP1 
DLD LAMP2 CAT NONO SETD7 CPNE1 PLD3 SART3 
LAP3 IMPDH1 NMT1 FDXR ST13 UBFD1 RARS POLD1 
TRMT10C ACTN1 HSDL2 CLTB PSME3 MGEA5 KPNA6 
PDIA4 NAGK RPS14 PGD NME1 RPS16 PYCRL PEBP1 
IWS1 CP NANS SF3B3 GPC1 SDHA LANCL1 PNP 
ANKZF1 ACTR2 PGK1 OAT MPST 
Hu, et al. 221 ESPL1 HSPB6 HNRPD HSPB8 PPP1R14A ANXA1 
ATP1A3 DSP ALOX5 SERPINF1 PKD1 TRPM8 TTF2 
RXRA NFATC4 POU3F4 CENTD2 NFATC1 PLN GRK1 
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BIRC5 CIAO1 PLCG1 DAP3 SIP1 C21ORF66 ITGB4 
BTBD12 FAM44A RASGRF1 PIN1 GSTA4 EP400 
ABCA1 ARID3A PPP1R8 CSDE1 PPP1R9A AICDA 
BCAM NPR1 AQP2 KCNH2 PDE4C DDX39 LIPE TNNI3 
IRF3 TAF10 PLCB3 EZR TFAP2B CIITA CRHR2 RBM19 
MAPT GMFB AURKA C14ORF106 KCNJ13 RGS14 
CSRP3 ABCB1 KCNA4 PPP1R1B GPBP1L1 RRAD WT1 
SNAI1 CTPS MYBPC3 SOX9 ADRB1 CSK NOXA1 TH 
LCK HAGH CACNA1H PHOX2A DES XRCC4 RDBP 
NAB2 RNF12 GLI1 GRIA1 ASPSCR1 PCTK1 ACCN2 
VTN CCND1 RUNX1T1 POP7 ESR1 KCNN3 SNUPN 
PFKFB3 NEUROD1 PDE4D NFATC3 PRDX5 U2AF1 
SREBF2 BCOR AVPR2 RUVBL2 CSNK1A1 E2F7 
APOBEC3F EXOSC5 MDFI GSK3B GNA13 PTPN7 SGK 
TRPV1 DUOX1 ITGA4 VDR HLCS STK24 CHGB DDEF2 
PRKAR2B PPP1R13L H3F3A MC4R PHF17 CSDC2 
GATA3 MYOM2 FOXN3 PFKFB2 HIST2H3A CUL5 
UTP18 LRP1 MCOLN1 RCHY1 CLDN3 CBL MYLK 
CAPN2 CREB1 ERBB2 FIP1L1 TFAP2C C20ORF32 
AKAP9 TRPV4 NCBP2 PDE5A NR5A2 HDAC8 RBM22 
CRIP2 DAXX KCNJ3 HRH1 RYR2 RPS19 NOS3 ID2 
RB1 CFTR DHX29 C19ORF2 PDE4B TSC22D4 
SEC14L2 SAP30BP PDE11A SOX6 DNAJB2 HNRPK 
GFAP NRIP2 AQP5 RNUXA PPP2R5D TP53 CBX3 
VASP GAS7 CASP9 ZNF496 KCNN2 RBBP5 ETV5 
ARHGDIA ARFGEF1 PPP1R1C PPP1R1A LOC51035 
CUX1 FXYD1 BMI1 KCND2 TPPP PPP1R14C UNC84B 
LOC100133382 GSK3A GRK7 TPH2 METTL3 ETV1 NF2 
GAD1 SLC4A4 NCOA4 C13ORF15 LOC648998 SRF 
GATA4 VHL MDM4 PAH HCLS1 CBFA2T3 
Imamura, et al. 946 DBNL SLMAP RPTOR TFIP11 BCL2L12 ZHX3 ERCC5 
NBAS HIVEP1 TACC2 ATRX BYSL VAMP8 NBN 
CXCR4 U2SURP WASL EIF6 G3BP1 CHD8 RBM15 
NUFIP2 MAST2 SLTM SCAF8 TPX2 EP300 GYS1 
MON1B CHORDC1 PACSIN2 C2orf49 ZEB1 TRIM33 
TOPBP1 PARN CD2BP2 THRAP3 NUP214 TPD52L2 
SOX13 EIF3B MFSD6 SRPK1 USP20 PTCD3 BET1L 
MCRS1 HMGN1 UBE2E3 UBA1 NMNAT1 SHC1 PRDX6 
SAAL1 RAB3GAP1 TAOK3 RIOK1 HERC2 SLC12A4 
BASP1 CLCC1 USP6NL BAZ1B SDAD1 PPP1R15B 
LARP7 ARHGEF12 KPNA2 ATL2 SNRNP70 SLC35F6 
RBM17 PTOV1 RALY ZCRB1 KPNA3 PDCD4 TMEM45A 
CDK12 DDB2 RBM10 JADE3 PHF3 BCLAF1 TRA2B 
RBM33 RAD23B STK17A MTRR NCOR2 PEX14 
PGRMC2 APEH GTF3C3 TBC1D5 MAPKAP1 HIST1H1E 
THOC2 CEP170 TPI1 MINK1 EZH2 MSH6 MYO1C 
SRSF6 HDAC7 HSPD1 SLC15A4 SIPA1 OSMR 
CCDC43 LSM14A ATAD1 NELFE WIZ IMUP RBM4 
CSF1 SLC35B2 EDC3 SORT1 CEP170B COPA 
SETDB1 CARMIL1 SRSF11 PCDH7 TJAP1 PHC3 ORC1 
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ACOX1 FAM102B SON PLCL2 USP24 TRAM1 
KIAA1143 TWF1 NUP153 MYH9 TTYH3 ATP11C 
SLC12A6 AVEN C9orf16 URI1 RAP1GAP NOP2 USP42 
USP16 RAD9A SCML2 NIPBL POGZ RICTOR USP10 
PODXL2 RPS3 PI4K2A RAD18 WDR75 LRRC8A 
SFSWAP DYNC1LI2 PRRC2B COIL CDK17 ZMYND8 
APMAP ZNF687 PTGES3 TSC2 ZNF609 CPSF7 KDM2A 
EML3 CASC3 TCF12 ATP7A ZNF641 HABP4 NFIL3 
DSG2 WDR62 TANC1 DHX16 TBXA2R LEMD2 
MIS18BP1 UBXN7 DIDO1 PRKCD LYSMD2 ARAP1 
NGDN SAC3D1 ZNF639 PUS1 PPIG ITPRIPL2 UNG 
DPF2 BCL9L CBARP BRD8 PJA2 DCUN1D5 SMC4 
ANKLE2 TMEM230 NOP58 RPRD1B CHMP7 FRYL 
PTPN2 AP3B1 HCFC1 EPB41L1 AHNAK EXOSC9 UBL7 
KRT17 ABCC4 ZFP36L2 RPL4 PBRM1 PPP1R12A 
VAMP4 PRPF3 CHMP2B DDX24 RNF20 RBM6 USP9X 
WAPL VAPA SH3PXD2A HNRNPUL2 RBBP6 
ARHGEF16 HUWE1 BRF1 TMPO PARG RRAS2 ASAP2 
MCM3 PPL CEP131 RPS2 STRIP1 SSRP1 PRPF4B 
NRBP1 PDAP1 BRD4 CHAF1A RNF113A MYPN 
TOR1AIP1 PACSIN3 BCKDK CSRP1 ITSN1 SVIL 
PPHLN1 TBC1D2B AFF4 SUB1 AKAP10 CHAMP1 
PRPF6 PCBP1 NSD1 ATP2B2 NCAPD3 PDE8A 
SH3KBP1 PLA2G4A SYNRG RIF1 UNC13D PROSER2 
ABCC2 GPATCH8 DDI2 KIF4A PGM1 CPD MEPCE 
KIF21A UNK KRT8 SAMD1 SCD MAP7 RBM7 OSBPL3 
ANTXR1 TERF2 HASPIN SLC38A2 CD2AP CCDC86 
ATN1 SMN2 MPZL1 XPO4 EPS15 TRPT1 GPS1 WIPI2 
IFNAR1 SEPT9 EHD2 STX7 SPEN RMDN3 NAP1L4 
GPRC5A ANKRD17 UBE2J1 CCNK SZRD1 CDC26 
C1orf52 NCKAP5L FAM129B PDS5B CD97 EAF1 
MPHOSPH8 NOTCH2 NOC2L TICRR ADD1 PSMD2 
CHTF18 ATXN2 MYO18A ZBTB7A MADD PRRC2C 
SLC4A2 ACLY ARHGAP12 ARHGEF18 SUGP1 ARRB1 
HNRNPUL1 VIRMA SIN3A STRN3 POLR3E CHMP3 
TXNL1 CEBPZ CCNYL1 OBSCN ANAPC1 SRRT CBX8 
MELK RBM3 BMS1 SCFD1 RRBP1 IL1RAP VDAC1 
PPP1R10 CDK16 CIR1 FTSJ3 SF3B2 KAT5 FLYWCH2 
UTP14A TPD52L1 SLC19A1 XRCC1 SLC4A7 RRP1B 
EEF1B2 DKC1 PAK1IP1 GNL1 ZNRF2 SLC7A11 NELFB 
SEC22B PPP1R12C CDS2 AHCTF1 SENP3 ATG9A 
EEF2K NEDD1 DNAJB6 OCIAD1 TCEAL4 NFIC DDX46 
PRPF38B WDR26 ILF3 MUS81 BCL2L13 NUP50 
ARFIP2 LEMD3 KRI1 TXLNA BUB1 PIEZO1 GTF3C2 
PWWP2A GAL ALDOA RCC1 EIF3H SKIV2L KIF1B 
DIS3L2 SNTB2 SURF2 PIAS1 ZRANB2 ARGLU1 DOT1L 
CLASP2 ZC3H14 CNOT2 EIF2AK3 RPRD2 SNW1 
RPP30 TRIM16 CDC40 IRF2BPL ATF7IP SEC31A 
FOXK1 RECQL5 WEE1 ZC3H18 HNRNPC BSG FXR1 
NUP210 TIMM8A BIN1 SRRM1 RANBP3 PPAN 
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PABPN1 PTDSS1 FMNL1 ACSS2 GLCCI1 BAG6 
MMTAG2 SH2D4A SLC7A2 GZF1 DDX55 ARMCX3 
QSOX2 FERMT2 NSUN2 YBX1 LRFN4 TPD52 PNISR 
DTD1 CARHSP1 STK10 SLCO4A1 HERC1 PTPN23 
STK11IP DGCR8 ZC3H13 PHACTR4 RTN4 TAX1BP1 
GAPVD1 PHRF1 COPB2 CTR9 BRI3BP LMO7 TBC1D4 
PPP1R2 HNRNPH1 GIT1 HMOX1 KPNA4 MDC1 
CHCHD3 HIST1H1B EPB41 NUP98 INO80B NUCKS1 
DFFA RBM34 PAXX RCOR1 U2AF2 SEC16A EBAG9 
TRMT1 TMEM51 KMT2D SLU7 DAB2 LEO1 MARCKS 
TTLL12 TELO2 MAF1 NIFK C7orf50 USP15 PGRMC1 
DNAJA2 CCNL1 HDAC4 LYN ZFP91 CDCA3 YAF2 
WDR33 AMFR RAI1 NOP56 MAPK1 MPHOSPH10 
ATAD2 BPTF DENR HNRNPA2B1 HACD3 TLE3 PHF6 
ANAPC2 DNMT1 EPB41L2 TACC1 SLC16A6 PDCL 
ZC3HC1 DYNC1LI1 PEA15 YRDC VPS4B RREB1 
FNBP4 DNMBP FXR2 LIFR ZC3H8 SNAP23 TFDP1 
ARHGAP1 CLASP1 EEF1D MGA TFAP4 AFAP1 
IRF2BP1 CDK13 SRSF10 BCR TWISTNB UTP3 CLINT1 
RTTN PCNP ZFC3H1 RPL15 SMAP RIOK2 KIAA1671 
REXO4 MYCBP2 ABCF1 UFD1 SMARCA4 SEPT2 
RPS6KA4 LATS1 BRD7 ZBTB21 CEP55 EYA3 HOXC10 
NEMF EML4 MED1 ATF2 TMEM245 SRSF1 DIAPH1 
ESF1 LAMTOR1 TRAF4 RRM2 CTPS1 NUDC TOP2A 
SLC20A1 DNAJC2 TOM1L1 IGF1R GOLGA2 TRA2A 
CAMSAP2 RFC1 NOB1 ABCC5 EIF2A GTF3C4 ASMTL 
SNAPC5 MOCOS AFDN TTF1 SLC30A1 NCBP1 TBX3 
SLC9A1 DNAJC21 HDAC2 NEXN PLEC NRDC IL6ST 
SART1 MTDH NCAPD2 HSP90AB1 UBAP2L HSPE1 
PPP4R3A RBM5 NCL EIF4EBP1 PPP1R9B SLC43A2 
TMEM131 WDR44 GPN1 WDHD1 UBE4B MCM2 KRT18 
DBN1 TGS1 LRWD1 PTS RPL27A MCM4 TCEA1 
SPTBN2 OTUD5 TOMM70 OGFR DDX54 ARHGAP5 
DDX21 PWP1 ADAR HTATSF1 ALPI HSF1 POP1 
KMT2A PKN1 WTAP MTA1 GPAM ESYT2 BUB1B 
JMJD1C TIMELESS AKT1S1 DDX10 CCNH SURF6 
MTCL1 PHF14 ERCC6 KIF13A KRT7 TMX1 RRP12 
PHF8 HSPH1 TMEM87A PLEKHA2 DMAP1 ESCO2 
UBA2 SEC62 SRSF2 RAB12 DNTTIP2 DDX51 ZMYM4 
PRKAR1B GBF1 HEXIM2 ZC3H11A VCL TCF3 ZNF106 
C18orf25 SMN1 RANBP10 MKI67 PANK2 NHS PSMD1 
CLSPN DTL EPS8L2 BICD2 SRFBP1 SRSF9 ARL6IP4 
RBMX C19orf24 TGFBR2 LRRFIP2 PAXBP1 PURB 
ACAP2 NAF1 PPP4R2 BUD13 SDE2 SLC39A10 CDCA2 
NFX1 MDN1 PPA2 MED24 MAP3K7 OXSR1 EHD1 
REEP4 RAB11FIP5 PPIP5K2 GTF2I SLC38A1 PPFIA1 
PLCD3 PDS5A CRK NCAPH2 PKM TBC1D15 ADAM17 
ZNF830 CDV3 ZFR ZC3H4 HNRNPA3 NOLC1 ELAVL1 
HNRNPLL NCOA2 USP5 RPP25 ABCA2 CANX EXO1 
DAP CUL4A AJUBA CDC42BPB CIAPIN1 DMD 
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STAMBPL1 TMX2 LYSMD1 TCF20 ZNHIT3 PPM1G 
C9orf40 ELMSAN1 SSH3 TBC1D2 PEX19 RBM39 
PRKAB1 RALGAPA1 SHTN1 KIF20A KLC2 SSX2IP 
EIF2S2 FNDC3B USO1 SIRT1 AREL1 PCBP2 MFAP1 
CLIP1 NEK9 UPF3B RPL23A GTF2IRD1 MORC2 ADNP 
RFFL RBM15B ERICH1 WDR55 DDX39B NUMA1 MIOS 
HDGF TLE4 WRNIP1 TOP2B CNNM3 GIPC1 FAM117B 
TAF15 SORBS3 GMPS ZNF592 MED19 EIF4G2 
GTF3C1 PAGR1 FAM208A SYNPO POLD3 VAMP7 
AMPD2 RSF1 KHDRBS1 MON1A PPP1R18 POU2F1 
GAPDH PHF10 CLNS1A PSEN1 APC NUP43 FUNDC2 
EPS15L1 SEC61B NMD3 RSL1D1 RBM25 CDC42EP1 
TOE1 TPR GATAD2B MAP1S AKAP11 FMNL2 SUPT7L 
HMGA1 WDR3 YTHDC1 TTC33 RANBP2 LIG3 STK38 
TRAFD1 ATP2A2 CTTNBP2NL CAST MGRN1 STRN 
GAB1 PNN PTDSS2 MTMR3 BMP2K TRIM25 DDX3X 
SCAF11 USP39 HNRNPU ATXN2L FLII PRCC CLASRP 
NCAPG CWF19L2 BRAF GOLGA4 RPL14 HNRNPA1 
TMOD3 TMF1 RALBP1 CAAP1 GEMIN5 UBR4 FCHO2 
DDX20 KTN1 FUNDC1 MYBBP1A PHKB SLC16A1 
USP8 SLC17A5 EPHB4 CLN3 MISP STX4 TMEM106B 
MBD1 NDRG3 TP53BP2 VDAC2 ATP2B1 RPS6KA3 
CENPF STT3B SYAP1 BET1 CD3EAP SNX17 HDLBP 
RANGAP1 PITPNM1 HECW1 SGPP1 DCAF8 RPS27 
RLF KLF3 CDCA8 ZNF638 MTFR1 
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Overview of Thesis Work 
In this introduction, I have described the need for more cancer research, even 
though there have been great strides in knowledge and treatment options in just the last 
fifty years. I highlighted the advantage of how studying a rare cancer with a defined 
genetic event in a young person could provide a simpler model for probing at the 
pathogenesis of a cancer, and further described a particular rare liver cancer that 
affects adolescents and young adults as a result of a gene fusion: DNAJB1-PRKACA. I 
also described that although there is much known about PKA biology, we still do not 
have a complete understanding of all substrates of this kinase, let alone its oncogenic 
variant, DNAJB1-PRKACA. Knowing the direct substrates of this oncogenic kinase 
found in FLC can inform therapeutic decisions and contribute to a stepwise 
understanding of the progression of this particular cancer while also furthering our 
understanding of proteins found in pathways involved in other cancers.  
Methods of directly identifying substrates of kinases are non-trivial and each 
method has its own caveats to consider. However, a desirable method should have two 
ways of conferring specificity of the readout: part of the method should ensure the 
amount of activity in the sample is predominately from the kinase of interest and not 
from other kinases in the sample, and another part of the method should ensure that the 
detection of the phosphorylation event from the kinase of interest is distinguishable from 
the phosphorylation event of another kinase in the sample.  With this approach in mind, 
the goal of my thesis work was as follows: To specifically identify the direct 
substrates of DNAJB1-PRKACA that are relevant to the pathogenesis of 
fibrolamellar hepatocellular carcinoma.  
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Chapter II will describe my work to determine a method of substrate identification 
that would yield a robust list of potential substrates of DNAJB1-PRKACA compared to 
PRKACA. The approach I first tested was developed by the Shokat lab and uses an 
analog-sensitive kinase in combination with a selective adenosine triphosphate (ATP) 
analog.  Analog-sensitive kinases have their gate-keeper amino acid in the active 
pocket of a kinase mutated to open up the pocket in a way that allows for the 
preferential selection of an ATP analog that has a bulky group attached to the 
adenosine group. In addition to the bulky group, the ATP analog has a thiol group 
attached to the γ-phosphate that allows for the identification of substrates with a 
thiophosphate versus a regular phosphate. Initially, purified kinases of interest were 
made with a Glutathione S-transferase (GST) tag, but later I switched to a method of 
purification using beads bound to a specific peptide known as Protein Kinase Inhibitor 
(PKI) peptide to purifiy the kinase without a tag; a tagless kinase provides more 
confidence that the kinetics and protein interactions of your purified kinase are reporting 
the behavior of the kinase in situ. We have successfully used this method to purify 
PRKACA. However, the single mutation of the gatekeeper residue for the analog-
sensitive kinases rendered the PKI peptide unable to bind sufficiently to purify the 
kinases. I could have continued with the GST-tagged versions of the kinases instead, 
but I was now more concerned about how greatly the mutation of the gatekeeper 
residue could affect the readout of the potential substrates of interest if a specific binder 
was significantly affected by the single amino acid change. Indeed, other studies have 
found that changing this gatekeeper methionine to an alanine or glycine changed the 
activity of the kinase. Previously, the Shokat lab has also introduced additional 
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mutations in the active site of their analog-sensitive kinases to retain more activity to 
more closely resemble the native kinase. Since my goal was to identify the substrates of 
DNAJB1-PRKACA, this approach could undermine the validity of my results.  
As an alternative, I pivoted to a method that kills the endogenous kinase activity 
of a lysate using 5’-(4-Fluorosulfonylbenzoyl)adenosine (FSBA); this kinase-inactive 
lysate can then be used in a kinase reaction with your purified kinase of interest and an 
ATP analog that has a tag on the γ-phosphate to identify direct substrates via MS. The 
ATP-γ-S analog I initially used for this method was effective in demonstrating kinase 
activity changes via western blots, but the thiol-tags were not reliably identified using 
mass spectrometry. With the improvement of phosphopeptide enrichment methods and 
encouragement from the Proteomics Core, a pilot experiment was done next to enrich 
phosphopeptides from a kinase reaction using FSBA-treated mouse liver lysate and 
either PRKACA and DNAJB1-PRKACA with regular ATP. This pilot yielded promising 
results that showed substrate differences between PRKACA and DNAJB1-PRKACA so 
a triplicate experiment was designed using human hepatocyte lysate instead of mouse 
liver lysate.  
In Chapter III, I will discuss the results of the assay using FSBA-treated human 
hepatocyte lysate in kinase reactions to compare the substrate differences of three 
kinases: DNAJB1-PRKACA, PRKACA, and PRKACA (L206R). The PRKACA (L206R) is 
a variant of PRKACA that is thought to be constitutively active and is found in adrenal 
tumors of patients with Cushing’s disease. Recent publications probe at potential 
substrate differences between PRKACA and PRKACA (L206R) (Lubner et al. 2017; 
Bathon et al. 2019), so this kinase was added to my assay, in part, as a further control 
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of kinase substrate specificity. The data show that the kinases used for the reactions 
were all of similar activity and amount and that the phosphopeptide enrichment from 
each condition was consistent and robust. The raw data was analyzed using MaxQuant, 
and further analysis was done with Perseus and various bioinformatics software to show 
that there are differences in substrate preferences between the three kinds of PRKACA.  
In Chapter IV, I will discuss how the results of a total phosphome study of FLC 
patient tumor and normal samples compare against my in vitro assay that identifies 
potential direct substrates of DNAJB1-PRKACA. This comparison allows for the 
generation of a more focused list of substrates for further study that are capable of 
being phosphorylated by DNAJB1-PRKACA in vitro that also appear phosphorylated in 
FLC tumors.  The thesis will conclude with future directions and discussion of the 
implications for the pathogenesis of FLC based on the direct substrates of interest. 
37 
CHAPTER II: Determining a Method for Substrate Identification of DNAJB1-
PRKACA 
Background and rationale 
In the previous chapter, I described the challenges involved with directly 
identifying substrates of a particular kinase. Each method that was established at the 
time I started pursuing this question had its own pros and cons to consider as previously 
discussed. I chose to start with using the analog-sensitive kinase approach to determine 
if there were substrate differences between PRKACA and DNAJB1-PRKACA. Figure 4 
depicts the workflow of this analog-sensitive kinase method that was previously 
described in detail in Chapter I. The paper describing this method claimed that PRKACA 
could tolerate the mutations necessary to make an analog-sensitive version (Hertz et al. 
2010), which meant DNAJB1-PRKACA should also tolerate the necessary mutations; 
additionally, the first author of this methods paper was at our university and actively 
collaborating with us at the time.   
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Figure 4. Analog-Sensitive Kinase Approach to Identifying Direct Substrates. 
A. Kinase reactions in this method react cell lysate mixtures with analog-sensitive 
kinases that have their gatekeeper residue mutated to allow for the preferential 
selection of a bulky-ATP analogy that has thiophosphate in the gamma position.  
B. Resulting thiophosphoproteins can be alkylated to create a thiophosphate ester at 
the site of phosphorylation that can now be recognized by a specific antibody for 
western blot, immunoprecipitation, and mass spectrometry analysis. 
Thiophosphoproteins can also be trypsinized and enriched for thiophosphopeptides for 
mass spectrometry analysis. Created with BioRender and adapted from (Hertz et al. 
2010). 
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Purifying Recombinant DNAJB1-PRAKCA and PRKACA Using a Glutathione S-
Transferase Tag 
The first step towards attempting the analog-sensitive kinase approach of direct 
substrate identification was to generate purified kinases. I received pET151 protein 
expression plasmid constructs that were previously made in the lab for DNAJB1-
PRKACA and PRKACA that had a thrombin cleavage site and GST tag at the C-
terminal end of each kinase. GST tags allow for a one-step purification of relatively pure 
protein, has established antibodies that can recognize it via western blot analysis, helps 
with solubility of proteins, and was suggested as favorable by a collaborator for a 
different project to try to generate antibodies against DNAJB1-PRKACA.The pET151 
plasmids allow for protein expression from the bacterial T7 promoter upon induction with 
isopropyl β-D-1-thiogalactopyranoside (IPTG) in BL21 (DE3) Competent E. coli. These 
plasmid constructs for the non-analog-sensitive kinases would later serve as templates 
to introduce the necessary gatekeeper mutations for the analog-sensitive mutants via 
site-directed mutagenesis. 
 It was important to first be able to show that I could purify active versions of 
PRKACA-GST and DNAJB1-PRKACA-GST without the gatekeeper mutation and that 
the GST tag could be removed so that the kinase used for in vitro reactions would 
structurally resemble what is found in vivo as much as possible.  
 I used these plasmid constructs to express PRKACA-GST with the thrombin 
cleavage site in BL21 (DE3) Competent E. coli and then successfully purified this kinase 
with glutathione agarose beads. However, when I tested for cleavage of the GST tag 
from PRKACA with thrombin, the entire kinase was degraded (Figure 5). 
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Figure 5. Thrombin Treatment of Purified PRKACA-GST. 
For both the (A) anti-PKA western blot and the (B) anti-GST western blot, the first 
lane contains PRKACA-GST treated with thrombin and the second lane is the 
negative control of PRKACA in the absence of thrombin.  
     Table 2. pET151 Constructs with TEV Cleavage Site. 
DNAJB1-PRKACA Constructs PRKACA Constructs 
DNAJB1-PRKACA-TEV-GST PRKACA-TEV-GST 
DNAJB1-PRKACA-TEV-(GGGGS)-GST PRKACA -TEV-GGGGS-GST 
DNAJB1-PRKACA-TEV-(GGGGS)x2-GST PRKACA -TEV-(GGGGS)x2-GST 
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I decided to use site-directed mutagenesis to replace the thrombin cleavage site 
with a Tobacco Etch Virus (TEV) cleavage site since the sequence is more specific than 
the sequence cleavage site for thrombin (Waugh 2011). I also took this opportunity to 
make more constructs that also included a flexible linker to the carboxyl side of the TEV 
cleavage site in case the cleavage was sterically hindered by the close proximity of the 
kinase and GST (Table 2). 
Once I had the constructs in Table 2, I expressed and purified DNAJB1-
PRKACA-TEV-GST, DNAJB1-PRKACA-TEV-(GGGGS)-GST, and DNAJB1-PRKACA-
TEV-(GGGGS)x2-GST. I then tested for cleavage of the GST tag from DNAJB1-
PRKACA with TEV protease over the course of four hours. Figure 6 shows that the 
flexible linker was indeed necessary for efficient cleavage of GST from DNAJB1-
PRKACA with TEV protease. Concurrently, I tested the activity of these three versions 
of DNAJB1-PRKACA using ADP-Glo (Promega). This method uses two reactions to get 
a readout of kinase activity. First, a reaction with the kinase of interest and a substrate, 
in this case a known PKA substrate called Kemptide, is conducted with a consumable 
amount of ATP for a defined period of time. Then luciferin and luciferase are added to 
the mixture for a second reaction. In this second reaction, luciferase catalyzes the 
mono-oxygenation of luciferin to yield oxyluciferin and one photon of light in the 
presence of ATP. Light will be detected after the second reaction if any ATP is left from 
the first. The less light that is detected, the more active the kinase was from the first 
reaction. If no light can be detected, then the kinase consumed all the ATP in the first 
reaction. Light was only detected in the no kinase control and not detected with all three 
versions of DNAJB1-PRKACA. 
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Figure 6. Time-Course of TEV Cleavage of DNAJB1-PRKACA-GST of  
Varying Linker Length. 
The red boxes represent DNAJB1-PRKACA, the blue boxes represent GST, the 
blue rectangles represent the TEV cleavage site, and the green rectangles 
represent one GGGGS flexible linker. Each row corresponds to the same 
molecular weight in the three tested conditions with different linker lengths. The 
top three rows are western blots probed with an anti-PKA antibody. The middle 
three rows are western blots probed with anti-GST antibody. And the last three 
rows are stained with coomassie to visualize total protein at that molecular 
weight.  
At this point, I now knew the conditions needed to produce cleaved and active 
DNAJB1-PRKACA and was ready to proceed to making the analog-sensitive mutants. 
However, a collaborator then suggested a different purification method that would allow 
for tagless purification of PRKACA and perhaps DNAJB1-PRKACA (Olsen and Uhler 
1989). 
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Tagless Purification of Analog-Sensitive Mutant Kinases Reveal a Methodological 
Concern  
A visiting student in our lab at the time, Solomon Levin, tried the tagless 
purification method for both PRKACA and DNAJB1-PRKACA in pET151 protein 
expression vectors with great success. This method takes advantage of a well-studied 
small specific peptide (PKI) that can reversibly bind to the active site of PRKACA (Olsen 
and Uhler 1989). This peptide is bound to agarose beads, similar to a GST purification, 
to efficiently and specifically purify PRKACA and DNAJB1-PRKACA. I was able to 
repeat this kind of purification as shown in Figure 7.  
Figure 7. Tagless Purification of DNAJB1-PRKACA. 
Both the (A) anti-PKA western blot and the (B) the coomassie, show a robust 
band around 46kDa, which is the weight of DNAJB1-PRKACA. 
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Using site-directed mutagenesis on the pET151 constructs for DNAJB1-PRKACA 
and PRKACA, I changed the gatekeeper residue from methionine to either alanine or 
glycine to see if one mutation worked more favorably than the other. However, 
introducing this point mutation rendered the tagless purification method ineffective as 
shown in Figure 8.   
I expected some decrease in purification efficiency since the method relied on 
the specific binding of a small peptide, but to see such a dramatic loss of purification 
efficiency was alarming. While it was possible to make these analog-sensitive mutants 
with the GST-tagged constructs I previously showed I could express and purify kinases 
from, it seemed unfavorable to move forward with a kinase that exhibited such a large 
change in active site binding capabilities when the goal of my project is to determine 
whether two similar kinases, DNAJB1-PRKACA and PRKACA, display a difference in 
substrate specificity. Since I now had a way of purifying the kinases without a tag, I also 
wanted to use a method that did not require any additional mutations so the structure of 
the purified kinase would be one less caveat to interpreting any data.  
At this time, I learned about 5’-(4-Fluorosulfonylbenzoyl)adenosine (FSBA) from 
the recently published K-BILDS methods paper (Embogama and Pflum 2017). FSBA 
irreversibly inhibits many kinases by reacting with a catalytic lysine in the active site. By 
treating cell lysates with FSBA, it is possible to significantly knockdown kinase activity.  
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Figure 8. Purification of DNAJB1-PRKACA to Analog-Sensitive DNAJB1-PRKACA. 
(A-D) are Coomassie stained to visualize total protein content. (E-H) are western blots 
with an anti-PKA antibody to detect the presence of the DNAJB1-PRKACA, here 
marked as ‘Chimera’. AS1 correlates to changing the gatekeeper methionine to a 
glycine and AS2 correlates to changing the methionine to an alanine. (A-G) are the 
results of protein purifications and (D and H) depict the protein detected after a 
necessary buffer exchange. 
46 
FSBA Inhibits Endogenous Kinase Activity in HeLa Cells and Mouse Liver Lysate 
I pivoted to this method that knocks down the endogenous kinase activity of a 
lysate using FSBA. This would allow for the kinase-inactive lysate to be used in a kinase 
reaction with a purified kinase and an ATP analog that has a tag on the γ-phosphate to 
identify direct substrates via MS. Figure 9 graphically summarizes the K-BILDS method 
discussed in Chapter I. This method uses an ATP with a biotin tag on the gamma 
phosphate but making this ATP analog is non-trivial.  
I chose to modify this approach and use a commercially available ATP-γ-S 
analog instead; this experimental setup is shown in Figure 10. First, a cell lysate would 
be treated with FSBA to knock down endogenous kinase activity. It is crucial to 
sufficiently remove unbound FSBA after treatment so that no residual FSBA will inhibit 
the activity of the added purified kinase. The purified tagless PRKACA or DNAJB1-
PRKACA would then be added to the inactive lysates with ATP-γ-S to yield 
thiophosphorylated substrates. Using purified PRKACA or DNAJB1-PRKACA without a 
tag allows for kinase reactions with the kinases in as unmodified of a state as possible 
in an in vitro setting. At this point, the thiophosphorylated substrates could either be 
alkylated to yield a thiophosphate ester that could be recognized by an established 
antibody (Abcam, ab92570) or, alternatively, these thiophosphorylated substrates could 
be trypsinized and enriched for thiophosphopeptides to be identified by MS. If the 
thiophosphorylated substrates are alkylated to produce a thiophosphate ester tag, the 
samples could be run on a gel to visualize changes in thiophosphorylation patterns by 
western blot or in-gel digested for MS analysis to identify the substrates. These 
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thiophosphate esters could also be used to immunoprecipitate the substrates containing 
the tag with a specific antibody (Abcam, ab133473) for MS analysis.  
Figure 9. K-BILDS Method Schematic. 
Created with BioRender and adapted from (Embogama and Pflum 2017). 
48 
Figure 10. Substrate Identification Method Schematic Combining FSBA and Thiol-
Tags.  
This method combines aspects of the analog-sensitive kinase work flow with the K-
BILDS work flow to maximize available resources. Created with BioRender. 
My first step of setting up this pipeline was to show that I could also knock down 
kinase activity in HeLa lysates with FSBA as I saw in the K-BILDS paper, and to then 
see if I could visualize increased activity when adding PRKACA or DNAJB1-PRKACA to 
the inactivated-lysate. FSBA needs to be dissolved in DMSO and the final concentration 
of DMSO added to the lysates upon FSBA treatment is 20 mM. There was concern that 
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this high DMSO concentration could be solely responsible for any decrease in kinase 
activity seen. Figure 11a does show that there is a large decrease in activity between 
untreated and lysates treated with DMSO at 20 mM, but there is a further decrease of 
activity between the DMSO treated and FSBA treated lysates. Just a reminder that after 
FSBA treatment, FSBA is thoroughly washed out along with the DMSO so its presence 
is not directly affecting the kinase reaction. Figure 11a also shows that when both 
PRKACA and DNAJB1-PRKACA are added activity does increase as evidenced by the 
darker bands; this effect may seem light in western blots but is at least comparable to 
what is seen in previously published work for this method. Mass spectrometry is more 
sensitive and should pick up even more than the visible differences. Since FLC is a 
disease of the liver, I wanted to identify substrates of these kinases from the liver. To do 
this, I harvested and lysed mouse livers with a technician in the lab to create a large 
pool of mouse liver proteins to use instead of HeLa cells. Once I obtained this lysate, I 
also wanted to see if more phosphorylation could be detected by western blot if more 
kinase was added and indeed more phosphorylation can be detected with increasing 
amounts of PRKACA (Figure 11b). Figure 11b also demonstrates that the kinases in 
mouse liver lysate are not significantly inhibited by 20 mM DMSO, but they are greatly 
inhibited by 10 mM FSBA.  
Interestingly, another lab published a substrate identification paper with a very 
similar method of FSBA kinase inhibition in a cell lysate and ATP-γ-S to be able to tag 
substrates for the PNG kinase (Hara et al. 2018). They also first attempted to use the 
analog-sensitive kinase approach but found that the gatekeeper mutations rendered the 
PNG inactive. It is possible to introduce other mutations to compensate for this change 
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in activity, but at the point where you are introducing multiple mutations into a crucial 
part of the kinase, it is hard to have confidence in the accuracy and specificity of 
substrates identified using this mutant kinase.  
Figure 11. Purified Kinases Phosphorylate FSBA-Treated Lysates. 
A. Kinases are inhibited in HeLa lysate by FSBA and DMSO, but more phosphorylation 
or kinase activity is seen when either kinase is added.  
B. Kinases are inhibited in mouse liver lysate by FSBA but not by DMSO. Increasing 
amounts of PRKACA demonstrate that the increase in phosphorylation is due to the 
amount of purified kinase added. western blots used thiophosphate ester specific 
antibody from Abcam (ab92570). 
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Ineffective Substrate Identification via Mass Spectrometry from Kinase Reactions 
Using ATP-γ-S  
The workflow in Figure 10 was currently working to the point of being able to 
visualize activity changes via western blot with the anti-thiophosphate ester antibody. I 
was initially planning on doing a thiophosphopeptide enrichment by trypsin digesting the 
initial kinase reaction with FSBA-treated lysate, DNAJB1-PRKACA or PRKACA, and 
ATP-γ-S, and then pulling out the thiophosphopeptides with iodoacetyl agarose beads. 
This mixture could then be treated with Oxone to release the thiosphosphate ester 
linked peptides by spontaneous hydrolysis and identified by mass spectrometry (Hertz 
et al. 2010; Allen et al. 2007). However, after reading the recent paper identifying 
substrates of PNG kinase, I learned that they collaborated with Sebastian Lourido, who 
had a custom fast protein liquid chromatography (FPLC) system that yielded better 
results (Rothenberg et al. 2016). I put off trying the thiophosphopeptide enrichment in 
favor of contacting him for a potential collaboration. In the meantime, I attempted to 
identify the thiophosphopeptides via in-gel digestion or immunoprecipitation (IP).  
At this time, I also learned of work being done in the Rice lab by Lefteris 
Michailidis and Ype de Jong that allows for an efficient method for growing human 
hepatocytes in mice and harvesting them for experimental use. While there is great 
homology between mouse and human liver proteins, I wanted to carry out these 
phosphorylation experiments in as close to the same liver substrate pool as is available 
to DNAJB1-PRAKCA in patient FLC tumors. It is possible, but unlikely, that the cell of 
origin of FLC are not hepatocytes, but human hepatocyte lysate would still provide a 
pool of human substrates from the same organ of disease that I believe could be more 
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relevant than mouse liver lysate to dissecting possible phosphorylations critical for FLC. 
I obtained a small aliquot of these cells to lyse and test if endogenous kinase activity 
could be diminished with FSBA treatment. Figure 12A shows that overall activity in the 
untreated human hepatocyte lysate is significantly less than the activity in the untreated 
lysate from mouse livers seen in 11B, but activity is still diminished upon FSBA 
treatment. Though similar to the mouse liver lysate, the endogenous kinase activity of 
the human hepatocyte lysate does not seem to be affected by 20 mM DMSO treatment 
(Figure 12A). This makes the human hepatocyte lysate an even more advantageous 
lysate to use moving forward. 
I used the remaining FSBA-treated hepatocyte lysate I had at the time to do a 
comparison of thiophosphopeptides identified via in-gel digestion between the mouse 
liver lysate and human hepatocyte lysate. The western blots from these kinase 
reactions show increased activity in the presence of DNAJB1-PRKACA in mouse liver 
lysate and human hepatocyte lysate, but only an increased pattern of activity was seen 
when PRKACA was added to mouse liver lysate and not human hepatocyte lysate (12B 
and C). This was only a single replicate visualized once by western blot, but these 
same blots were probed with an anti-PKA antibody that showed similar amounts of the 
kinases were definitely added (Figure 12D and E), and the kinases used for these 
reactions came from the same aliquot, so this was an unexpected result. Working with 
Soren Heissel in the Proteomics Resource Center, bands were excised from a 
coomasie stained gel in the places where thiophosphate ester tags were visualized via 
western blot as indicated by the red (Figure 12F-H).  
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Figure 12. In-Gel Digestion of Kinase Reactions with ATP-γ-S in Mouse Liver 
Lysate and Human Hepatocyte Lysate. 
(A) FSBA-treatment of human hepatocytes. (B, D, and F) western blots of kinase 
reactions with FSBA-treated mouse liver lysate. (C, E, and G) western blots of kinase 
reactions with FSBA-treated human hepatocyte lysate. (H) Bands were cut out from this 
coomassie stained gel for in-gel digestion and MS analysis. The red boxes on this gel 
match the red boxes on the blots in F and G. (A-C, F, and G) western blot with anti-
thiophosphate ester antibody. (D-E) western blot with anti-PKA antibody.  
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There were more than 7600 peptides identified from MS analysis for this 
experiment, but only a handful had what could be considered a thiophosphate tag on an 
amino acid (Table 4). When the kinase used ATP-γ-S to phosphorylate a substrate, a 
thiophosphate group was added to an amino acid, most likely serine or threonine since 
PRKACA is a Ser/Thr Kinase. This thiophosphate was then alkylated with PNBM to 
create a thiophosphate ester. As noted in the paper from the Shokat lab (Allen et al. 
2007), this structure can fragment, leaving a different signature behind which is denoted 
as ‘TPE D’ in Table 4 and Table 5. The non-fragmented thiophosphate ester is denoted 
as ‘Thiop’ for these tables.  The MS searches for these structures were conducted as 
previously published (Allen et al. 2007).  
To compare the thiophosphopeptides found at the same molecular weight in the 
different conditions, I grouped the bands that were cut out for the in-gel digestion into 
‘Band Groups’ based on which kinase was present in the initial reaction. These ‘Band 
Groups’ are listed in Table 3 with their corresponding members and used in Table 4 to 
easily visualize which ‘Band Group’ a thiophosphopeptide was identified from. None of 
the thiophosphopeptides identified in these gel digestions belonged to proteins that 
were established PKA substrates, and only Krt17 and Canx were also initially identified 
in the wide-reaching screen from Imamura, et al but not in the other published lists of 
putative substrates. If a thiophosphopeptide was identified in the ‘No Kinase’ Band 
Groups, it should have been identified in all of the corresponding bands for PRKACA 
and DNAJB1-PRKACA; this was not the case. The minimal detection of 
thiophosphopeptides and lack of consistency was very discouraging. 
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Table 3. Band Cut Outs for In-Gel Digestion and MS Identification of 
Thiophosphopeptides. 
Band Groups for Comparison Corresponding Red Box Label 
from In-Gel Digestion 
PRKACA Band 1 Mouse-9; Human-1 
PRKACA Band 2 Mouse-11; Human-2 
DNAJB1-PRKACA Band 1 Mouse-13; Human-3 
DNAJB1-PRKACA Band 2 Mouse-14; Human-4 
No Kinase Band 1 Mouse-17; Human-7 
No Kinase Band 2 Mouse-19; Human-8 
Table 4. Thiophosphopeptides Identified Using In-Gel Digestion and MS. 
I also continued with the IP experiment using mouse liver lysate since I already 
had the materials, and there would be a lag time before I could receive more human 
hepatocytes to lyse and treat with FSBA. For the IP of substrates with thiophosphate 
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ester tags, I prepared three 1mg samples of FSBA mouse liver lysate that either had no 
kinase added, 10ug of DNAJB1-PRKACA added, or 10ug of PRKACA added with ATP-
γ-S. The three possible results I was hoping to see from the IP were examples of a 
thiophosphopeptide in: 1) just the sample treated with DNAJB1-PRKACA, 2) just the 
sample treated with PRKACA, or 3) both the samples treated with DNAJB1-PRKACA or 
PRKACA but not the sample without added kinase. Before submitting the IP samples to 
the Proteomics Core for MS analysis, I took a small aliquot to run on a gel to ensure that 
increased activity was visualized via western blot in the samples that had kinases added 
and that protein content was consistent between the samples as visualized by 
coomassie staining (Figure 13).  While thiophosphopeptides were also identified in the 
no kinase control as seen previously, the signal was stronger in the conditions with 
added kinase which was promising for the mass spectrometry results since the total 
amount of protein also looked consistent between samples in the Coomassie stained 
gel.  
However, there was only a single potential candidate protein identified in each of 
the predicted categories as seen in Table 5. Only Wipi2 was identified in a previous 
PKA substrate screen, but again it was the Imamura, et al. screen that initially casted a 
very wide net of putative substrates. Also, in this experiment, Wipi2 was recognized by 
DNAJB1-PRKACA and not PRAKCA. Even though this pilot IP experiment with mouse 
liver lysate only had one sample per condition; these results were very discouraging. It 
is additionally notable that only the degraded thiophosphate ester structure was able to 
be identified in this experiment.  
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Figure 13. Immunoprecipitated Thiophosphopeptides from Kinase 
Reactions with FSBA-treated Mouse Liver Lysate and ATP-γ-S.  
A. The thiophosphate ester antibody (ab92570) was used to visualize the 
amounts of thiophosphorylated substrates that were immunoprecipitated from 
kinase reactions with ATP-γ-S.  
B. Coomassie staining shows that the amount of protein loaded from each 
sample was fairly consistent. It is also possible to see the band at 41kDa for 
PRKACA that was added. The DNAJB1-PRKACA band at 46kDa seems to be 
masked by other proteins at the same molecular weight, but the band is slightly 
darker where this kinase should be as well.  
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Table 5. Thiophosphopeptides Identified by MS from Proteins 


















S8(TPE D) STESQLMSKGDADTK 
The thiophosphopeptide enrichment was never attempted in our lab since there 
was such difficulty identifying these specific tags with our Proteomics Resource Center 
using the published mass and structures. We also did not move forward with the 
collaboration to alternatively enrich thiophosphopeptides using a custom FPLC system. 
However, the ATP-γ-S and anti-thiophosphate ester antibody have been extremely 
useful tools to assess the knockdown of endogenous kinase activity in a cell lysate with 
FSBA. 
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Phosphopeptide Enrichment from Kinase Reactions with ATP is Sufficient to See 
Differences in Substrate Specificity in Mouse Liver Lysate 
With current phosphopeptide enrichment technology, I was encouraged by 
members of the Proteomics Resource Center to try kinase reactions with regular ATP to 
see if we could detect increased phosphorylation upon addition of DNAJB1-PRKACA or 
PRKACA in FSBA-treated liver lysates. Since at this point, I was still waiting for more 
human hepatocytes to lyse, I did a pilot experiment using FSBA-treated mouse liver 
lysate for a kinase reaction with regular ATP in single replicates in three conditions: 
added PRKACA, added DNAJB1-PRKACA, and no kinase added. Phosphopeptide 
enrichment was done by Soren Heissel in the Proteomics Resource Center, using in-
house constructed titanium dioxide microtips followed by Thermo’s High-Select Fe-NTA 
Phosphopeptide Enrichment Kit. A generalized overview of how this experiment was 
carried out is depicted in Figure 14.  
Figure 15 clearly demonstrates that phosphopeptides are more abundant when 
either the DNAJB1-PRAKCA or PRKACA are added to a kinase reaction. Analysis of 
the identified phosphosites was performed within the Perseus framework (v. 1.6.1.3). 
The histograms in Figure 15C are not normalized since this pilot experiment was not 
done in triplicate, but the raw intensity measurements still clearly show that the amount 
and distribution of phosphopeptides identified in the samples with kinases added is 
more abundant than when no kinase is added.  
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Figure 14. Schematic Overview of a Method to Identify Phosphopeptides 
Using FSBA-Treated Lysates.  
FSBA is still used to knock down endogenous kinase activity in a cellular lysate 
(A). Then separate kinase reactions are carried out with either ATP or ATP-γ-S 
and the kinase of interest (B). Thiophosphorylated substrates are then alkylated 
and run on a gel to be able to visualize FSBA knockdown of endogenous kinases 
and increased activity upon kinase addition (C). Then the phosphorylated 
substrates obtained from the kinase reaction in B can be digested and enriched 
for phosphopeptides and analyzed by MS.  
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Figure 15. Phosphopeptide Increase in Presence of Added Kinases in FSBA-
Treated Mouse Liver Lysate.  
Western blots using an (A) anti-thiophosphate ester antibody (ab92570) and a (B) 
Phospho-(Ser/Thr) Antibody from CST (9631) against different kinase reactions. (C) 
Histograms of raw intensity measurements of enriched phosphopeptides (x-axes). (D) 
Scatter plots of raw intensity measurements of enriched phosphopeptides. 
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Each individual point on the scatter plot in Figure 15D represents a unique 
phosphopeptide that was identified in their respective samples at their particular 
intensity (or prevalence) in the sample. The scatter plots show that a great portion of the 
reaction with DNAJB1-PRKACA added or PRKACA added differ in prevalence 
compared to when no additional kinase was added. Since DNAJB1-PRKACA and 
PRKACA both have the active site of their kinase encoded by the same exon, it is not 
surprising that the majority of phosphopeptides identified in both samples are similar to 
each other. However, it is exciting to see that there are quite a few phosphopeptides 
that are unique to both of these samples.  
To clearly represent this difference seen in potential substrates, the gene names 
of all unique proteins with phosphopeptides were inputted into the proportional Venn 
diagram webtool, BioVenn (Hulsen et al. 2008). 360 proteins were identified with 
phosphorylation sites in the reactions with added kinases that were not present in the 
reaction with no added kinase.  And excitingly, 64 proteins were only identified in the 
reaction with DNAJB1-PRKACA added. Granted, since this is just a single sample per 
condition, the possibility of a false positive here is high. However, these were highly 
encouraging results to move forward and repeat this experiment in triplicate in the 
human hepatocyte lysate. Especially since in this experiment, many known and 
suggested PKA substrates were able to be identified (Table 6).  
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Figure 16. Venn Diagram of the Number of Mouse Proteins with Phosphosites 
Found in Samples with PRKACA, DNAJB1, or No Kinase Added.  
500 unique proteins with identified phosphosites from the sample with PRKACA added 
is represented in red on the right. 230 unique proteins with identified phosphosites from 
the no kinase added sample is represented in grey in the middle. 572 unique proteins 
with identified phosphosites from the sample with DNAJB1-PRKACA added is 
represented in green on the left. This proportional Venn Diagram was generated using 
Biovenn (Hulsen et al. 2008).  
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Table 6 was generated similarly to Table 1, but since there are more than five 
conditions, it is not possible to have this represented in an image with this software. 
However, the information from the table generated by the same Bioinformatics and 
Evolutionary Genomics Venn diagram web tool 
(http://bioinformatics.psb.ugent.be/webtools/Venn/) is more informative. The previous 
comparison of the five published methods had a total of 1713 putative PKA substrates; 
this table shows that between DNAJB1-PRKACA and PRKACA in this in vitro assay in 
mouse liver lysate, 339 more putative substrates were added to this list to total 2052 
putative substrates of a PKA kinase. 
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Table 6. Gene Name Overlap of Putative PKA Substrates from Five Published 
Methods and the in vitro Mouse Data. 
Overview of Studies 
Study Identifying 
Substrates 
Total Number of Putative Kinase Substrates 
Embogama, et al. 279 
Hamaguchi, et al. 45 
Hu, et al. 301 
Imamura, et al. 1132 
Isobe, et al. 197 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
454 
PRKACA in vitro  
Mouse Liver Lysate 
392 
Total Number of Unique Putative Kinase Substrates: 2052 
Specific Overlaps Between Studies 




Overlap of Putative Kinase Substrates 
Hamaguchi, et al. 
Hu, et al. 
Imamura, et al. 
Isobe, et al. 
1 CAD 
Hamaguchi, et al.  
Imamura, et al. 
Isobe, et al. 
PRKACA in vitro  
Mouse Liver Lysate 
1 TNKS1BP1 
Embogama, et al. 
Hu, et al. 
Imamura, et al. 
Isobe, et al. 
1 SPTBN1 
Imamura, et al. 
Isobe, et al. 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
10 NSFL1C CTNND1 COBLL1 IRF2BP2 
ARHGAP17 PRKAR2A ARPP19 EIF4B 
OPTN YBX3 
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Embogama, et al. 
Hamaguchi, et al. 
Hu, et al. 
Imamura, et al. 
1 PDE3A 
Embogama, et al.  
Imamura, et al. 
Isobe, et al. 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
1 LMNA 
Hu, et al. 
Imamura, et al. 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
7 NPM1 STMN1 NDRG1 TRIM28 ARFGAP2 
LASP1 HSP90AA1 
Embogama, et al. 
Hu, et al. 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
2 YWHAH PRKACA 
Embogama, et al. 
Hamaguchi, et al.  
Imamura, et al. 
PRKACA in vitro  
Mouse Liver Lysate 
1 RPLP2 
Embogama, et al.  
Imamura, et al. 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
7 SLC9A3R1 SPAG9 EGFR PDIA6 
MARCKSL1 GORASP2 KHSRP 
Hu, et al. 
Imamura, et al. 
Isobe, et al. 
2 SMARCAD1 PCM1 
Hu, et al. 
Isobe, et al. 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
2 CTNNB1 BAD 
Hu, et al. 
Isobe, et al. 
PRKACA in vitro 
Mouse Liver Lysate 
1 LSR 
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Hamaguchi, et al. 
Imamura, et al. 
Isobe, et al. 
5 SPECC1L SIK2 REPS1 LIMCH1 DENND4C 
Imamura, et al. 
Isobe, et al. 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
3 TJP1 YAP1 WNK1 
Embogama, et al.  
Isobe, et al. 
PRKACA in vitro  
Mouse Liver Lysate 
1 AGPS 
Isobe, et al. 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
8 CCS SRP14 NCK1 MIA3 HSPA4 SNX2 
PLEKHF2 KARS 
Embogama, et al. 
Hu, et al. 
Imamura, et al. 
9 NASP YWHAZ GFPT1 CTTN SMARCC2 
ACACA YWHAE ZYX FLNA 
Hamaguchi, et al. 
Hu, et al. 
Imamura, et al. 
1 RAF1 
Hu, et al. 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
8 STK24 LRP1 MYLK CRIP2 CBX3 VASP 
PRDX5 ARHGDIA 
Embogama, et al.  
Imamura, et al. 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
1 DPYSL2 
Imamura, et al. 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
42 BET1L UBA1 RBM17 HSPD1 ATP11C DDI2 
GPS1 ACLY HMOX1 EEF1D PCNP NUDC 
HSP90AB1 TCEA1 HTATSF1 EPS8L2 
PPIP5K2 USP5 SHTN1 GAPDH SEC61B 
DBNL EIF6 TPD52L2 PRDX6 SNRNP70 
VAPA HUWE1 ZNRF2 SEC22B OCIAD1 
ALDOA DIS3L2 RANBP3 PHACTR4 
MARCKS CANX EIF2S2 MIOS HDGF 
GMPS CLNS1A 
Embogama, et al. 
DNAJB1-PRKACAc in 
vitro Mouse Liver Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
19 ECHS1 TKT HYOU1 NUCB1 SARS ETFA 
MTHFD1 ACAA2 SBDS RNH1 CAT CLTB 
SDHA PGK1 ACADS PSME1 PRKCSH CLU 
ST13 
68 
Hamaguchi, et al. 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate  
PRKACA in vitro  
Mouse Liver Lysate 
2 CDK18 DAPK2 
Hu, et al. 
Isobe, et al. 
7 NUP133 LRRFIP1 SRC ZHX1 NFKB1 MAP2 
SUFU 
Imamura, et al. 
Isobe, et al. 
52 MYO9B TNS3 PI4KB ATG2B ARHGAP21 
DCP1A XRN2 DYNC1H1 OSBP SORBS2 
FAM83H PXN ARFGEF2 IRS2 EIF5B PUM2 
HECTD1 CTNNA1 TXLNG RBM14 PRKD2 
MARK2 NCOR1 C2CD2L FKBP15 
RAB11FIP1 ABCC1 ARHGAP35 DOCK7 
ABLIM1 MEF2D SQSTM1 BNIP2 ENAH 
LIMA1 WWC1 PLEKHG3 SIPA1L1 PKN2 
RIN1 AKAP1 MAP3K2 MICAL3 FBL 
PRRC2A OSBPL11 TJP2 HPS5 LARP4B 
PARD3 PUM1 ITPR3 
Hamaguchi, et al. 
Isobe, et al. 
6 NF1 RPL18A KIAA1522 ARHGEF7 NHSL1 
PITPNM3 
Isobe, et al. 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
2 SAYSD1 GOLGA5 
Isobe, et al. 
PRKACA in vitro  
Mouse Liver Lysate 
1 CASP6 
Hu, et al. 
Imamura, et al. 
36 CD44 HSPB1 LUZP1 TERF2IP SMC3 
DNAJC5 NCOA3 NEDD4L FYN SAFB2 
TRIP10 EIF4ENIF1 LIG1 LARP4 DNM1L 
PDE3B ANKS1A MATR3 PTPN12 CDCA7L 
STUB1 LARP1 VIM PRKAR1A HIRIP3 
PYGO2 FOXP4 SP100 EMD ATRIP LAS1L 
TBC1D10B AKAP13 CHAF1B UHRF1 
CEBPB 
Embogama, et al. 
Hu, et al. 
8 YWHAG PSMC5 MSN TGM2 HLA-A PTBP1 
XPO1 PSMA8 
Hamaguchi, et al. 
Hu, et al. 
2 CAMKK1 C19ORF21 
Hu, et al. 
PRKACA in vitro  
Mouse Liver Lysate 
1 ASPSCR1 
Embogama, et al. 
Imamura, et al. 
43 PDHA1 CLUH PALLD YWHAQ RANBP1 
HNRNPK BAG3 NACA MYO1E HNRNPD 
SF3A1 EFHD2 BOD1L1 SSB PPP6R3 
HDAC1 IGF2R MCMBP SRRM2 TCOF1 
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MAP4 PSMA3 ACTL6A KDM5C SLC1A5 
RCC2 INF2 EPRS CAP1 FLNB TP53BP1 
EIF4G1 LRRC47 TK1 SLC4A1AP SLC16A3 
EDC4 PAICS SUPT6H MAGED2 SERBP1 
EIF3G PAK2 
Hamaguchi, et al. 
Imamura, et al. 
4 SAFB ZNF318 C2CD5 ACIN1 
Imamura, et al. 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
12 PCBP1 EIF3H PRCC WASL APMAP SZRD1 
ACSS2 PGRMC1 PEA15 CDV3 DAP CLIP1 
Imamura, et al. 
PRKACA in vitro  
Mouse Liver Lysate 
4 TMEM230 BCL2L13 UBA2 STRN 
Embogama, et al. 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
3 TLN1 ARFIP1 PSME3 
Embogama, et al. 
PRKACA in vitro  
Mouse Liver Lysate 
3 LAP3 AP2M1 CP 
Hamaguchi, et al. 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
1 KLC4 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA in vitro Mouse 
Liver Lysate 
257 CNBP ACOT12 HMGCS2 NDUFS1 SLK 
CLTA ALDOC HSPA1L VWA5A BHMT 
DSTN ALDH2 C3 LCMT1 GCLM SCP2 
NDUFS4 GPD1 FAM213B CES1F ELAC2 
PSMD11 ALAD SNX6 NDUFA2 BTF3 
UCHL4 GM20425 RPS21 ATP1A1 PFKL GC 
CYP2C70 ALDH6A1 PHB2 WDR91 LXN 
CNGA2 SET ATP5H AKAP2 ACADVL FDX1 
TALDO1 SEPHS1 SNRPG SERPINA1B 
DECR2 CYP2B10 GATD3A EPN1 RPL24 
MAVS VCP ALDH5A1 CES3A URAD 
MOCS1 SNAP29 SDS ASNA1 FCGRT 
TSSC4 ASL SASH1 ACADM NAMPT TTC36 
OXSM CMC2 NECAP1 APOH NDUFV1 
GIMAP4 CFL1 F13B AKR1D1 D2HGDH 
DNAJC8 BCKDHA ACSL1 CDC42EP5 
MRPS31 SEMA6D MRPS36 TST CCDC180 
NADK H2-KE6 NDUFB11 CPOX EVA1A 
CYP4F17 PPP1R11 CPS1 MESD LCP1 
EIF4H ETFB IDH1 CFDP1 TIMM50 HDGFL2 
CALD1 HIBADH ALB AKR1C6 ERRFI1 
GPX1 CIDEB FTL1 LBH ACTG1 MTFR1L 
KEG1 HSD17B6 CYP2A5 TYMP 
SERPINA1C COMT UQCRC2 ACTR3 
GPHN ADH1 CNPY2 JPT1 RIDA ACOT1 
70 
NAXE LDHD DNAJB1 CA14 LYPLA1 
ACAT1 TAGLN2 RAPH1 AFG3L2 SULT2A8 
MRPL12 PARVA PKLR KIF5B PIGR NT5C 
GM9774 RAB21 TUBA1B PSMC6 SSR3 
CORO1B SERPINA3N EARS2 SELENBP2 
UQCRFS1 AKR7A2 CALR SPR SULT2A1 
OXR1 SLIRP DHTKD1 CYP2E1 CTH 
ATP5F1A GYKL1 GSDMDC1 CYP2F2 
ALDH7A1 TOM1 DNAJC12 AMACR 9-Sep 
GOPC PNPLA8 GLYCTK ADCY10 ASGR1 
EEF1A1 ATP5PF IDH3A ACSM5 PSMA2 
GLUD1 HPD EEF2 HMGN5 DPP3 ISOC2A 
ATP6V1B2 NSF CYP1A2 SERPINA3K 
ACAD9 PYGL STARD10 NUBP1 ETFDH 
HSPA9 ALDH8A1 ENSA ETHE1 PRODH 
ACAT2 GNMT PPP2R1A GLUL HNRNPAB 
ALDH1A1 FMO5 HSP90B1 SMOC1 GSTA3 
NIT1 GRN SNX3 INMT AFMID ACSF3 
THUMPD1 KIF13B UBQLN1 TIMM44 
FAM162A MTSS1 SARDH ATP5F1B UGP2 
GPRIN3 NNT ANK3 ATP5C1 P4HB ZFP69 
COX4I1 AMT HSD11B1 BOLA1 GPT2 
ALDOB CYP2D22 CTSZ APOA1 SEPHS2 
FTCD AGMAT ECI1 ATIC MUG1 APPL1 
LRPAP1 PNPO AARS S100A13 CCDC9 
SERHL ACAA1B CBR1 
Isobe, et al. 93 CHD9 PDLIM2 SPIRE2 MIB2 TOMM34 
SEC23IP IRS1 ZZEF1 TIAM1 PSMF1 
OSBPL10 PPM1H TAB2 HBP1 ATP6V0A2 
MAP4K3 CLIP2 SLC7A6OS MRPS9 
PTPN14 BLOC1S5 TMEM259 PCYT1B 
MRPL37 ZNF608 KIAA1109 DOCK1 
EIF2AK2 WDTC1 CGNL1 KLHDC7A 
WDFY3 TIAM2 SLAIN2 ARHGAP29 
BORCS6 ERBIN JUP PBXIP1 CHCHD6 
FGD3 SNX12 VIPAS39 DOPEY1 RAB18 
PHLDB2 KAZN BAIAP2 PARD6B VEPH1 
MAP3K5 TBC1D12 NEK4 PI4KA MYO5B 
CAMK2D ARHGEF2 CASP8 ITSN2 NULL 
VILL MTOR PEAK1 EPS8L1 LYST MTCH1 
WDR4 CLMN KLC3 IGSF5 MAP4K5 
UHRF1BP1L SCYL2 AFAP1L2 ERBB3 
SSH1 PURG SHROOM3 AP3D1 NFATC2 
MPDZ COBL HERC4 ARHGEF17 SNX1 
RTKN CGN SKT MAP4K4 PTPN13 TNS2 
ARHGAP27 ZAK 
Hu, et al. 212 HNRPD PPP1R14A SERPINF1 CENTD2 
GRK1 BIRC5 CIAO1 SIP1 C21ORF66 
RASGRF1 PIN1 EP400 PPP1R9A BCAM 
NPR1 AQP2 PDE4C DDX39 IRF3 TAF10 
71 
EZR TFAP2B CIITA GMFB AURKA 
C14ORF106 KCNJ13 RGS14 CSRP3 
KCNA4 PPP1R1B GPBP1L1 RRAD SNAI1 
SOX9 ADRB1 NOXA1 HAGH CACNA1H 
XRCC4 NAB2 GLI1 GRIA1 CCND1 
RUNX1T1 POP7 ESR1 KCNN3 PDE4D 
NFATC3 SREBF2 RUVBL2 E2F7 
APOBEC3F MDFI GSK3B GNA13 SGK 
TRPV1 HLCS CHGB DDEF2 PPP1R13L 
H3F3A MC4R CSDC2 GATA3 FOXN3 
PFKFB2 HIST2H3A UTP18 RCHY1 CLDN3 
CAPN2 CREB1 ERBB2 TRPV4 PDE5A 
HDAC8 DAXX KCNJ3 HRH1 ID2 RB1 
DHX29 PDE4B SEC14L2 SOX6 DNAJB2 
HNRPK NRIP2 RNUXA TP53 CASP9 
ZNF496 KCNN2 PPP1R1A FXYD1 BMI1 
KCND2 TPPP UNC84B GRK7 TPH2 ETV1 
SLC4A4 C13ORF15 LOC648998 CBFA2T3 
ESPL1 HSPB6 HSPB8 ANXA1 ATP1A3 
DSP ALOX5 PKD1 TRPM8 TTF2 NFATC4 
RXRA POU3F4 NFATC1 PLN PLCG1 DAP3 
ITGB4 BTBD12 FAM44A GSTA4 ABCA1 
ARID3A PPP1R8 CSDE1 AICDA KCNH2 
LIPE TNNI3 PLCB3 CRHR2 MAPT RBM19 
ABCB1 WT1 CTPS MYBPC3 CSK TH LCK 
PHOX2A DES RDBP RNF12 PCTK1 VTN 
ACCN2 SNUPN PFKFB3 NEUROD1 U2AF1 
BCOR AVPR2 CSNK1A1 EXOSC5 PTPN7 
DUOX1 ITGA4 VDR PRKAR2B PHF17 
MYOM2 CUL5 MCOLN1 CBL FIP1L1 
TFAP2C C20ORF32 AKAP9 NCBP2 NR5A2 
RBM22 RYR2 RPS19 NOS3 CFTR 
C19ORF2 TSC22D4 SAP30BP PDE11A 
GFAP AQP5 PPP2R5D GAS7 RBBP5 ETV5 
ARFGEF1 PPP1R1C LOC51035 CUX1 
PPP1R14C LOC100133382 GSK3A 
METTL3 NF2 GAD1 NCOA4 SRF GATA4 
VHL MDM4 PAH HCLS1 
Imamura, et al. 888 SLMAP TFIP11 ZHX3 ERCC5 TACC2 BYSL 
CXCR4 U2SURP G3BP1 CHD8 RBM15 
SCAF8 TPX2 EP300 GYS1 MON1B 
CHORDC1 C2orf49 ZEB1 TRIM33 PARN 
CD2BP2 THRAP3 SRPK1 PTCD3 HMGN1 
NMNAT1 SHC1 SAAL1 TAOK3 RIOK1 
HERC2 SLC12A4 CLCC1 USP6NL BAZ1B 
SDAD1 PPP1R15B LARP7 KPNA2 ATL2 
ZCRB1 KPNA3 PDCD4 DDB2 RBM10 
BCLAF1 TRA2B RAD23B STK17A MTRR 
NCOR2 GTF3C3 HIST1H1E CEP170 TPI1 
MSH6 SRSF6 HDAC7 SIPA1 CCDC43 
72 
ATAD1 NELFE IMUP SORT1 SETDB1 
CARMIL1 SRSF11 PCDH7 TJAP1 ORC1 
SON PLCL2 TRAM1 AVEN C9orf16 USP42 
NIPBL POGZ RICTOR RAD18 LRRC8A 
PRRC2B CDK17 ZNF687 KDM2A EML3 
HABP4 NFIL3 WDR62 DHX16 LEMD2 
MIS18BP1 UBXN7 DIDO1 LYSMD2 ARAP1 
NGDN SAC3D1 ITPRIPL2 UNG DPF2 
CBARP BRD8 PJA2 DCUN1D5 ANKLE2 
NOP58 RPRD1B CHMP7 FRYL PTPN2 
AP3B1 HCFC1 AHNAK UBL7 KRT17 RPL4 
PPP1R12A VAMP4 PRPF3 CHMP2B 
DDX24 RBM6 WAPL SH3PXD2A 
HNRNPUL2 RBBP6 ARHGEF16 PARG 
ASAP2 PPL CEP131 STRIP1 SSRP1 
PDAP1 BRD4 CHAF1A TOR1AIP1 
PACSIN3 BCKDK CSRP1 ITSN1 SVIL 
CHAMP1 NSD1 ATP2B2 NCAPD3 
PROSER2 ABCC2 GPATCH8 KIF4A PGM1 
CPD KRT8 MAP7 RBM7 OSBPL3 ANTXR1 
TERF2 HASPIN XPO4 EPS15 WIPI2 
IFNAR1 EHD2 RMDN3 ANKRD17 UBE2J1 
CCNK NCKAP5L FAM129B EAF1 NOTCH2 
ADD1 PSMD2 CHTF18 ATXN2 ARHGAP12 
VIRMA STRN3 CHMP3 CEBPZ ANAPC1 
SRRT MELK RBM3 BMS1 SCFD1 CDK16 
SF3B2 KAT5 FLYWCH2 TPD52L1 SLC19A1 
XRCC1 PAK1IP1 SLC7A11 CDS2 AHCTF1 
SENP3 EEF2K WDR26 MUS81 PWWP2A 
GAL RCC1 KIF1B PIAS1 ARGLU1 ZC3H14 
CNOT2 SNW1 RPP30 TRIM16 CDC40 
IRF2BPL RECQL5 WEE1 BSG TIMM8A 
BIN1 SRRM1 PABPN1 PTDSS1 FMNL1 
GLCCI1 MMTAG2 ARMCX3 QSOX2 YBX1 
LRFN4 PNISR CARHSP1 STK10 HERC1 
PTPN23 DGCR8 COPB2 CTR9 BRI3BP 
LMO7 HNRNPH1 KPNA4 MDC1 INO80B 
NUCKS1 RBM34 RCOR1 U2AF2 SEC16A 
TRMT1 KMT2D LEO1 TELO2 MAF1 
C7orf50 USP15 HDAC4 YAF2 WDR33 
AMFR MAPK1 MPHOSPH10 HNRNPA2B1 
TLE3 TACC1 PDCL ZC3HC1 DYNC1LI1 
YRDC VPS4B FXR2 ZC3H8 ARHGAP1 
CLASP1 TFAP4 AFAP1 CDK13 BCR 
TWISTNB RPL15 RIOK2 REXO4 ABCF1 
UFD1 SMARCA4 SEPT2 RPS6KA4 BRD7 
ZBTB21 CEP55 EYA3 HOXC10 EML4 ATF2 
CTPS1 TOM1L1 GOLGA2 TRA2A 
CAMSAP2 RFC1 ABCC5 ASMTL SNAPC5 
MOCOS AFDN SLC30A1 TBX3 DNAJC21 
73 
NRDC SART1 MTDH HSPE1 RBM5 NCL 
EIF4EBP1 PPP1R9B SLC43A2 WDR44 
MCM2 KRT18 TGS1 MCM4 SPTBN2 
TOMM70 ARHGAP5 DDX21 PWP1 ADAR 
POP1 MTA1 GPAM ESYT2 TIMELESS 
DDX10 KIF13A KRT7 PHF8 TMEM87A 
PLEKHA2 ESCO2 SEC62 DNTTIP2 ZMYM4 
ZNF106 MKI67 PANK2 NHS CLSPN BICD2 
ARL6IP4 PAXBP1 PURB ACAP2 PPP4R2 
BUD13 SDE2 SLC39A10 CDCA2 PPA2 
MED24 MAP3K7 EHD1 RAB11FIP5 GTF2I 
TBC1D15 ADAM17 ZNF830 ZC3H4 ELAVL1 
NCOA2 RPP25 ABCA2 EXO1 AJUBA 
CIAPIN1 DMD STAMBPL1 TCF20 PPM1G 
C9orf40 ELMSAN1 SSH3 RBM39 KLC2 
FNDC3B USO1 SIRT1 AREL1 PCBP2 
MFAP1 NEK9 UPF3B RPL23A ADNP RFFL 
RBM15B ERICH1 DDX39B TLE4 WRNIP1 
TOP2B CNNM3 FAM117B TAF15 SORBS3 
MED19 PAGR1 POLD3 VAMP7 AMPD2 
RSF1 MON1A POU2F1 APC RSL1D1 
RBM25 CDC42EP1 TPR MAP1S AKAP11 
WDR3 TTC33 TRAFD1 CTTNBP2NL 
MGRN1 PTDSS2 BMP2K USP39 HNRNPU 
ATXN2L FLII CLASRP CWF19L2 BRAF 
RPL14 HNRNPA1 TMOD3 RALBP1 CAAP1 
GEMIN5 UBR4 DDX20 KTN1 MYBBP1A 
PHKB SLC16A1 USP8 SLC17A5 EPHB4 
MBD1 TP53BP2 STT3B SYAP1 CD3EAP 
HDLBP PITPNM1 HECW1 RLF KLF3 
MTFR1 RPTOR BCL2L12 NBAS HIVEP1 
ATRX VAMP8 NBN NUFIP2 MAST2 SLTM 
PACSIN2 TOPBP1 NUP214 SOX13 EIF3B 
MFSD6 USP20 MCRS1 UBE2E3 
RAB3GAP1 BASP1 ARHGEF12 SLC35F6 
PTOV1 RALY TMEM45A CDK12 JADE3 
PHF3 RBM33 PEX14 PGRMC2 APEH 
TBC1D5 MAPKAP1 THOC2 MINK1 EZH2 
MYO1C SLC15A4 OSMR LSM14A WIZ 
RBM4 CSF1 EDC3 SLC35B2 CEP170B 
COPA PHC3 ACOX1 FAM102B KIAA1143 
USP24 TWF1 NUP153 MYH9 TTYH3 
SLC12A6 RAP1GAP URI1 NOP2 RAD9A 
USP16 SCML2 USP10 PODXL2 PI4K2A 
RPS3 WDR75 SFSWAP DYNC1LI2 COIL 
ZMYND8 PTGES3 TSC2 CPSF7 ZNF609 
CASC3 TCF12 ATP7A ZNF641 DSG2 
TANC1 TBXA2R PRKCD ZNF639 PUS1 
PPIG BCL9L SMC4 EPB41L1 EXOSC9 
ABCC4 ZFP36L2 PBRM1 RNF20 USP9X 
74 
BRF1 TMPO RRAS2 MCM3 RPS2 PRPF4B 
NRBP1 MYPN RNF113A PPHLN1 
TBC1D2B AFF4 AKAP10 SUB1 PRPF6 
PDE8A SH3KBP1 PLA2G4A SYNRG RIF1 
UNC13D MEPCE KIF21A UNK SAMD1 SCD 
SLC38A2 CD2AP CCDC86 ATN1 MPZL1 
SMN2 TRPT1 SEPT9 STX7 SPEN NAP1L4 
GPRC5A C1orf52 CDC26 CD97 PDS5B 
MPHOSPH8 NOC2L TICRR MYO18A 
ZBTB7A MADD PRRC2C SLC4A2 
ARHGEF18 ARRB1 SUGP1 HNRNPUL1 
SIN3A POLR3E TXNL1 CCNYL1 OBSCN 
CBX8 RRBP1 IL1RAP PPP1R10 VDAC1 
CIR1 FTSJ3 UTP14A EEF1B2 RRP1B 
SLC4A7 DKC1 GNL1 NELFB PPP1R12C 
ATG9A NEDD1 DNAJB6 DDX46 NFIC 
TCEAL4 PRPF38B ILF3 NUP50 ARFIP2 
KRI1 LEMD3 TXLNA BUB1 PIEZO1 
GTF3C2 SKIV2L SNTB2 SURF2 ZRANB2 
CLASP2 DOT1L EIF2AK3 RPRD2 ATF7IP 
SEC31A FOXK1 HNRNPC ZC3H18 FXR1 
NUP210 PPAN BAG6 SH2D4A SLC7A2 
GZF1 DDX55 FERMT2 NSUN2 TPD52 
DTD1 SLCO4A1 STK11IP ZC3H13 RTN4 
GAPVD1 TAX1BP1 PHRF1 PPP1R2 
TBC1D4 GIT1 CHCHD3 HIST1H1B EPB41 
NUP98 DFFA PAXX EBAG9 TMEM51 SLU7 
DAB2 TTLL12 NIFK DNAJA2 LYN CCNL1 
ZFP91 CDCA3 NOP56 RAI1 BPTF ATAD2 
DENR HACD3 PHF6 ANAPC2 DNMT1 
EPB41L2 SLC16A6 RREB1 FNBP4 LIFR 
DNMBP SNAP23 TFDP1 MGA IRF2BP1 
SRSF10 UTP3 CLINT1 RTTN ZFC3H1 
SMAP KIAA1671 MYCBP2 LATS1 NEMF 
MED1 SRSF1 TMEM245 LAMTOR1 ESF1 
DIAPH1 TRAF4 RRM2 SLC20A1 TOP2A 
DNAJC2 IGF1R NOB1 GTF3C4 EIF2A TTF1 
NCBP1 SLC9A1 HDAC2 NEXN PLEC IL6ST 
NCAPD2 UBAP2L PPP4R3A TMEM131 
GPN1 WDHD1 UBE4B DBN1 LRWD1 PTS 
RPL27A OTUD5 OGFR DDX54 HSF1 ALPI 
KMT2A PKN1 WTAP BUB1B JMJD1C 
AKT1S1 CCNH SURF6 MTCL1 PHF14 
ERCC6 TMX1 RRP12 HSPH1 DMAP1 
SRSF2 RAB12 DDX51 PRKAR1B HEXIM2 
GBF1 ZC3H11A VCL TCF3 C18orf25 SMN1 
RANBP10 PSMD1 DTL SRFBP1 SRSF9 
C19orf24 RBMX TGFBR2 LRRFIP2 NAF1 
NFX1 MDN1 OXSR1 REEP4 SLC38A1 
PPFIA1 PLCD3 NCAPH2 CRK PDS5A PKM 
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ZFR HNRNPA3 NOLC1 HNRNPLL CUL4A 
CDC42BPB LYSMD1 TMX2 ZNHIT3 
TBC1D2 PEX19 PRKAB1 RALGAPA1 
KIF20A SSX2IP GTF2IRD1 MORC2 WDR55 
NUMA1 GIPC1 ZNF592 EIF4G2 GTF3C1 
FAM208A SYNPO KHDRBS1 PPP1R18 
PHF10 PSEN1 NUP43 FUNDC2 EPS15L1 
NMD3 TOE1 GATAD2B FMNL2 HMGA1 
SUPT7L RANBP2 YTHDC1 LIG3 STK38 
ATP2A2 CAST GAB1 PNN MTMR3 DDX3X 
TRIM25 SCAF11 NCAPG GOLGA4 TMF1 
FCHO2 FUNDC1 MISP CLN3 STX4 
TMEM106B NDRG3 ATP2B1 VDAC2 
CENPF RPS6KA3 BET1 SNX17 RANGAP1 
SGPP1 DCAF8 RPS27 CDCA8 ZNF638 
Embogama, et al. 179 PFKP DECR1 CSPG4 HSD17B10 LMAN1 
NT5DC1 DDB1 PAIP1 DDX5 USP47 GDA 
IPO9 PUF60 RPL35 IMPDH2 RTF1 
EXOSC2 USP14 USP7 PRDX4 SPG20 
NUP88 NOMO1 DHX15 FKBP4 SF3A3 
FUBP1 AHCYL1 ACO2 UBQLN2 HEXIM1 
TPT1 RDX UMPS EHBP1L1 LDLR ITGB1 
RPN1 PSMC4 CASP1 CECR5 PSMD12 
FKBP5 PRMT1 TYMS MCM5 PLS3 PLOD2 
RPS24 SH3GL1 WIBG ANXA2 DUSP12 
BUB3 CNN2 WDR61 ACY1 PRMT5 RPS10 
CLIC4 NHLRC2 FTO PTPRF RAB6A 
POLDIP2 MINPP1 AKAP12 PRPF8 RPL28 
IARS UBE2O PPP2R2A CKMT1A TUBA1C 
PAAF1 SLC3A2 COPS3 DNM2 VARS 
PSMD4 DDX17 TIPRL DAK LAMP2 NONO 
CPNE1 IMPDH1 NMT1 UBFD1 POLD1 
ACTN1 HSDL2 NME1 RPS16 PEBP1 
SF3B3 PNP ANKZF1 ACTR2 OAT TBCB 
SDHB DDOST PSMA1 RPL29 PTPN11 
DDX47 CYFIP1 ATP1B1 UFD1L ARF1 
SMC1A HSPA4L OXCT1 MTHFD2 MYOF 
STOM GPKOW FKBP10 MPI WARS SFN 
CSE1L TXNDC5 PFKM ELP3 TES PLOD3 
PSMC1 MCCC2 IVD PSMD14 SF1 YWHAB 
PARP1 DHX9 PSMA4 SERPINH1 CAPZA1 
SEC24C SERPINB4 SERPINB1 POFUT 
TUBB6 MRPL2 GNB2L1 SF3B1 HMGCL 
ACAA1 ASNS PC CHD4 CDC73 GOLIM4 
GDI2 RRM1 PRDX2 KLC1 GALE DRAP1 
DLD SETD7 PLD3 SART3 FDXR RARS 
TRMT10C MGEA5 KPNA6 PDIA4 NAGK 
RPS14 PGD PYCRL IWS1 NANS GPC1 
LANCL1 MPST 
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Hamaguchi, et al. 20 CDC25B OFD1 MARK3 PITPNM2 CEP72 
KIAA0556 PHACTR2 GLI2 HSPC075 BAT2 
EVL CRY2 PCNX CASP11 TMCC1 
CAMKK2 SIK3 C2ORF55 PDE8B LRCH3 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
66 MSRB1 PYROXD2 MMGT1 SUGCT 
SLCO2B1 ACAA1A EIF1 DGLUCY 
UQCRC1 RCSD1 ACSF2 HS1BP3 NDRG2 
PGAM1 CNDP2 DCAF11 TNNT2 B2M 
ANP32A GLOD4 GPD1L PFAS CR1L 
CEP290 GBE1 ASPG PDP2 RTRAF 
CACNB2 PDHX SSR1 HADHA MUSTN1 
RUFY3 WIPF1 ADSS PSMA6 ARCN1 TSFM 
ITIH4 SPHK2 CYP2D11 CDH13 HAL 
CSMD1 RPS3A1 AADAT PRKAA2 OPLAH 
PCDH1 WASHC2 NUCB2 EIF5 GM20604 
HSPA5 H6PD HNRNPM MMUT FLAD1 
IFI35 DOCK5 HAAO CYP2C29 SLCO1B2 
KCTD12 C6 
PRKACA in vitro  
Mouse Liver Lysate 
16 FKBP8 ALDH1L1 SIRT5 FAM50B SCO1 
ALDH4A1 MAPRE3 PCX ECI2 ETNPPL 
IGSF10 ITPA RILP ACBD4 ARID4B ACOX2 
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and corresponding cut site. I used site-directed mutagenesis to replace the thrombin 
cleavage site with a TEV cleavage site since the TEV sequence is more specific. I also 
decided to include two different lengths of flexible linkers after the TEV site because I 
was concerned about whether the TEV protease would be able to access the cut site 
between the kinase and GST tag. Upon a time-course experiment with TEV cleaving 
each of with different constructs, I did see that the constructs with the flexible linkers did 
indeed cleave better, likely to do the increased ease of accessibility to the cut site. I also 
confirmed that these DNAJB1-PRKACA-GST proteins were active kinases. I was still 
concerned that the few amino acids left from the TEV cleavage site could affect activity, 
but before I tested whether the kinases with GST cleaved had similar activity levels to 
the GST-tagged versions, we learned of a method that would let us purify the kinases 
without an attached affinity tag at all.  
Conclusions 
In order to try the analog-sensitive kinase approach for direct substrate 
identification, it was necessary to first obtain purified kinases without the gatekeeper 
residue mutated to ensure that activity of the kinases was as expected.  Additionally, 
affinity-tags are usually necessary to purify proteins, but these tags can alter the 
dynamics and activity of the kinase. Thus, it was also necessary to demonstrate that 
these tags could be cleaved off of the kinases of interest. The original constructs I 
started working with to express PRKACA-GST or DNAJB1-PRKACA-GST had a 
thrombin cut site in between the kinase and affinity tag. Upon cleavage with thrombin, 
the entire PRKACA degraded. It was then necessary to switch to a different protease 
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I pivoted to an approach that uses FSBA to irreversibly bind to the catalytic lysine 
of many kinases to render them inactive. I demonstrated that I was able to knock down 
endogenous kinase activity in HeLa cells, mouse liver lysate, and human hepatocyte 
lysate. I was also able to show that more phosphorylation occurred in these FSBA-
treated lysates upon addition of DNAJB1-PRKACA or PRKACA.  
 However, in collaboration with Soren Heissel in the Proteomics Resource 
Center, the thiophosphate ester tags that result from the use of ATP-γ-S in kinase 
reactions and the following alkylation reaction with PNBM are not able to be reliably 
identified when following the published methods.  
In collaboration with Soren Heissel, kinase reactions with PRKACA and DNAJB1-
PRKACA were done with FSBA-treated mouse liver lysate and regular ATP and the 
resulting phosphopeptides were enriched. Differences between substrate specificity was 
seen between the three conditions of PRKACA added, DNAJB1-PRAKCA added, and 
no kinase added; more putative substrates were unique to DNAJB1-PRKACA (64) than 
PRKACA (6).  
This approach attaches a peptide (PKI) to agarose beads that specifically binds 
to PRKACA in order to be able to pull out this kinase from a lysate mixture. This method 
worked more efficiently to purify larger amounts of PRKACA and DNAJB1-PRKACA 
than with the GST-tag.  
I expected some decrease in purification efficiency using this method for the 
analog-sensitive mutants since PKI specifically binds to the active site of PRKACA, but I 
did not expect to see such a dramatic decline in binding capacity from the single amino 
acid change. If this specific peptide that binds to PRKACA experienced such a dramatic 
change in kinetics, it is likely that other substrates would, too. At this point, I no longer 
wanted to move forward with the analog-sensitive kinase approach. 
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However, being able to use the tagless kinases for my in vitro assays has greatly 
improved my confidence in a future read out. A recombinant protein without a tag 
closely represents the kinases in vivo in terms of their intrinsic structure. Any change in 
substrate preference seen with the in vitro assay now should be due to something 
intrinsic about the kinase or assay and not due to the affinity tag or additional amino 
acids not found in the kinase in vivo.  
While it was disappointing to arrive at the conclusion that moving forward with the 
analog-sensitive kinase approach was no longer desirable, it was validating to learn of 
other groups who reached the same conclusion. Killing the endogenous kinase activity 
of a lysate to confer activity specificity of the added kinase of study while keeping the 
added kinase as close to its native form as possible is an approach with many 
advantages anyway. While an in vitro assay does not allow for the detection of 
substrate differences that are due to a difference in localization or compartmentalization 
of the DNAJB1-PRKACA compared to PRKACA, it does allow for the detection of 
changes in substrate binding partner that are purely affinity based. The J-domain of 
DNAJB1-PRKACA could attract binding partners that PRKACA could not in such a way 
to allow for these binding partners of the J domain to now be newly phosphorylated. 
Discussion 
While using the GST-tagged versions of DNAJB1-PRKACA and PRKACA wound 
up not being the best option for the assay I used moving forward, these proteins are still 
helpful tools to have in our lab to study these kinases relevant to FLC. Attaching 
PRKACA or DNAJB1-PRKACA to the PKI-agarose would make the active site 
inaccessible for any experiments that would need to be carried out on bead or column; 
the GST-tagged versions would not have this problem.   
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However, primary hepatocytes have historically been hard to grow, and the cost of 
purchasing primary hepatocytes can easily become prohibitive to designing large-scale 
screens. The Rice lab has developed a way to efficiently grow and harvest a large 
quantity of human hepatocytes; being able to get enough human hepatocytes for this 
assay is a gamechanger in terms of being able to have human-relevant liver substrate 
phosphorylation data.  
Being able to obtain more human hepatocytes through the collaboration with the 
Rice lab became even more crucial and exciting after seeing the results of the 
phosphopeptide enrichment from kinase reactions using regular ATP and FSBA-treated 
mouse liver lysate. It makes sense that DNAJB1-PRKACA mostly had the same 
substrates as PRKACA since DNAJB1-PRKACA is only missing one exon of PRKACA. 
It was exciting to see a noticeable number of substrates appear only in the DNAJB1-
PRKACA sample. However, since this was done as a single replicate with mouse liver 
lysate, I did not want to get ahead of myself with drawing any conclusions about specific 
proteins from this data. Rather, I wanted to move forward as quickly as possible with 
obtaining data in triplicate using human hepatocyte lysate to see if a similar result could 
be obtained.  
The main reason our lab is interested in studying whether DNAJB1-PRAKCA has 
different phosphorylation targets compared to PRKACA is to better understand FLC, the 
cancer this oncogenic kinase is driving and also to potentially develop therapeutics 
against this kinase. Being able to identify which human liver proteins DNAJB1-PRKACA 
could differentially phosphorylate would be ideal compared to identifying differences 
with mouse liver proteins or even human proteins in a different cellular context.  
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Chapter III:  Phosphopeptide Enrichment of Putative Substrates of PRKACA and 
Variants from Human Hepatocyte Lysate 
Background and Rationale 
The pilot experiment of enriching phosphopeptides from kinase reactions using 
FSBA-treated mouse liver lysate yielded very promising results that there could be 
multiple substrate differences between DNAJB1-PRKACA and PRKACA. The pilot 
experiment was only done in single replicates with DNAJB1-PRKACA, PRKACA, and a 
no kinase condition as the negative control. For the next round of phosphopeptide 
enrichments, I wanted to repeat these conditions in triplicate to begin to see what 
changes might be statistically significant. As previously stated, I also wanted to use 
FSBA-treated human hepatocytes since the phosphorylation sites of human liver 
proteins could differ from the mouse phosphorylation sites. Additionally, I added another 
PRKACA variant that is found in the adrenal tumors of Cushing’s disease. It is thought 
that this variant, PRKACA (L206R), cannot properly interact with the regulatory subunits 
of PKA and thus is constitutively active in the cell. Two recent publications have 
suggested there could be a difference in substrate specificity for the L206R mutant 
compared to the native PRKACA (Lubner et al. 2017; Bathon et al. 2019). For my in 
vitro assay, the interaction with the regulatory subunits should not be a contributing 
factor to substrate specificity since each kinase is being added to the FSBA-treated 
lysate in its free catalytic form.  
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Consistency of Kinase Reaction Samples Contributes to Robustness of the Data 
It was important to know that the kinases added to the reaction were folded 
properly, active, and added in the same amount to each kinase reaction. If these 
conditions are met and as long as your substrate pool is the same, any differences seen 
in substrate specificity is likely due to an intrinsic aspect of the kinase and not because 
different amounts of kinase with different activities are being compared against each 
other. I worked with the High Throughput and Spectroscopy Resource Center at 
Rockefeller to make sure that the kinases I was using met these conditions. Figure 
17A-C demonstrates that the same amount of DNAJB1-PRKACA, PRKACA, and 
PRKACA (L206R) have similar kinase activities when tested using the ADP-Glo Kinase 
Assay (Promega). Protein quality was measured with the Tycho NT.6 per the 
manufacturer’s protocol to show that the kinases were all properly folded (Figure 17D). 
This technology automatically detects and identifies the inflection temperature of each 
sample as a function of increasing temperature; a peak in the first derivative view 
corresponds to the detected inflection temperature of the sample.  
The kinase reactions were all carried out for 1 hour at 30°C with 500ug of human 
hepatocyte lysate from the same FSBA-treated aliquot and 5ug of a kinase in the 
presence of 1mM ATP; kinase reactions were quenched with 20mM EDTA. The 
samples were then flash frozen and given to Soren Heissel at the Proteomics Resource 
Center. He then prepared these samples for phosphopeptiide enrichment as written in 
the methods.  
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Figure 17. Quality Kinases Used in Triplicate in vitro Assay. 
(A-B) Kinase Activity as measured with ADP-Glo Kinase Assay (Promega).  
(C) Protein quality measured with the Tycho NT.6; a peak in the first derivative 
view corresponds to the detected inflection temperature of the sample. 
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The abundance reading of total peptides was normalized to the median 
abundance in each sample to allow for comparison between the samples. Figure 18A 
shows that the abundance reading in all of the samples across all conditions and 
triplicate sets were comparable; this suggests that making a single pool of the FSBA-
treated human liver lysate to aliquot 500ug for each kinase reaction allowed for 
consistency and reproducibility across samples. Total peptide was viewed in Proteome 
Discoverer (ThermoFisher). Only phosphosite data was analyzed using Perseus 
(Tyanova et al. 2016). The total phosphopeptide amounts were normalized to the 
median abundance of each sample which showed that more phosphopeptides were 
enriched from all three triplicate sets that had an added kinase than were enriched from 
the no kinase added control (Figure 18B). The histograms in Figure 18C visualize the 
same point: more phosphopeptides are enriched from the samples that had additional 
kinases than from the no kinase control.   
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Figure 18. More Phosphopeptides Found in Kinase Reaction Samples Compared 
to the No Kinase Control. 
(A) Total peptides were normalized to the median abundance of each sample in 
Proteome Discoverer. (B) Total phosphopeptides were normalized to the median 
abundance of each sample using Perseus. (C) Histograms of the intensity values of 
enriched phosphopeptides on the x-axes were normalized to the median intensity 
values of each sample using Perseus.  
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Differences in Substrate Specificity Between PRKACA, PRKACA (L206R), and 
DNAJB1-PRKACA 
Now that I established that the kinases used in the reactions were of good quality 
and that the detection of phosphopeptides was consistently more than the no kinase 
condition for all three kinases tested, I began to look at the differences in which peptides 
were phosphorylated that could be detected between these samples. A PCA plot clearly 
depicts that the four conditions in triplicate do cluster separately from each other 
(Figure 19A). This suggests that the substrate specificity for PRKACA, PRKACA 
(L206R), and DNAJB1-PRKACA are different from each other since these kinases are 
acting on the same pool of substrates. This is also supported by the heatmap in Figure 
19B and the Venn diagrams in Figures 20-22. The heatmap shows distinct signatures 
between the four conditions, but the portion of the branch highlighted in aqua blue 
focuses on a group of proteins whose phosphorylation changes are similar between 
PRKACA (L206R) and DNAJB1-PRKACA. This could be an interesting group of 
proteins to focus on since both of these PRKACA variants are found in tumors. Table 7 
lists the proteins and specific phosphosites detected in this region of the heatmap. 
Inputting the list of gene names in Table 7 to STRING version 11.0 (Szklarczyk et al. 
2019) creates an interactome map that shows a prevalence of proteins that regulate 
mRNA (Figure 20 and Tables 8 and 9) and proteins involved in a variety of catabolic 
processes (Figure 21 and Table 10). STRING uses Gene Ontology (GO) Kyoto 
Encyclopedia of Genes and Genomes (KEGG) databases as part of its analysis.  
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Figure 19. PCA Plot and Heatmap of Phosphopeptide Data Analyzed in Perseus. 
(A) A principal component analysis (PCA) plot generated in Perseus from the 
phosphopeptide data depicts each triplicate set as distinct groups. (B) The heatmap 
was generated in Perseus using a false discovery rate (FDR)-corrected ANOVA test 
(FDR=0.01).  The aqua blue branch of the heatmap highlights the group of proteins with 
phosphosites detected in the presence of only PRKACA (L206R) and DNAJB1-
PRKACA; the proteins in this section are listed in Table 7. 
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Table 7. PRKACA (L206R) and DNAJB1-PRKACA Putative Target Overlap. 
Uniprot 








peroxidase 2 GPX2 
X6RCC3 129 
Stromal membrane-associated 
protein 2 SMAP2 
J3KT37 77 
Band 4.1-like protein 3;Band 




protein beta isoform PITPNB 
E9PMS6 1185 LIM domain only protein 7 LMO7 





A0A0R4J2E8 234 Matrin-3 MATR3 
A0A0R4J2E8 188 Matrin-3 MATR3 
Q5VTI5 862 
Pleckstrin homology domain-





A0A2R8YDF7 246 Lysine-specific demethylase 4A KDM4A 
A3KFL1 124 
Exosome complex component 
RRP4 EXOSC2 
A6NDB9 375 Paralemmin-3 PALM3 
E9PCT1 464 
Serine/arginine repetitive matrix 
protein 1 SRRM1 
E9PCT1 724 
Serine/arginine repetitive matrix 
protein 1 SRRM1 
B4DY08 220 
Heterogeneous nuclear 
ribonucleoproteins C1/C2 HNRNPC 
G3V1D0 128 
Echinoderm microtubule-
associated protein-like 3 EML3 
B8ZZJ0 2 Small ubiquitin-related modifier 1 SUMO1 
C9JGI3 50 Thymidine phosphorylase TYMP 
C9JZZ0 59 Apolipoprotein A-V APOA5 
D6RAS7 117 40S ribosomal protein S3a RPS3A 
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E7EPN9 1265 Protein PRRC2C PRRC2C 
S4R3H4 503 
Apoptotic chromatin 








condensation inducer in the 
nucleus ACIN1 
E7ET36 19 Transferrin receptor protein 2 TFR2 
E7EX73 1022 
Eukaryotic translation initiation 
factor 4 gamma 1 EIF4G1 
E7EX17 406 
Eukaryotic translation initiation 
factor 4B EIF4B 
E9PG73 672 
Peptidyl-prolyl cis-trans 
isomerase G PPIG 
E9PN6 14 
Tumor protein p53-inducible 
protein 11 TP53I11 
E9PJD9 11 60S ribosomal protein L27a RPL27A 
E9PK91 177 
Bcl-2-associated transcription 
factor 1 BCLAF1 
E9PK91 648 
Bcl-2-associated transcription 
factor 1 BCLAF1 
E9PQA1 7 Small acidic protein C11orf58;SMAP 
E9PMG1 143 
RalBP1-associated Eps domain-




H7BXL1 33 Transmembrane protein 41A TMEM41A 
H3BNA8 21 LYR motif-containing protein 1 LYRM1 
H7C113 141 
Phospholipid-transporting 
ATPase IG ATP11C 
H7C1N2 102 Protein cordon-bleu COBL 
M0QXG9 29 
BRISC and BRCA1-A complex 





Trans-Golgi network integral 
membrane protein 2 TGOLN2 
O43493 71 
Trans-Golgi network integral 
membrane protein 2 TGOLN2 
O43903 282 Growth arrest-specific protein 2 GAS2 
O75533 336 Splicing factor 3B subunit 1 SF3B1 
P00167 5 Cytochrome b5 CYB5A 
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P00367 94 
Glutamate dehydrogenase 1, 
mitochondrial GLUD1 
P00918 151 Carbonic anhydrase 2 CA2 
P02545 423 Prelamin-A/C;Lamin-A/C LMNA 
P06744 237 Glucose-6-phosphate isomerase GPI 
P07148 56 Fatty acid-binding protein, liver FABP1 
P08238 452 Heat shock protein HSP 90-beta HSP90AB1 
P08240 473 
Signal recognition particle 
receptor subunit alpha SRPR 
P08559 293 
Pyruvate dehydrogenase E1 
component subunit alpha, 
somatic form, 
mitochondrial;Pyruvate 
dehydrogenase E1 component 
subunit alpha, testis-specific 
form, mitochondrial PDHA1;PDHA2 
P09601 229 Heme oxygenase 1 HMOX1 
P23284 189 
Peptidyl-prolyl cis-trans 
isomerase B PPIB 
P25685 16 
DnaJ homolog subfamily B 
member 1 DNAJB1 
P26368 79 
Splicing factor U2AF 65 kDa 
subunit U2AF2 
P30085 147 UMP-CMP kinase CMPK1 
P30086 13 
Phosphatidylethanolamine-











reticulum ATPase VCP 
Q01518 308 
Adenylyl cyclase-associated 
protein 1 CAP1 







Q08495 152 Dematin DMTN 
Q15149 2039 Plectin PLEC 









Q53EL6 457 Programmed cell death protein 4 PDCD4 
Q5JRA6 678 
Melanoma inhibitory activity 
protein 3 MIA3 
Q63ZY3 540 
KN motif and ankyrin repeat 
domain-containing protein 2 KANK2 
Q6PKG0 1040 La-related protein 1 LARP1 
Q8N573 91 Oxidation resistance protein 1 OXR1 
Q8NDI1 1035 EH domain-binding protein 1 EHBP1 
Q99442 313 Translocation protein SEC62 SEC62 
Q9BX68 101 
Histidine triad nucleotide-binding 
protein 2, mitochondrial HINT2 
Q9C0C2 1666 




binding protein, mitochondrial SLIRP 
Q9H788 51 




subunit METTL14 METTL14 
Q9HCN8 55 
Stromal cell-derived factor 2-like 
protein 1 SDF2L1 
Q9NSK0 566 Kinesin light chain 4 KLC4 
Q9NVD7 19 Alpha-parvin PARVA 
Q9NZN5 22 
Rho guanine nucleotide 
exchange factor 12 ARHGEF12 
Q9P2B2 875 
Prostaglandin F2 receptor 




phosphatase 2, mitochondrial PDP2 
U3KPZ7 859 RNA-binding protein 27 RBM27 
Q9UK59 514 Lariat debranching enzyme DBR1 
Q9Y385 266 
Ubiquitin-conjugating enzyme 
E2 J1 UBE2J1 
E9PCT1 613 
Serine/arginine repetitive matrix 
protein 1 SRRM1 
B0QZK8 51 
Heterochromatin protein 1-






Mitochondrial import inner 




subunit CDC26 CDC26 
A0A0A0MQU8 49 Interferon alpha-6 IFNA6 
E7EX17 450 
Eukaryotic translation initiation 
factor 4B EIF4B 




containing protein alpha SGTA 
S4R2Y4 87 Chromobox protein homolog 3 CBX3 
Q9H307 100 Pinin PNN 
Q9Y2V2 32 
Calcium-regulated heat stable 
protein 1 CARHSP1 
Q9UPM8 751 AP-4 complex subunit epsilon-1 AP4E1 
Q9UPM8 757 AP-4 complex subunit epsilon-1 AP4E1 
Q9UPM8 755 AP-4 complex subunit epsilon-1 AP4E1 
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Figure 20. STRING Interactome Map of Proteins with Phosphosites Enriched by 
PRKACA (L206R) and DNAJB1-PRKACA. 
The list of genes used to generate this list comes from Table 7. Proteins in this table all 
contain phosphosites that were enriched in the kinase reactions with PRKACA (L206R) 
and DNAJB1-PRKACA but not in the PRKACA or No Kinase samples. The colored dots 
correspond to categories in Table 8 and 9 as determined by STRING analysis.  
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Table 8. STRING Analysis of Biological Process (GO) of Proteins with 
Phosphopeptides Enriched by PRKACA (L206R) and DNAJB1-PRKACA. 
Table 9. STRING Analysis of Molecular Function (GO) of Proteins with 
Phosphopeptides Enriched by PRKACA (L206R) and DNAJB1-PRKACA. 
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Figure 21. STRING Interactome Map of Proteins with Phosphopeptides Enriched 
by PRKACA (L206R) and DNAJB1-PRKACA: Highlighting Proteins Involved in 
Catabolic Processes. 
The list of genes used to generate this list comes from Table 7. Proteins in this table all 
contain phosphopeptides that were enriched in the kinase reactions with PRKACA 
(L206R) and DNAJB1-PRKACA but not in the PRKACA or No Kinase samples. The 
colored dots correspond to categories in Table 10 as determined by STRING analysis.  
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Table 10. STRING Analysis of Biological Process (GO) of Proteins with 
Phosphopeptides Enriched by PRKACA (L206R) and DNAJB1-PRKACA: 
Highlighting Proteins Involved in Catabolic Processes. 
The Venn diagrams (Figures 22-24) also show that the substrate specificity is 
more similar between PRKACA and DNAJB1-PRKACA than PRKACA and PRKACA 
(L206R). Figures 19B, 23, and 24 all show that PRKACA (L206R) loses the ability to 
phosphorylate a large number of substrates that are phosphorylated by PRKACA (and 
DNAJB1-PRKACA). Despite these differences, it is important to reiterate that these 
three kinases all share a large majority of substrates (346 potential substrates in my 
assay). 
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Figure 22. Venn Diagram of the Number of Human Proteins with Phosphosites 
Found in Samples with DNAJB1-PRKACA, PRKACA, or No Kinase Added. 
794 unique proteins with identified phosphosites from the sample with PRKACA added 
is represented in red on the right. 274 unique proteins with identified phosphosites from 
the no kinase added sample is represented in blue in the middle. 811 unique proteins 
with identified phosphosites from the sample with DNAJB1-PRKACA added is 
represented in green on the left. This proportional Venn Diagram was generated using 
Biovenn (Hulsen et al. 2008).  
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Figure 23. Venn Diagram of the Number of Human Proteins with Phosphosites 
Found in Samples with PRKACA, PRKACA (L206R), or No Kinase Added.  
794 unique proteins with identified phosphosites from the sample with PRKACA added 
is represented in red on the right. 275 unique proteins with identified phosphosites from 
the no kinase added sample is represented in blue in the middle. 644 unique proteins 
with identified phosphosites from the sample with PRKACA (L206R) added is 
represented in green on the left. This proportional Venn Diagram was generated using 
Biovenn (Hulsen et al. 2008).  
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Figure 24. Venn Diagram of the Number of Human Proteins with Phosphosites 
Found in Samples with PRKACA, PRKACA (L206R), or DNAJB1 Added.  
Any gene names that were also identified in the sample with no kinase added were 
removed from the gene name lists for the kinases in order to draw this comparison. 526 
unique proteins with identified phosphosites from the sample with PRKACA added is 
represented in red on the right. 375 unique proteins with identified phosphosites from 
the sample with PRKACA (L206R) added sample is represented in blue in the middle. 
540 unique proteins with identified phosphosites from the sample with DNAJB1-
PRKACA added is represented in green on the left. This proportional Venn Diagram 
was generated using Biovenn (Hulsen et al. 2008). 
100 
Comparison of Putative Substrates Yielded from Mouse Liver in vitro Assay and 
Human Hepatocyte in vitro Assay 
It is not possible to do any meaningful statistical analysis between the pilot 
experiment using mouse liver lysate and the triplicate experiment using human 
hepatocyte lysate since the pilot experiment with mouse liver lysate only had one 
replicate. However, it is possible to compare the list of gene names of proteins that had 
phosphopeptides enriched in each assay (Figure 25). This broad comparison shows 
that while there are many similarities between proteins that have phosphopeptides 
enriched in mouse and human liver contexts, far more seem species specific.  This is 
also highlighted with a Venn diagram (Figure 26) and corresponding table (Table 11). 
These  were generated by inputting the gene names of the putative substrates from 
each kinase condition from the in vitro mouse liver and human hepatocyte assays into 
the Bioinformatics and Evolutionary Genomics Venn diagram web tool 
(http://bioinformatics.psb.ugent.be/webtools/Venn/).  
Using this list, I took the DNAJB1-PRKACA putative substrates only recognized 
in mouse liver lysate and the DNAJB1-PRKACA putative substrates only recognized in 
human hepatocyte lysate and did analysis in STRING (Figures 27-28 and Tables 12-
15). For this comparison, I included tables for molecular and cellular function using the 
GO database and KEGG pathways when these analyses were available. These 
analyses suggest that the putative DNAJB1-PRKACA substrates unique to mouse liver 
may not be very interrelated or implicated in critical pathways. However, the DNAJB1-
PRKACA putative substrates unique to human hepatocytes seem to be involved in 
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metabolic pathways and perhaps often localized to the endoplasmic reticulum and 
mitochondria.  
I also did a comparison using the Bioinformatics and Evolutionary Genomics 
Venn diagram web tool again to see how many of the putative substrates identified from 
my in vitro assays using mouse liver lysate and human hepatocyte lysate were also 
identified by the sources discussed in Chapter I and listed in Table 1 (Table 19). While 
there was a great deal of overlap, both in vitro assays identified unique putative 
substrates. This, again, highlights the importance of methodology and source material 
for identification of phosphosites and the crucial need for further validation to determine 
a true in vivo direct substrate of a kinase.  
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Figure 25. Venn Diagram of the Total Number of Human Proteins Identified with 
Phosphosites and the Total Number of Mouse Proteins Identified with 
Phosphosites.  
609 unique proteins with identified phosphosites found enriched in the mouse liver in 
vitro experiments are represented in red on the right. 833 unique proteins with identified 
phosphosites found enriched in human hepatocytes is represented in green on the left. 
This proportional Venn Diagram was generated using Biovenn (Hulsen et al. 2008).  
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Figure 26. Venn Diagram of Putative Substrates in Mouse Liver and Human 
Hepatocytes For PRKACA, PRKACA (L206R), DNAJB1-PRKACA.  
The Venn Diagram was generated by inputting the gene names of the putative 
substrates from each condition into the Bioinformatics and Evolutionary Genomics Venn 
diagram web tool (http://bioinformatics.psb.ugent.be/webtools/Venn/). 
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Table 11. Overlap of Putative Substrates in Mouse Liver and Human Hepatocytes. 
Overview of Studies 
Kinases Used for 




Human PRKACA 1077 
Human DNAJB1-PRKACA 822 
Human PRKACA (L206R) 922 
Mouse PRKACA 572 
Mouse DNAJB1-PRKACA 501 
Total Number of Unique Putative Kinase Substrates: 1457 
Specific Overlaps Between Studies 





Overlap of Putative Kinase Substrates 
Human DNAJB1-PRKACA 
Human PRKACA (L206R) 
Mouse PRKACA 
Mouse DNAJB1-PRKACA 
186 DBNL COBLL1 ACTR3 PDHA1 TKT TLN1 
ACOT1 NDUFS1 TPD52L2 CASP6 IRF2BP2 
SLCO2B1 CLTA ACAT1 ALDOC PDCD4 
MDH1 PRKAR2A BHMT RAPH1 TPI1 
DNAJC5 DSTN ALDH2 C3 HSPD1 HYOU1 
ALDH4A1 PARVA SCP2 NPM1 UQCRC1 
NUCB1 PIGR BTF3 HSPA4 SLC9A3R1 
CDHR5 RAB21 PSMC6 SSR3 ATP1A1 
VAPA CORO1B MTHFD1 YWHAH ALDH6A1 
PHB2 NDRG2 UQCRFS1 DDI2 PGM1 SET 
PRKAR1A TALDO1 ARG1 SULT2A1 RMDN3 
CTNNB1 NAP1L4 OXR1 SLIRP BAD 
CYP2E1 SNX2 ANP32A ACLY PRDX5 
ALDH7A1 TJP1 TOM1 SEC22B AMACR 
OCIAD1 ACAA2 BCL2L13 VCP ALDOA 
RAVER1 LASP1 ALDH5A1 ACADS STMN1 
PSME1 HSP90AA1 LRRC47 CARHSP1 
PHACTR4 PRKCSH ALDH1L1 HPD 
NUCKS1 CCS TSSC4 ASL SRP14 ACADM 
PGRMC1 OPTN CTNNA1 ACAD9 TTC36 
PYGL STARD10 LRP1 OXSM PEA15 
NDRG1 HSPA9 MYLK SOD1 PCNP APOH 
NDUFV1 CFL1 ALDH8A1 SGTA CLU ACAT2 
TNKS1BP1 NUDC DNAJC8 BCKDHA 
MTHFS ALDH1A1 MRPS31 HSP90AB1 
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TGOLN2 HSP90B1 GSTA3 WDR44 NIT1 
TCEA1 KHSRP MRPS36 TRIM28 HTATSF1 
TST NSFL1C AFMID ACIN1 VCL TIMM44 
CBX3 VASP PDIA6 NCK1 CAT LSR 
ARHGDIA CETN2 CPS1 CANX DAP UGP2 
PRKACA IDH1 CFDP1 MIA3 ST13 CLIP1 
P4HB PGLS CALD1 HIBADH ALDOB LMNA 
CLTB ACOX2 CAST ACTG1 NME1 APPL1 
IWS1 CP LRPAP1 PNPO HSD17B6 AARS 






41 CNPY2 PRDX6 TAGLN2 AFG3L2 PKLR 
NDUFS4 PSMD11 SNX6 RPS21 AP2M1 
PCBP1 CALR SPR AKAP2 ACADVL 
SEPHS1 SZRD1 ARFGAP2 RPL24 ASGR1 
PSMA2 DPP3 ATP6V1B2 NSF NAMPT 
UGDH PPP2R1A ACSL1 SORD SNX3 
THUMPD1 CPOX CTNND1 USP5 PEX19 
AHSG COX4I1 ALB CTSZ SEC61B ATIC 
Human DNAJB1-PRKACA 
Human PRKACA (L206R) 
Mouse PRKACA 
Mouse DNAJB1-PRKACA 
33 GPHN ECHS1 DNAJB1 ATP11C GPD1 
ALAD ETFA FDX1 GPS1 GRB14 EPN1 
GCLC EEF1A1 EIF4B GLUD1 HMOX1 EEF2 
EBAG9 HACL1 FABP1 ETFDH EEF1D H6PD 
GLUL EPS8L2 GORASP2 EVA1A ETFB 
EIF2S2 HDGF GAPDH FTCD TYMP 
Human PRKACA 
Human DNAJB1-PRKACA 
Human PRKACA (L206R) 
Mouse DNAJB1-PRKACA 
15 SUMO1 KLC4 PGRMC2 PGAM1 CNDP2 
PFAS HSPA5 HNRNPM ARFIP1 LAD1 YAP1 
PSMA6 ARCN1 SYAP1 NADK2 
Human PRKACA 
Human DNAJB1-PRKACA 
Human PRKACA (L206R) 
Mouse PRKACA 
2 CBS RPLP2 
Human PRKACA 











3 CDH13 PDHX CDV3 
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Human DNAJB1-PRKACA 
Human PRKACA (L206R) 
Mouse DNAJB1-PRKACA 







Human PRKACA (L206R) 
422 TFIP11 MAP4 ZHX3 HSPB1 C1ORF53 
MACF1 AIFM1 LMAN1 TMEM160 ADD3 
HEL-S-117 SLTM RPL19 MYO9B ATP1A3 
MESDC2 MATR3 POLI SMARCC1 DSP 
THRAP3 ST13P5 PDLIM2 LYAR SLCO1B3 
PIR AK3 CTAGE5 CYP2D6 TGM2 NASP 
ARHGEF7 RPL29 SARS2 ARHGEF12 
GLUD2 PTPN11 RALY SHROOM1 BCLAF1 
RBM33 RAD23B SLC27A3 CAMSAP3 DMTN 
HIST1H1E GSTA2 ANGPTL3 PIN1 RPS28 
NDUFS8 LSM14A YWHAQ PREP DTX3L 
SCRN2 HSP90AB2P PPM1A PPP1R8 
ALCAM TWF1 CCT2 CSDE1 MYH9 ATP5B 
HSD17B4 TOMM34 XRCC6 TF ASS1 LETM1 
SPTBN1 BCAP31 PBDC1 LDHB NME1-
NME2 C9ORF142 ACTC1 POTEE UFD1L 
PRDX4 ABHD12 UFL1 ISOC2 IMMT 
HIST1H1A SERPINA1 HP1BP3 PPIG OSBP 
STBD1 ALDH1L2 CYP4F3 NOP58 ALDH1A2 
RPRD1B MAMSTR MTTP WIPF3 C17ORF59 
AHNAK PPP1R12A CHMP2B BCAP29 
SORBS2 PSMF1 HNRNPUL2 YWHAZ 
SULT1A2 CTAGE15 TMPO LYRM5 
ZC3HAV1 ARPC5 PPL ACOT2 CYP2A6 
PRPF4B CHMP6 MIA2 MANF CASC4 
ANXA6 VAPB LIMA1 CTAGE6 BHMT2 
UMPS PRKAB2 PHYKPL UBE2M CTAGE9 
SULT1A1 KIN27 PROSER2 LARP1 
MARVELD3 LOC113230 ALDH1B1 RANBP1 
CBX1 CAP1 SEPT9 WBP11 BABAM1 
ADH1C UBE2J1 HNRNPK CLIP2 WDR4 
POTEKP VTN HEXB SAFB2 ITGA6 NOC2L 
PSIP1 ADD1 PRRC2C MVD CYP4F12 
HSPA1A SUMF2 CTAGE4 IRS2 C9ORF78 
PPIB MXRA5 CYP2A13 SCFD1 RRBP1 
HSP90AA5P SPATS2L MAT2B VDAC1 
PPP1R10 PPIA RABAC1 RDH16 PRKACB 
CRAT AK2 ILF3 RPL30 STX16-NPEPL1 
SRSF3 NDUFV2 C11ORF58 ATP5EP2 
ANXA5 BLVRB CPT2 MYOCD SEC31A 
ANP32D SSFA2 ZC3H18 HNRNPC SF1 
LSM7 TIMM8A SRRM1 PABPN1 NAP1L1 
PLIN1 SH2D4A EEF1A2 CD14 PHAX TPD52 
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AK1 ACSS3 PGM2 ZC3H13 CGREF1 
THOC3 ARPC2 SULT1E1 LMO7 THAP4 
MAN1A1 C14ORF166 HIST1H1B CGNL1 
NUP98 PGK2 ATP5A1 UROD CD276 NIFK 
METTL14 EIF1B ATP1A2 UROC1 ACY1 
NME2 ATPIF1 PYGB DDRGK1 RPL21 API5 
HIST1H1T WIPF2 APOL5 PPM1B POTEF 
SORBS1 YRDC VPS4B ST13P4 RPL5 
CYP4F2 STX12 MRPL39 IGFBP1 SMAP 
RPS3A ASPDH HINT2 PALM3 CYP2D7 
ABCF1 MUT CMPK1 SEPT2 SLC38A3 XPO1 
WDR87 SSH1 PALMD HTATIP2 SSB 
WDR77 PDZK1P1 RPL28 PHACTR2 ATP5J 
SRP54 DNPH1 SF3B1 MICAL3 ACAA1 
STIP1 PLEC CA2 MTDH SLC25A20 NCL 
ARPC1B AP3D1 PRKACG OGFR SEMA4G 
ADH1A HSF1 NDUFA7 METAP2 NME2P1 
REPS1 KNG1 PHF14 SEC14L2 PA2G4 
PRDX2 RPL13 TMX1 HSPH1 ACTB SEC62 
PCBD1 MPDZ YLPM1 CYP2C8 KANK2 
ALDH1A3 UQCRFS1P1 ACTG2 OXNAD1 
COPB1 PRPSAP2 ARHGEF6 DAK POTEI 
LRRFIP2 COBL PTGFRN SRPR ADH1B 
CRK SNX1 PKM HSPA1B RBM8A 
HNRNPA3 NOLC1 PGAM4 TKFC CTAGE8 
PDZK1 HSP90AB3P POFUT1 ABCB11 TJP2 
SCRIB RBM39 CUX1 GSTA5 ABHD14A-
ACY1 ACTA1 TPPP RBM27 SEPT11 LARP4 
SNTB1 NUMA1 WRNIP1 RPS25 SDF2L1 
ACTA2 SORBS3 EIF3CL TACO1 HIST1H1D 
STX16 SYNPO CDC5L CTNNA2 AMPD2 
CYB5A KIAA1598 PGAM2 DBR1 PSME2 
HIST1H1C PLEKHA5 MAP1S ATP5E 
SERBP1 ZFYVE19 RANBP2 MTCH2 
APBB1IP PNN MIEN1 PGM3 ANP32B HEXA 
AP4E1 NRD1 CASK SMAP2 SRRM2 PEBP1 
DTNA HNRNPA1 KTN1 HNRNPA1L2 
EEF1A1P5 TCOF1 TTC38 BAIAP2 CES1 
PIPOX ADD2 PITPNB BAAT STX4 
ARFGAP1 PPP1R7 NDUFA5 PDLIM5 
ABLIM1 WASF2 HNRNPUL2-BSCL2 HDLBP 





7 HUWE1 BAG6 ASNA1 NUMB SBDS SARDH 
NNT 
Human PRKACA (L206R) 
Mouse PRKACA 
Mouse DNAJB1-PRKACA 
3 G3BP1 ACBD4 UBA2 
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Human PRKACA 
Human PRKACA (L206R) 
Mouse DNAJB1-PRKACA 
2 APMAP PRCC 
Human DNAJB1-PRKACA 
Mouse DNAJB1-PRKACA 
4 WASL EIF3H HADH TSFM 
Human DNAJB1-PRKACA 
Mouse PRKACA 
174 RAB2A NAPRT QARS RGN RPL17-
C18ORF32 SQRDL SPECC1L UGT1A1 
LYRM2 CYP2C19 RPL35 PDIA3 ALDH3A2 
NEDD4 HIST3H3 HSP90AA4P APOE 
MYO1C PMM1 ACOX1 HMGN3 SND1 
HIST1H2BC PTGES3 APOB HIST1H2BL CS 
ZNF318 CPSF7 PRDX1 ITGA1 PPP2R1B 
DKFZP586F0420 PICALM HSPA4L CYP7A1 
KHK DNAJC3 MTSS1L ARHGEF16 TARS 
CDK6 CTSB HIST1H2BN LUC7L SUB1 
PCBP3 ALG13 ZYX MAP2K2 CMC1 CD2AP 
MYH10 HYPK MYH11 UBE2D3 PLRG1 
CYP2C9 PRKDC MYO18A DNAJC1 
SLCO1B1 SMS HMBOX1 RPL17 ACOT9 
TXNDC5 POR CTSD NAA15 RP2 ARFIP2 
ADRM1 MCEE PLAA SHMT1 SRP9 HMGB2 
IVD ISG15 PROC HSD17B13 PARP1 PRDX3 
CHCHD3 SEC16A SCYL2 PML YWHAG 
MYH14 LEO1 LMNB1 TFAM DUSP3 PSAP 
ACADSB HGD HMGN2 HIBCH TIMM10 
COPE UQCC2 POLDIP2 CFL2 PABPC4 
ITFG3 AIMP1 PPIF ABAT SCARB2 PSMA7 
SRPRB C2CD2L KRT18 SPECC1L-
ADORA2A ATP6V1G1 STOML2 SETSIP 
HMGB1P1 HIST1H2BK METTL7A CADM1 
C21ORF33 TOMM70A ITIH1 OTUB1 NHSL1 
CHP1 PSMC5 MLEC PAXBP1 MAP3K7 
HTRA2 ZC3H4 IARS2 IGBP1 DDX58 ACACB 
DMD PABPC1 SERF2 HIST1H2BM RPL8 
HSD17B8 PFN1 PCBP2 QRSL1 DDO 
HIST1H2BD H2BFS XYLB AGXT UBE2V1 
HIST2H2BF DCTN2 MECR PMM2 
HIST1H2BH HSP90AB4P SSBP1 PDIA4 
ANXA4 BMP2K HNRNPL CHCHD4 SNAP91 
SUOX SHMT2 ST20-MTHFS PAH LTA4H 
HMGB1 LBR BAIAP2L1 
Human DNAJB1-PRKACA 
Human PRKACA (L206R) 
101 GMPR2 ITGA5 GSTA1 SOS1 NUFIP2 
GUCY1A3 GOLM1 FBP2 FASN EXOSC2 
RPS4Y2 FRS2 ENOSF1 DENND1A HAO1 
GPI STIM1 RPS4X IRS1 LAGE3 EML3 FTH1 
KIAA1217 PACSIN3 FETUB GANAB EEPD1 
APOA5 EIF3D FHIT EPS15 ARFGEF2 
CDC26 FLNB GIGYF2 ECHDC3 GPX2 
TRANK1 EPB41L3 RPS4Y1 ABCA12 MIEF1 
109 
EHBP1 ARGLU1 ZC3H14 GCDH EIF4G1 
KDM4A GAPVD1 COPB2 HNRNPH1 U2AF2 
EIF5B GLRX3 RPS6 C2ORF72 G3BP2 
HACD3 AASS FMO3 EIF3A EMC10 
FAM134A KIAA1671 FKBP3 EIF3J PPP1R3E 
EIF2A LRP2 TMEM109 PDHA2 FAH EIF3C 
RNPEP FBP1 RPL27A DUT FBL HADHB 
GAS2 ENO3 ENO1 PPFIBP2 TMEM41A 
REEP4 GTF2I GSTO1 ECHDC2 RSRC2 
IFNA6 TCEA3 HNRNPH2 FUNDC2 
PLEKHA6 GATM HNRNPU FLNA FCHO2 
EHHADH ALPL EEF1G 
Mouse PRKACA 
Mouse DNAJB1-PRKACA 
211 ADH1 ACOT12 JPT1 RIDA AGFG1 HMGCS2 
NAXE LDHD PI4KB BET1L CXADR UBA1 
ATG2B ARHGAP17 SLK CA14 ACSBG2 
LYPLA1 SNRNP70 RBM17 HSPA1L 
ARHGAP39 VWA5A APEH SULT2A8 
CCDC43 MRPL12 ADH5 LCMT1 GCLM 
KIF5B FAM213B CES1F NUDT7 ELAC2 
PTMS ANKS1 NDUFA2 DPYD CASP8 SARS 
UCHL4 HAL GM20425 NT5C GM9774 NKTR 
TUBA1B CSRP3 TPMT SERPINA3N PFKL 
EARS2 MCM3 STRIP1 HBA-A1 SELENBP2 
GC CYP2C70 WDR91 LXN MAPRE3 
AKR7A2 ARPP19 CNGA2 ATP5H SPAG9 
PCX ASPSCR1 DPPA3 DHTKD1 CTH 
ATP5F1A GLOD4 DAPK2 GYKL1 GSDMDC1 
CYP2F2 SNRPG CSMD1 DNAJC12 ZNRF2 
SERPINA1B 9-Sep DECR2 GOPC PNPLA8 
CYP2B10 GLYCTK PLEKHF2 GATD3A 
MAVS DIS3L2 ADCY10 ECI2 KARS ATP5PF 
IDH3A URAD CES3A RANBP3 MOCS1 
ACSM5 CDK18 SNAP29 STK24 SDS PTMA 
ETNPPL HEBP1 HMGN5 FCGRT MARCKS 
ISOC2A PCDH1 SASH1 LDLRAP1 CYP1A2 
SERPINA3K CDO1 GSTM1 NUBP1 AKAP1 
EFHD2 EGFR SNAP23 CMC2 NECAP1 
LNPK GIMAP4 ENSA F13B AKR1D1 ETHE1 
PRODH D2HGDH HNRNPAB CDC42EP5 
CES2E CRIP2 SEMA6D EIF4EBP1 SMOC1 
METTL26 GRN FKBP15 FAM50B INMT 
CACNB2 SSR1 ACSF3 RILP CCDC180 
KIF13B NADK H2-KE6 UBQLN1 NDUFB11 
RNH1 FAM162A PPP4R2 HAAO MTSS1 
MARCKSL1 PPIP5K2 ATP5F1B SLCO1B2 
CYP4F17 PPP1R11 MESD LCP1 EIF4H 
GPRIN3 LAP3 TIMM50 PRKAB1 YBX3 
SHTN1 ANK3 HDGFL2 ATP5C1 2-Sep 
ZFP69 AMT MIOS HSD11B1 ARID4B 
KCTD12 BOLA1 GMPS GPT2 CYP2D22 
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APOA1 SEPHS2 AKR1C6 CLNS1A ERRFI1 
CIDEB AGMAT ECI1 FTL1 STRN LBH MUG1 
MTFR1L KEG1 CYP2A5 SERPINA1C 
CCDC9 SERHL ACAA1B 
Human PRKACA 
Mouse DNAJB1-PRKACA 
3 AHCY HS1BP3 AKT1S1 
Human PRKACA (L206R) 
Mouse DNAJB1-PRKACA 
1 EIF4EBP2 
Human PRKACA (L206R) 
Human PRKACA 
27 DDT LYRM1 PALLD OGDH DOCK8 TSC2 
ANXA2P2 SVIL INF2 UGT2A3 CLMN DDX46 
BAT3 PRPF40A UCHL3 ANXA2 SH3BP5L 
HNRNPA2B1 ZDHHC5 MVK PRKAR1B 
PBXIP1 DDTL CRYL1 MFAP1 SLC4A4 
OR51A7 
Human DNAJB1-PRKACA 85 GALK1 RPL36A HMGN1 FKBP7 FUBP3 
FBXO22 THOC2 YWHAE ERBB2IP TFR2 
SDC2 C4A DSG2 GLG1 PCCB GPALPP1 
FUBP1 ACO2 TJP3 ECE1 STOM FAM114A2 
NEDD4L PLEKHG3 HARS RPS10-NUDT3 
RUVBL1 DDAH2 HIRIP3 GRHPR 
HNRNPUL1 SFN HSD17B7 DMGDH STX5 
EEF1B2 PHYH FMO1 PLS3 ELMOD2 
RPL36A-HNRNPH2 EPHX2 DDX50 H1F0 
ETF1 ARHGEF5 ALS2 YWHAB SEC23A 
GLYATL1 C4B EIF2AK2 LMAN2 EPB41 
DFFA FAM83G GTF2H1 PFKFB2 DENR 
RPS10 SYMPK DAB2IP ACSM2A FGA 
GGT7 ESF1 EPHX1 APOO PC PSMD4 
COA7 UBXN1 TP53I11 ERP44 ESYT2 
SAP30BP GBF1 ENPP1 FAM114A1 FDXR 
GLB1 ESPN MAT2A ACSM2B S100A9 
Mouse DNAJB1-PRKACA 52 MSRB1 PYROXD2 CYP2D11 MMGT1 
DPYSL2 SUGCT ACAA1A DGLUCY TJAP1 
RCSD1 ACSF2 DCAF11 TNNT2 B2M BAG3 
SAYSD1 RPS3A1 GSK3B GPD1L AADAT 
ACSS2 PRKAA2 OPLAH CR1L CEP290 
WASHC2 NUCB2 EIF5 GBE1 GM20604 
ASPG RTRAF MMUT GM13889 TOMM70 
FLAD1 IFI35 DOCK5 CYP2C29 CUL4A 
TRAK1 MUSTN1 SIK3 RUFY3 WIPF1 ADSS 
PSME3 WNK1 GORASP1 ITIH4 SPHK2 C6 
Mouse PRKACA 11 CCNY TMEM230 SGK2 BSG IGSF10 SIRT5 
ITPA ITIH2 STAB2 SCO1 
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Human PRKACA 38 ACTN4 RBM15 PNPT1 PDCD5 PLIN2 
UBXN4 PLXNB1 NUDT12 PALM2 PALM2-
AKAP2 UQCRB NRAP DPYS NACA TNS1 
MDH2 VPS53 NUMBL RCC1 ACOX3 
UBE2D1 CYP2C18 CYP27A1 CDK5RAP3 
PLIN5 ARFGAP3 SLC25A10 CAP2 UBE2D4 
RNMTL1 PPM1F USO1 MLXIPL ZNF326 
PHYHD1 UBE2D2 UBR4 DAAM1 
Human PRKACA (L206R) 24 SMARCC2 EPS8 ERO1L RAF1 GPKOW 
SLC16A2 PSMD12 KIAA0368 DKC1 ASGR2 
YAF2 SAP18 DPP9 MAP2 DR1 PDXDC1 
NCKIPSD EXOG ECM29 PAK4 HMGCS1 
ARAF PSMB10 FAM21C 
Figure 27. STRING Analysis of Putative Substrates of Only DNAJB1-PRKACA in 
Mouse from Mouse versus Human Comparison. 
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Table 12. STRING Cellular Component (GO) Analysis of Putative Substrates of 
only DNAJB1-PRKACA in Mouse from Mouse versus Human Comparison. 
Table 13. STRING Molecular Function (GO) Analysis of Putative Substrates of 
Only DNAJB1-PRKACA in Mouse from Mouse versus Human Comparison. 
Table 14. STRING Cellular Component (GO) analysis of Putative Substrates of 
Only DNAJB1-PRKACA in Human from Mouse versus Human Comparison. 
Table 15. STRING KEGG Pathways Analysis of Putative Substrates of Only 
DNAJB1-PRKACA in Human from Mouse versus Human Comparison. 
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Figure 28. STRING analysis of Putative Substrates of only DNAJB1-PRKACA in 
Human from Mouse versus Human Comparison. 
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Table 16. Overlap of Putative Substrates between Mouse and Human in vitro 
Studies and Previously Published PKA Substrate Studies. 
Overview of Studies 
Identifying Study Total Putative 
Kinase Substrates 
Identified 
Embogama, et al. 279 
Hamaguchi, et al. 45 
Hu, et al. 301 
Imamura, et al. 1132 
Isobe, et al. 197 
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
1077 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
454 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
822 
PRKACA in vitro  
Human Hepatocyte Lysate 
922 
PRKACA in vitro  
Mouse Liver Lysate 
392 
Total Number of Unique Putative Kinase Substrates: 2687 





Overlap of Putative Kinase Substrates 
Embogama, et al.  
Imamura, et al.  
Isobe, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate  
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
1 LMNA 
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Embogama, et al.  
Hu, et al.  
Imamura, et al.  
Isobe, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
1 SPTBN1 
Hamaguchi, et al. 
Imamura, et al.  
Isobe, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
1 TNKS1BP1 
Imamura, et al.  
Isobe, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
5 NSFL1C COBLL1 IRF2BP2 PRKAR2A OPTN 
Hu, et al.  
Imamura, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
6 NPM1 STMN1 NDRG1 TRIM28 LASP1 
HSP90AA1 
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Embogama, et al.  
Hu, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
2 YWHAH PRKACA 
Embogama, et al. 
Hamaguchi, et al. 
Imamura, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
1 RPLP2 
Embogama, et al. 
Imamura, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
3 SLC9A3R1 PDIA6 KHSRP 
Hu, et al.  
Isobe, et al.  
DNAJB1-PRKACA in vitro  
Human Hepatocyte Lysate 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
2 CTNNB1 BAD 
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Hu, et al.  
Isobe, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
1 LSR 
Hamaguchi, et al. 
Imamura, et al.  
Isobe, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
1 REPS1 
Imamura, et al.  
Isobe, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
1 CTNND1 
Imamura, et al.  
Isobe, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
1 EIF4B 
Imamura, et al.  
Isobe, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA (L206R) in vitro 
2 TJP1 YAP1 
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Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
Isobe, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
6 CCS SRP14 NCK1 MIA3 HSPA4 SNX2 
Embogama, et al.  
Hu, et al.  
Imamura, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
2 NASP YWHAZ 
Hu, et al.  
Imamura, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
1 ARFGAP2 
Hu, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
6 LRP1 MYLK CBX3 VASP PRDX5 ARHGDIA 
119 
Embogama, et al. 
Imamura, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
1 GORASP2 
Imamura, et al. 
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
16 HSPD1 DDI2 ACLY PCNP NUDC HSP90AB1 
TCEA1 HTATSF1 DBNL TPD52L2 VAPA 
SEC22B OCIAD1 ALDOA PHACTR4 CANX 
Embogama, et al. 
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
14 TKT HYOU1 NUCB1 MTHFD1 ACAA2 CAT 
CLTB SDHA PGK1 ACADS PSME1 PRKCSH 
CLU ST13 
Hamaguchi, et al. 
Imamura, et al.  
Isobe, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
1 SPECC1L 
Imamura, et al.  
Isobe, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
9 MYO9B OSBP SORBS2 IRS2 CTNNA1 ABLIM1 
LIMA1 MICAL3 TJP2 
120 
Human Hepatocyte Lysate 
Embogama, et al.  
Isobe, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
1 AGPS 
Hamaguchi, et al.  
Isobe, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro 
Human Hepatocyte Lysate 
1 ARHGEF7 
Isobe, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
1 CASP6 
Embogama, et al.  
Hu, et al.  
Imamura, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
1 ZYX 
Embogama, et al.  
Hu, et al.  
Imamura, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
1 FLNA 
121 
Hu, et al.  
Imamura, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
7 HSPB1 DNAJC5 SAFB2 LARP4 MATR3 LARP1 
PRKAR1A 
Embogama, et al.  
Hu, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
2 TGM2 XPO1 
Embogama, et al. 
Imamura, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
12 PDHA1 YWHAQ RANBP1 HNRNPK SSB 
SRRM2 TCOF1 MAP4 CAP1 LRRC47 SERBP1 
PAK2 
Hamaguchi, et al. 
Imamura, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
2 SAFB ACIN1 
Imamura, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
3 USP5 SEC61B PRDX6 
122 
Imamura, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
8 ATP11C GPS1 HMOX1 EEF1D EPS8L2 
GAPDH EIF2S2 HDGF 
Imamura, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
4 PGRMC1 PEA15 DAP CLIP1 
Imamura, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
1 BCL2L13 
Embogama, et al. 
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
2 ECHS1 ETFA 
Embogama, et al. 
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
2 TLN1 ARFIP1 
123 
Embogama, et al. 
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
1 CP 
Hamaguchi, et al. 
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
1 KLC4 
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
78 NDUFS1 CLTA ALDOC BHMT DSTN ALDH2 
C3 SCP2 BTF3 ATP1A1 ALDH6A1 PHB2 SET 
TALDO1 VCP ALDH5A1 TSSC4 ASL ACADM 
TTC36 OXSM APOH NDUFV1 CFL1 DNAJC8 
BCKDHA MRPS31 MRPS36 TST CPS1 IDH1 
CFDP1 CALD1 HIBADH ACTG1 HSD17B6 
COMT UQCRC2 ACTR3 ACOT1 ACAT1 
RAPH1 PARVA PIGR RAB21 PSMC6 SSR3 
CORO1B UQCRFS1 SULT2A1 OXR1 SLIRP 
CYP2E1 ALDH7A1 TOM1 AMACR HPD ACAD9 
PYGL STARD10 HSPA9 ALDH8A1 ACAT2 
ALDH1A1 HSP90B1 GSTA3 NIT1 AFMID 
TIMM44 UGP2 P4HB ALDOB APPL1 LRPAP1 
PNPO AARS S100A13 CBR1 
Hamaguchi, et al. 
Hu, et al.  
Imamura, et al.  
Isobe, et al. 
1 CAD 
Imamura, et al.  
Isobe, et al.  
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
3 ARHGAP17 ARPP19 YBX3 
124 
Imamura, et al.  
Isobe, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
1 C2CD2L 
Imamura, et al.  
Isobe, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
3 ARFGEF2 EIF5B FBL 
Hamaguchi, et al.  
Isobe, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
1 NHSL1 
Isobe, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
1 GOLGA5 
Isobe, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
12 PDLIM2 TOMM34 PSMF1 CLIP2 CGNL1 
BAIAP2 WDR4 SSH1 AP3D1 MPDZ COBL 
SNX1 
Embogama, et al. 
Hamaguchi, et al. 
Hu, et al.  
Imamura, et al. 
1 PDE3A 
Embogama, et al.  
Hu, et al.  
Imamura, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
1 YWHAE 
Embogama, et al.  
Hu, et al.  
Imamura, et al.  
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
1 SMARCC2 
125 
Hamaguchi, et al.  
Hu, et al.  
Imamura, et al.  
PRKACA (L206R) in vitro  
Human Hepatocyte Lysate 
1 RAF1 
Embogama, et al.  
Hu, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
2 YWHAG PSMC5 
Hu, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
10 PIN1 SEC14L2 TPPP CBFA2T3 ATP1A3 DSP 
PPP1R8 CSDE1 VTN CUX1 
Embogama, et al. 
Imamura, et al.  
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
3 SPAG9 EGFR MARCKSL1 
Embogama, et al. 
Imamura, et al.  
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
2 PALLD INF2 
Embogama, et al. 
Imamura, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
2 FLNB EIF4G1 
Hamaguchi, et al. 
Imamura, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
1 ZNF318 
126 
Imamura, et al.  
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
1 HUWE1 
Imamura, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
1 EIF6 
Imamura, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
3 PCBP1 SZRD1 CDV3 
Imamura, et al.  
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
2 PRCC APMAP 
Imamura, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
92 TFIP11 ZHX3 THRAP3 PDCD4 BCLAF1 
RAD23B HIST1H1E TPI1 NOP58 RPRD1B 
AHNAK PPP1R12A CHMP2B HNRNPUL2 PPL 
PROSER2 PGM1 RMDN3 UBE2J1 ADD1 
SCFD1 TIMM8A SRRM1 PABPN1 CARHSP1 
LMO7 NUCKS1 YRDC VPS4B ABCF1 SEPT2 
MTDH NCL WDR44 SEC62 RBM39 WRNIP1 
SORBS3 AMPD2 MAP1S HNRNPA1 KTN1 
SYAP1 HDLBP MTFR1 SLTM ARHGEF12 
RALY RBM33 PGRMC2 LSM14A TWF1 MYH9 
PPIG TMPO PRPF4B SEPT9 NAP1L4 NOC2L 
PRRC2C RRBP1 PPP1R10 VDAC1 ILF3 
SEC31A HNRNPC ZC3H18 SH2D4A TPD52 
ZC3H13 HIST1H1B NUP98 NIFK SMAP PLEC 
OGFR HSF1 PHF14 TMX1 HSPH1 VCL 
LRRFIP2 CRK PKM HNRNPA3 NOLC1 NUMA1 
SYNPO RANBP2 CAST PNN STX4 
127 
Embogama, et al. 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
1 SBDS 
Embogama, et al. 
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
1 AP2M1 
Embogama, et al. 
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
16 LMAN1 PRDX4 UMPS ACY1 RPL28 DAK 
NME1 PEBP1 RPL29 PTPN11 UFD1L SF1 
SF3B1 ACAA1 PRDX2 IWS1 
Hamaguchi, et al. 
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
1 PHACTR2 
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
29 NDUFS4 PSMD11 SNX6 RPS21 AKAP2 
ACADVL SEPHS1 RPL24 NAMPT ACSL1 
CPOX ALB CNPY2 TAGLN2 AFG3L2 PKLR 
CALR SPR ASGR1 PSMA2 DPP3 ATP6V1B2 
NSF PPP2R1A SNX3 THUMPD1 COX4I1 CTSZ 
ATIC 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
1 CNBP 
128 
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
15 GPD1 ALAD FDX1 EPN1 EVA1A ETFB TYMP 
GPHN DNAJB1 EEF1A1 GLUD1 EEF2 ETFDH 
GLUL FTCD 
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
DNAJB1-PRKACA in vitro  
Mouse Liver Lysate 
PRKACA (L206R) in vitro  
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
11 SLCO2B1 UQCRC1 NDRG2 PGAM1 CNDP2 
ANP32A PFAS PSMA6 ARCN1 HSPA5 
HNRNPM 
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
3 ALDH1L1 ALDH4A1 ACOX2 
Hu, et al.  
Imamura, et al. 
Isobe, et al. 
2 SMARCAD1 PCM1 
Hu, et al.  
Isobe, et al.  
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
1 MAP2 
Hamaguchi, et al. 
Imamura, et al.  
Isobe, et al. 
3 SIK2 LIMCH1 DENND4C 
Imamura, et al.  
Isobe, et al.  
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
1 WNK1 
Imamura, et al.  
Isobe, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
1 PLEKHG3 
129 
Isobe, et al.  
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
2 PLEKHF2 KARS 
Isobe, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
1 SCYL2 
Isobe, et al.  
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
2 PBXIP1 CLMN 
Isobe, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
1 IRS1 
Hu, et al.  
Imamura, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
2 NEDD4L HIRIP3 
Hu, et al.  
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
2 STK24 CRIP2 
Hu, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
1 PAH 
Embogama, et al. 
Hu, et al.  
Imamura, et al. 
3 GFPT1 CTTN ACACA 
Embogama, et al. 
Imamura, et al.  
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
1 DPYSL2 
Embogama, et al. 
Imamura, et al.  
PRKACA in vitro  
Human Hepatocyte Lysate 
1 NACA 
130 
Hu, et al.  
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
1 SLC4A4 
Imamura, et al.  
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
13 BET1L UBA1 RBM17 PPIP5K2 SHTN1 
SNRNP70 ZNRF2 DIS3L2 RANBP3 MARCKS 
MIOS GMPS CLNS1A 
Imamura, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
2 EIF3H WASL 
Imamura, et al.  
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
1 UBA2 
Imamura, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
20 ARHGEF16 SEC16A LEO1 KRT18 PAXBP1 
MAP3K7 ZC3H4 DMD PCBP2 BMP2K MYO1C 
ACOX1 PTGES3 CPSF7 SUB1 CD2AP 
MYO18A ARFIP2 CHCHD3 PEX19 
Imamura, et al.  
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
6 SVIL HNRNPA2B1 MFAP1 TSC2 DDX46 
PRKAR1B 
Imamura, et al.  
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
21 EML3 PACSIN3 EPS15 ARGLU1 ZC3H14 
COPB2 HNRNPH1 U2AF2 GTF2I HNRNPU 
NUFIP2 CDC26 GAPVD1 EBAG9 HACD3 
KIAA1671 EIF2A RPL27A REEP4 FUNDC2 
FCHO2 
Embogama, et al. 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
2 SARS RNH1 
131 
Embogama, et al. 
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
7 RPL35 POLDIP2 HSPA4L TXNDC5 IVD PARP1 
PDIA4 
Embogama, et al. 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
1 ANXA2 
Embogama, et al. 
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
1 EXOSC2 
Hamaguchi, et al. 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
2 CDK18 DAPK2 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
3 ASNA1 SARDH NNT 
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
3 GPX1 GNMT FMO5 
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
2 PDHX CDH13 
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
4 EIF1 PDP2 HADHA H6PD 
132 
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
289 SUMO1 HEL-S-117 RPL19 MESDC2 ST13P5 
LYAR PIR CTAGE5 CYP2D6 SHROOM1 
SLC27A3 DMTN GSTA2 RPS28 PREP 
HSP90AB2P PPM1A ALCAM TF ASS1 PBDC1 
LDHB NME1-NME2 C9ORF142 ACTC1 
ABHD12 UFL1 IMMT HIST1H1A HP1BP3 
CDHR5 ALDH1L2 C17ORF59 BCAP29 
SULT1A2 ACOT2 CHMP6 MIA2 MANF CASC4 
PHYKPL CTAGE9 MARVELD3 CBX1 WBP11 
CBS ADH1C POTEKP ITGA6 PSIP1 MVD 
CYP4F12 CTAGE4 MXRA5 HSP90AA5P 
SPATS2L RABAC1 PRKACB CRAT RAVER1 
SRSF3 NDUFV2 BLVRB MYOCD SSFA2 
NAP1L1 EEF1A2 CD14 PHAX AK1 ACSS3 
CGREF1 THAP4 MAN1A1 ATP5A1 CD276 
METTL14 UROC1 ATPIF1 PYGB API5 APOL5 
POTEF ST13P4 SOD1 CYP4F2 RPS3A 
ASPDH PALM3 MUT SLC38A3 WDR87 PALMD 
SGTA WDR77 LAD1 ATP5J SRP54 STIP1 
SLC25A20 ARPC1B NDUFA7 METAP2 KNG1 
PCBD1 KANK2 ALDH1A3 UQCRFS1P1 
PRPSAP2 POTEI PTGFRN SRPR CTAGE8 
ABCB11 GSTA5 ACTA1 SEPT11 SNTB1 
RPS25 SDF2L1 EIF3CL HIST1H1D CYB5A 
KIAA1598 PGAM2 PSME2 HIST1H1C 
PLEKHA5 MTCH2 MIEN1 HEXA NRD1 SMAP2 
DTNA HNRNPA1L2 PIPOX BAAT ARFGAP1 
PPP1R7 NDUFA5 PDLIM5 HNRNPUL2-BSCL2 
MLLT4 METTL1 IQGAP2 C1ORF53 MACF1 
AIFM1 TMEM160 ADD3 POLI SMARCC1 
SLCO1B3 AK3 SARS2 GLUD2 MDH1 
CAMSAP3 ANGPTL3 NDUFS8 DTX3L SCRN2 
CCT2 ATP5B HSD17B4 XRCC6 LETM1 
BCAP31 POTEE ISOC2 SERPINA1 STBD1 
CYP4F3 ALDH1A2 MAMSTR MTTP WIPF3 
CTAGE15 LYRM5 ZC3HAV1 ARPC5 CYP2A6 
ANXA6 VAPB CTAGE6 BHMT2 PRKAB2 
UBE2M SULT1A1 KIN27 LOC113230 ALDH1B1 
ARG1 BABAM1 HEXB HSPA1A SUMF2 
C9ORF78 PPIB CYP2A13 MAT2B PPIA RDH16 
AK2 RPL30 STX16-NPEPL1 C11ORF58 
ATP5EP2 ANXA5 CPT2 ANP32D LSM7 PLIN1 
PGM2 THOC3 ARPC2 SULT1E1 C14ORF166 
PGK2 UROD EIF1B ATP1A2 NME2 RPL21 
DDRGK1 HIST1H1T WIPF2 PPM1B SORBS1 
RPL5 STX12 MRPL39 IGFBP1 HINT2 CYP2D7 
CMPK1 HTATIP2 PDZK1P1 DNPH1 MTHFS 
CA2 TGOLN2 PRKACG SEMA4G ADH1A 
NME2P1 PA2G4 RPL13 ACTB YLPM1 CYP2C8 
ACTG2 OXNAD1 COPB1 ARHGEF6 ADH1B 
133 
HSPA1B RBM8A CETN2 PGAM4 TKFC PDZK1 
HSP90AB3P POFUT1 SCRIB ABHD14A-ACY1 
RBM27 PGLS ACTA2 TACO1 STX16 CDC5L 
CTNNA2 DBR1 ATP5E ZFYVE19 APBB1IP 
PGM3 ANP32B AP4E1 CASK EEF1A1P5 
TTC38 CES1 PITPNB ADD2 WASF2 NDUFB9 
NADK2 
Hu, et al. 
Isobe, et al. 
6 NUP133 LRRFIP1 SRC ZHX1 NFKB1 SUFU 
Hamaguchi, et al. 
Isobe, et al. 
4 NF1 RPL18A KIAA1522 PITPNM3 
Isobe, et al. 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
1 SAYSD1 
Isobe, et al. 
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
1 EIF2AK2 
Hu, et al. 
Imamura, et al. 
27 CD44 LUZP1 TERF2IP SMC3 NCOA3 FYN 
TRIP10 EIF4ENIF1 LIG1 DNM1L PDE3B 
ANKS1A PTPN12 CDCA7L STUB1 VIM PYGO2 
FOXP4 SP100 EMD ATRIP LAS1L TBC1D10B 
AKAP13 CHAF1B UHRF1 CEBPB 
Embogama, et al. 
Hu, et al. 
4 MSN HLA-A PTBP1 PSMA8 
Hamaguchi, et al. 
Hu, et al. 
2 CAMKK1 C19ORF21 
Hu, et al. 
PRKACA in vitro  
Mouse Liver Lysate 
1 ASPSCR1 
Hu, et al. 
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
2 PFKFB2 SAP30BP 
Embogama, et al. 
Imamura, et al. 
26 CLUH BAG3 MYO1E HNRNPD SF3A1 EFHD2 
BOD1L1 PPP6R3 HDAC1 IGF2R MCMBP 
PSMA3 ACTL6A KDM5C SLC1A5 RCC2 EPRS 
TP53BP1 TK1 SLC4A1AP SLC16A3 EDC4 
PAICS SUPT6H MAGED2 EIF3G 
Hamaguchi, et al. 
Imamura, et al. 
1 C2CD5 
Imamura, et al. 
Isobe, et al. 
38 TNS3 PI4KB ATG2B ARHGAP21 DCP1A XRN2 
DYNC1H1 FAM83H PXN PUM2 HECTD1 
TXLNG RBM14 PRKD2 MARK2 NCOR1 
FKBP15 RAB11FIP1 ABCC1 ARHGAP35 
DOCK7 MEF2D SQSTM1 BNIP2 ENAH WWC1 
SIPA1L1 PKN2 RIN1 AKAP1 MAP3K2 PRRC2A 
OSBPL11 HPS5 LARP4B PARD3 PUM1 ITPR3 
134 
Imamura, et al. 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
1 ACSS2 
Imamura, et al. 
PRKACA in vitro  
Mouse Liver Lysate 
2 TMEM230 STRN 
Imamura, et al. 
PRKACA in vitro  
Human Hepatocyte Lysate 
6 RBM15 RCC1 USO1 UBR4 BAG6 AKT1S1 
Imamura, et al. 
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
11 HMGN1 ESYT2 THOC2 DSG2 HNRNPUL1 
EEF1B2 EPB41 DFFA DENR ESF1 GBF1 
Imamura, et al. 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
3 G3BP1 YAF2 DKC1 
Embogama, et al. 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
1 PSME3 
Embogama, et al. 
PRKACA in vitro  
Mouse Liver Lysate 
1 LAP3 
Embogama, et al. 
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
10 FUBP1 ACO2 PLS3 RPS10 PSMD4 STOM 
SFN YWHAB PC FDXR 
Embogama, et al. 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
2 PSMD12 GPKOW 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
1 HS1BP3 
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
1 TSFM 
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
1 FKBP8 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
1 ACBD4 
135 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
PRKACA in vitro  
Mouse Liver Lysate 
128 ACOT12 HMGCS2 SLK HSPA1L VWA5A 
LCMT1 GCLM FAM213B CES1F ELAC2 
NDUFA2 UCHL4 GM20425 PFKL GC CYP2C70 
WDR91 LXN CNGA2 ATP5H SNRPG 
SERPINA1B DECR2 CYP2B10 GATD3A MAVS 
CES3A URAD MOCS1 SNAP29 SDS FCGRT 
SASH1 CMC2 NECAP1 GIMAP4 F13B 
AKR1D1 D2HGDH CDC42EP5 SEMA6D 
CCDC180 NADK H2-KE6 NDUFB11 CYP4F17 
PPP1R11 MESD LCP1 EIF4H TIMM50 
HDGFL2 AKR1C6 ERRFI1 CIDEB FTL1 LBH 
MTFR1L KEG1 CYP2A5 SERPINA1C ADH1 
JPT1 RIDA NAXE LDHD CA14 LYPLA1 
SULT2A8 MRPL12 KIF5B NT5C GM9774 
TUBA1B SERPINA3N EARS2 SELENBP2 
AKR7A2 DHTKD1 CTH ATP5F1A GYKL1 
GSDMDC1 CYP2F2 DNAJC12 9-Sep GOPC 
PNPLA8 GLYCTK ADCY10 ATP5PF IDH3A 
ACSM5 HMGN5 ISOC2A CYP1A2 SERPINA3K 
NUBP1 ENSA ETHE1 PRODH HNRNPAB 
SMOC1 GRN INMT ACSF3 KIF13B UBQLN1 
FAM162A MTSS1 ATP5F1B GPRIN3 ANK3 
ATP5C1 ZFP69 AMT HSD11B1 BOLA1 GPT2 
CYP2D22 APOA1 SEPHS2 AGMAT ECI1 
MUG1 CCDC9 SERHL ACAA1B 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
15 DDT OGDH ANXA2P2 UGT2A3 UCHL3 MVK 
DDTL CRYL1 LYRM1 DOCK8 BAT3 PRPF40A 
SH3BP5L ZDHHC5 OR51A7 
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
78 ITGA5 RPS4Y2 FRS2 ENOSF1 DENND1A 
LAGE3 FTH1 FETUB GANAB EEPD1 EIF3D 
FHIT FAM122A GIGYF2 ECHDC3 GPX2 
TRANK1 EPB41L3 RPS4Y1 ABCA12 GCLC 
GCDH KDM4A HACL1 RPS6 C2ORF72 G3BP2 
AASS FMO3 EIF3A EMC10 FAM134A FKBP3 
EIF3J PPP1R3E LRP2 RNPEP FBP1 HADHB 
GAS2 ENO3 ENO1 TMEM41A IFNA6 
PLEKHA6 EHHADH ALPL GMPR2 GSTA1 
SOS1 GUCY1A3 GOLM1 FBP2 FASN HAO1 
GPI STIM1 RPS4X KIAA1217 APOA5 GRB14 
MIEF1 EHBP1 GLRX3 FABP1 TMEM109 
PDHA2 FAH EIF3C DUT PPFIBP2 GSTO1 
ECHDC2 RSRC2 TCEA3 HNRNPH2 GATM 
EEF1G 
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
PRKACA in vitro  
Human Hepatocyte Lysate 
142 RAB2A NAPRT RGN RPL17-C18ORF32 
UGT1A1 CYP2C19 PDIA3 ALDH3A2 HIST3H3 
HSP90AA4P APOE PMM1 HIST1H2BL 
DKFZP586F0420 PICALM CYP7A1 MTSS1L 
CTSB PCBP3 HYPK UBE2D3 PLRG1 CYP2C9 
PRKDC DNAJC1 SLCO1B1 SMS HMBOX1 
136 
RPL17 ACOT9 POR NAA15 PROC HSD17B13 
LMNB1 TFAM DUSP3 HMGN2 COPE CFL2 
ITFG3 HIST1H2BK TOMM70A OTUB1 CHP1 
IGBP1 ACACB SERF2 RPL8 AHSG DDO 
HIST1H2BD AGXT UBE2V1 MECR 
HIST1H2BH SHMT2 ST20-MTHFS LTA4H 
HMGB1 LBR BAIAP2L1 QARS SQRDL LYRM2 
NEDD4 HMGN3 SND1 HIST1H2BC APOB CS 
PRDX1 ITGA1 PPP2R1B KHK DNAJC3 TARS 
CDK6 HIST1H2BN LUC7L ALG13 MAP2K2 
CMC1 MYH10 MYH11 CTSD RP2 ADRM1 
MCEE PLAA SHMT1 SRP9 HMGB2 ISG15 
PRDX3 PML MYH14 PSAP ACADSB HGD 
UGDH HIBCH TIMM10 UQCC2 PABPC4 
AIMP1 PPIF ABAT SCARB2 PSMA7 SRPRB 
SORD SPECC1L-ADORA2A ATP6V1G1 
STOML2 SETSIP HMGB1P1 METTL7A CADM1 
C21ORF33 ITIH1 MLEC HTRA2 IARS2 DDX58 
PABPC1 HIST1H2BM HSD17B8 PFN1 QRSL1 
H2BFS XYLB HIST2H2BF DCTN2 PMM2 
SSBP1 HSP90AB4P ANXA4 HNRNPL 
CHCHD4 SNAP91 SUOX 
Isobe, et al. 76 CHD9 SPIRE2 MIB2 SEC23IP ZZEF1 TIAM1 
OSBPL10 PPM1H TAB2 HBP1 ATP6V0A2 
MAP4K3 SLC7A6OS MRPS9 PTPN14 
BLOC1S5 TMEM259 PCYT1B MRPL37 
ZNF608 KIAA1109 DOCK1 WDTC1 KLHDC7A 
WDFY3 TIAM2 SLAIN2 ARHGAP29 BORCS6 
ERBIN JUP CHCHD6 FGD3 SNX12 VIPAS39 
DOPEY1 RAB18 PHLDB2 KAZN PARD6B 
VEPH1 MAP3K5 TBC1D12 NEK4 PI4KA 
MYO5B CAMK2D ARHGEF2 CASP8 ITSN2 
NULL VILL MTOR PEAK1 EPS8L1 LYST 
MTCH1 KLC3 IGSF5 MAP4K5 UHRF1BP1L 
AFAP1L2 ERBB3 PURG SHROOM3 NFATC2 
HERC4 ARHGEF17 RTKN CGN SKT MAP4K4 
PTPN13 TNS2 ARHGAP27 ZAK 
Hu, et al. 198 HNRPD PPP1R14A SERPINF1 CENTD2 GRK1 
BIRC5 CIAO1 SIP1 C21ORF66 RASGRF1 
EP400 PPP1R9A BCAM NPR1 AQP2 PDE4C 
DDX39 IRF3 TAF10 EZR TFAP2B CIITA GMFB 
AURKA C14ORF106 KCNJ13 RGS14 CSRP3 
KCNA4 PPP1R1B GPBP1L1 RRAD SNAI1 
SOX9 ADRB1 NOXA1 HAGH CACNA1H 
XRCC4 NAB2 GLI1 GRIA1 CCND1 RUNX1T1 
POP7 ESR1 KCNN3 PDE4D NFATC3 SREBF2 
RUVBL2 E2F7 APOBEC3F MDFI GSK3B 
GNA13 SGK TRPV1 HLCS CHGB DDEF2 
PPP1R13L H3F3A MC4R CSDC2 GATA3 
FOXN3 HIST2H3A UTP18 RCHY1 CLDN3 
137 
CAPN2 CREB1 ERBB2 TRPV4 PDE5A HDAC8 
DAXX KCNJ3 HRH1 ID2 RB1 DHX29 PDE4B 
SOX6 DNAJB2 HNRPK NRIP2 RNUXA TP53 
CASP9 ZNF496 KCNN2 PPP1R1A FXYD1 
BMI1 KCND2 UNC84B GRK7 TPH2 ETV1 
C13ORF15 LOC648998 ESPL1 HSPB6 HSPB8 
ANXA1 ALOX5 PKD1 TRPM8 TTF2 NFATC4 
RXRA POU3F4 NFATC1 PLN PLCG1 DAP3 
ITGB4 BTBD12 FAM44A GSTA4 ABCA1 
ARID3A AICDA KCNH2 LIPE TNNI3 PLCB3 
CRHR2 MAPT RBM19 ABCB1 WT1 CTPS 
MYBPC3 CSK TH LCK PHOX2A DES RDBP 
RNF12 PCTK1 ACCN2 SNUPN PFKFB3 
NEUROD1 U2AF1 BCOR AVPR2 CSNK1A1 
EXOSC5 PTPN7 DUOX1 ITGA4 VDR 
PRKAR2B PHF17 MYOM2 CUL5 MCOLN1 CBL 
FIP1L1 TFAP2C C20ORF32 AKAP9 NCBP2 
NR5A2 RBM22 RYR2 RPS19 NOS3 CFTR 
C19ORF2 TSC22D4 PDE11A GFAP AQP5 
PPP2R5D GAS7 RBBP5 ETV5 ARFGEF1 
PPP1R1C LOC51035 PPP1R14C 
LOC100133382 GSK3A METTL3 NF2 GAD1 
NCOA4 SRF GATA4 VHL MDM4 HCLS1 
Imamura, et al. 729 SLMAP ERCC5 TACC2 BYSL CXCR4 U2SURP 
CHD8 SCAF8 TPX2 EP300 GYS1 MON1B 
CHORDC1 C2orf49 ZEB1 TRIM33 PARN 
CD2BP2 SRPK1 PTCD3 NMNAT1 SHC1 
SAAL1 TAOK3 RIOK1 HERC2 SLC12A4 
CLCC1 USP6NL BAZ1B SDAD1 PPP1R15B 
LARP7 KPNA2 ATL2 ZCRB1 KPNA3 DDB2 
RBM10 TRA2B STK17A MTRR NCOR2 
GTF3C3 CEP170 MSH6 SRSF6 HDAC7 SIPA1 
CCDC43 ATAD1 NELFE IMUP SORT1 
SETDB1 CARMIL1 SRSF11 PCDH7 TJAP1 
ORC1 SON PLCL2 TRAM1 AVEN C9orf16 
USP42 NIPBL POGZ RICTOR RAD18 LRRC8A 
PRRC2B CDK17 ZNF687 KDM2A HABP4 
NFIL3 WDR62 DHX16 LEMD2 MIS18BP1 
UBXN7 DIDO1 LYSMD2 ARAP1 NGDN 
SAC3D1 ITPRIPL2 UNG DPF2 CBARP BRD8 
PJA2 DCUN1D5 ANKLE2 CHMP7 FRYL 
PTPN2 AP3B1 HCFC1 UBL7 KRT17 RPL4 
VAMP4 PRPF3 DDX24 RBM6 WAPL 
SH3PXD2A RBBP6 PARG ASAP2 CEP131 
STRIP1 SSRP1 PDAP1 BRD4 CHAF1A 
TOR1AIP1 BCKDK CSRP1 ITSN1 CHAMP1 
NSD1 ATP2B2 NCAPD3 ABCC2 GPATCH8 
KIF4A CPD KRT8 MAP7 RBM7 OSBPL3 
ANTXR1 TERF2 HASPIN XPO4 WIPI2 IFNAR1 
EHD2 ANKRD17 CCNK NCKAP5L FAM129B 
138 
EAF1 NOTCH2 PSMD2 CHTF18 ATXN2 
ARHGAP12 VIRMA STRN3 CHMP3 CEBPZ 
ANAPC1 SRRT MELK RBM3 BMS1 CDK16 
SF3B2 KAT5 FLYWCH2 TPD52L1 SLC19A1 
XRCC1 PAK1IP1 SLC7A11 CDS2 AHCTF1 
SENP3 EEF2K WDR26 MUS81 PWWP2A GAL 
KIF1B PIAS1 CNOT2 SNW1 RPP30 TRIM16 
CDC40 IRF2BPL RECQL5 WEE1 BSG BIN1 
PTDSS1 FMNL1 GLCCI1 MMTAG2 ARMCX3 
QSOX2 YBX1 LRFN4 PNISR STK10 HERC1 
PTPN23 DGCR8 CTR9 BRI3BP KPNA4 MDC1 
INO80B RBM34 RCOR1 TRMT1 KMT2D 
TELO2 MAF1 C7orf50 USP15 HDAC4 WDR33 
AMFR MAPK1 MPHOSPH10 TLE3 TACC1 
PDCL ZC3HC1 DYNC1LI1 FXR2 ZC3H8 
ARHGAP1 CLASP1 TFAP4 AFAP1 CDK13 
BCR TWISTNB RPL15 RIOK2 REXO4 UFD1 
SMARCA4 RPS6KA4 BRD7 ZBTB21 CEP55 
EYA3 HOXC10 EML4 ATF2 CTPS1 TOM1L1 
GOLGA2 TRA2A CAMSAP2 RFC1 ABCC5 
ASMTL SNAPC5 MOCOS AFDN SLC30A1 
TBX3 DNAJC21 NRDC SART1 HSPE1 RBM5 
EIF4EBP1 PPP1R9B SLC43A2 MCM2 TGS1 
MCM4 SPTBN2 TOMM70 ARHGAP5 DDX21 
PWP1 ADAR POP1 MTA1 GPAM TIMELESS 
DDX10 KIF13A KRT7 PHF8 TMEM87A 
PLEKHA2 ESCO2 DNTTIP2 ZMYM4 ZNF106 
MKI67 PANK2 NHS CLSPN BICD2 ARL6IP4 
PURB ACAP2 PPP4R2 BUD13 SDE2 
SLC39A10 CDCA2 PPA2 MED24 EHD1 
RAB11FIP5 TBC1D15 ADAM17 ZNF830 
ELAVL1 NCOA2 RPP25 ABCA2 EXO1 AJUBA 
CIAPIN1 STAMBPL1 TCF20 PPM1G C9orf40 
ELMSAN1 SSH3 KLC2 FNDC3B SIRT1 AREL1 
NEK9 UPF3B RPL23A ADNP RFFL RBM15B 
ERICH1 DDX39B TLE4 TOP2B CNNM3 
FAM117B TAF15 MED19 PAGR1 POLD3 
VAMP7 RSF1 MON1A POU2F1 APC RSL1D1 
RBM25 CDC42EP1 TPR AKAP11 WDR3 
TTC33 TRAFD1 CTTNBP2NL MGRN1 PTDSS2 
USP39 ATXN2L FLII CLASRP CWF19L2 BRAF 
RPL14 TMOD3 RALBP1 CAAP1 GEMIN5 
DDX20 MYBBP1A PHKB SLC16A1 USP8 
SLC17A5 EPHB4 MBD1 TP53BP2 STT3B 
CD3EAP PITPNM1 HECW1 RLF KLF3 RPTOR 
BCL2L12 NBAS HIVEP1 ATRX VAMP8 NBN 
MAST2 PACSIN2 TOPBP1 NUP214 SOX13 
EIF3B MFSD6 USP20 MCRS1 UBE2E3 
RAB3GAP1 BASP1 SLC35F6 PTOV1 
TMEM45A CDK12 JADE3 PHF3 PEX14 APEH 
139 
TBC1D5 MAPKAP1 MINK1 EZH2 SLC15A4 
OSMR WIZ RBM4 CSF1 EDC3 SLC35B2 
CEP170B COPA PHC3 FAM102B KIAA1143 
USP24 NUP153 TTYH3 SLC12A6 RAP1GAP 
URI1 NOP2 RAD9A USP16 SCML2 USP10 
PODXL2 PI4K2A RPS3 WDR75 SFSWAP 
DYNC1LI2 COIL ZMYND8 ZNF609 CASC3 
TCF12 ATP7A ZNF641 TANC1 TBXA2R 
PRKCD ZNF639 PUS1 BCL9L SMC4 EPB41L1 
EXOSC9 ABCC4 ZFP36L2 PBRM1 RNF20 
USP9X BRF1 RRAS2 MCM3 RPS2 NRBP1 
MYPN RNF113A PPHLN1 TBC1D2B AFF4 
AKAP10 PRPF6 PDE8A SH3KBP1 PLA2G4A 
SYNRG RIF1 UNC13D MEPCE KIF21A UNK 
SAMD1 SCD SLC38A2 CCDC86 ATN1 MPZL1 
SMN2 TRPT1 STX7 SPEN GPRC5A C1orf52 
CD97 PDS5B MPHOSPH8 TICRR ZBTB7A 
MADD SLC4A2 ARHGEF18 ARRB1 SUGP1 
SIN3A POLR3E TXNL1 CCNYL1 OBSCN CBX8 
IL1RAP CIR1 FTSJ3 UTP14A RRP1B SLC4A7 
GNL1 NELFB PPP1R12C ATG9A NEDD1 
DNAJB6 NFIC TCEAL4 PRPF38B NUP50 KRI1 
LEMD3 TXLNA BUB1 PIEZO1 GTF3C2 SKIV2L 
SNTB2 SURF2 ZRANB2 CLASP2 DOT1L 
EIF2AK3 RPRD2 ATF7IP FOXK1 FXR1 
NUP210 PPAN SLC7A2 GZF1 DDX55 FERMT2 
NSUN2 DTD1 SLCO4A1 STK11IP RTN4 
TAX1BP1 PHRF1 PPP1R2 TBC1D4 GIT1 
PAXX TMEM51 SLU7 DAB2 TTLL12 DNAJA2 
LYN CCNL1 ZFP91 CDCA3 NOP56 RAI1 BPTF 
ATAD2 PHF6 ANAPC2 DNMT1 EPB41L2 
SLC16A6 RREB1 FNBP4 LIFR DNMBP 
SNAP23 TFDP1 MGA IRF2BP1 SRSF10 UTP3 
CLINT1 RTTN ZFC3H1 MYCBP2 LATS1 NEMF 
MED1 SRSF1 TMEM245 LAMTOR1 DIAPH1 
TRAF4 RRM2 SLC20A1 TOP2A DNAJC2 
IGF1R NOB1 GTF3C4 TTF1 NCBP1 SLC9A1 
HDAC2 NEXN IL6ST NCAPD2 UBAP2L 
PPP4R3A TMEM131 GPN1 WDHD1 UBE4B 
DBN1 LRWD1 PTS OTUD5 DDX54 ALPI 
KMT2A PKN1 WTAP BUB1B JMJD1C CCNH 
SURF6 MTCL1 ERCC6 RRP12 DMAP1 SRSF2 
RAB12 DDX51 HEXIM2 ZC3H11A TCF3 
C18orf25 SMN1 RANBP10 PSMD1 DTL 
SRFBP1 SRSF9 C19orf24 RBMX TGFBR2 
NAF1 NFX1 MDN1 OXSR1 SLC38A1 PPFIA1 
PLCD3 NCAPH2 PDS5A ZFR HNRNPLL 
CUL4A CDC42BPB LYSMD1 TMX2 ZNHIT3 
TBC1D2 PRKAB1 RALGAPA1 KIF20A SSX2IP 
GTF2IRD1 MORC2 WDR55 GIPC1 ZNF592 
140 
EIF4G2 GTF3C1 FAM208A KHDRBS1 
PPP1R18 PHF10 PSEN1 NUP43 EPS15L1 
NMD3 TOE1 GATAD2B FMNL2 HMGA1 
SUPT7L YTHDC1 LIG3 STK38 ATP2A2 GAB1 
MTMR3 DDX3X TRIM25 SCAF11 NCAPG 
GOLGA4 TMF1 FUNDC1 MISP CLN3 
TMEM106B NDRG3 ATP2B1 VDAC2 CENPF 
RPS6KA3 BET1 SNX17 RANGAP1 SGPP1 
DCAF8 RPS27 CDCA8 ZNF638 
Embogama, et al. 142 PFKP DECR1 CSPG4 HSD17B10 NT5DC1 
DDB1 PAIP1 DDX5 USP47 GDA IPO9 PUF60 
IMPDH2 RTF1 USP14 USP7 SPG20 NUP88 
NOMO1 DHX15 FKBP4 SF3A3 AHCYL1 
UBQLN2 HEXIM1 TPT1 RDX EHBP1L1 LDLR 
ITGB1 RPN1 PSMC4 CASP1 CECR5 FKBP5 
PRMT1 TYMS MCM5 PLOD2 RPS24 SH3GL1 
WIBG DUSP12 BUB3 CNN2 WDR61 PRMT5 
CLIC4 NHLRC2 FTO PTPRF RAB6A MINPP1 
AKAP12 PRPF8 IARS UBE2O PPP2R2A 
CKMT1A TUBA1C PAAF1 SLC3A2 COPS3 
DNM2 VARS DDX17 TIPRL LAMP2 NONO 
CPNE1 IMPDH1 NMT1 UBFD1 POLD1 ACTN1 
HSDL2 RPS16 SF3B3 PNP ANKZF1 ACTR2 
OAT TBCB SDHB DDOST PSMA1 DDX47 
CYFIP1 ATP1B1 ARF1 SMC1A OXCT1 
MTHFD2 MYOF FKBP10 MPI WARS CSE1L 
PFKM ELP3 TES PLOD3 PSMC1 MCCC2 
PSMD14 DHX9 PSMA4 SERPINH1 CAPZA1 
SEC24C SERPINB4 SERPINB1 POFUT TUBB6 
MRPL2 GNB2L1 HMGCL ASNS CHD4 CDC73 
GOLIM4 GDI2 RRM1 KLC1 GALE DRAP1 DLD 
SETD7 PLD3 SART3 RARS TRMT10C MGEA5 
KPNA6 NAGK RPS14 PGD PYCRL NANS 
GPC1 LANCL1 MPST 
Hamaguchi, et al. 19 CDC25B OFD1 MARK3 PITPNM2 CEP72 
KIAA0556 GLI2 HSPC075 BAT2 EVL CRY2 
PCNX CASP11 TMCC1 CAMKK2 SIK3 
C2ORF55 PDE8B LRCH3 
DNAJB1-PRKACA in vitro 
Mouse Liver Lysate 
47 MSRB1 PYROXD2 MMGT1 SUGCT ACAA1A 
DGLUCY RCSD1 ACSF2 DCAF11 TNNT2 B2M 
GLOD4 GPD1L CR1L CEP290 GBE1 ASPG 
RTRAF CACNB2 SSR1 MUSTN1 RUFY3 
WIPF1 ADSS ITIH4 SPHK2 CYP2D11 HAL 
CSMD1 RPS3A1 AADAT PRKAA2 OPLAH 
PCDH1 WASHC2 NUCB2 EIF5 GM20604 
MMUT FLAD1 IFI35 DOCK5 HAAO CYP2C29 
SLCO1B2 KCTD12 C6 
PRKACA in vitro  
Mouse Liver Lysate 
11 SIRT5 FAM50B SCO1 MAPRE3 PCX ECI2 
ETNPPL IGSF10 ITPA RILP ARID4B 
141 
PRKACA in vitro  
Human Hepatocyte Lysate 
35 ACTN4 PNPT1 PDCD5 PLIN2 UBXN4 NUDT12 
PALM2 PALM2-AKAP2 NRAP MDH2 VPS53 
ACOX3 CDK5RAP3 NUMB PLIN5 ARFGAP3 
SLC25A10 UBE2D4 PLXNB1 AHCY UQCRB 
DPYS TNS1 NUMBL UBE2D1 CYP2C18 
CYP27A1 CAP2 RNMTL1 PPM1F MLXIPL 
ZNF326 PHYHD1 UBE2D2 DAAM1 
DNAJB1-PRKACA in vitro 
Human Hepatocyte Lysate 
58 ERBB2IP TFR2 SDC2 GLG1 PCCB TJP3 ECE1 
FAM114A2 HARS RPS10-NUDT3 HSD17B7 
DMGDH STX5 PHYH RPL36A-HNRNPH2 
DDX50 ARHGEF5 ALS2 C4B GTF2H1 APOO 
COA7 TP53I11 GLB1 GALK1 RPL36A FKBP7 
FUBP3 FBXO22 C4A GPALPP1 RUVBL1 
DDAH2 GRHPR FMO1 ELMOD2 EPHX2 H1F0 
ETF1 SEC23A GLYATL1 LMAN2 FAM83G 
SYMPK DAB2IP ACSM2A FGA GGT7 HADH 
EPHX1 UBXN1 ERP44 ENPP1 FAM114A1 
ESPN MAT2A ACSM2B S100A9 
PRKACA (L206R) in vitro 
Human Hepatocyte Lysate 
18 EPS8 ERO1L SLC16A2 KIAA0368 DPP9 
PDXDC1 PAK4 HMGCS1 EIF4EBP2 ASGR2 
SAP18 DR1 NCKIPSD EXOG ECM29 ARAF 
PSMB10 FAM21C 
Sequence Motif Preferences 
One way to look at a group of peptide sequences is to visualize them with a 
sequence logo (Schneider and Stephens 1990; Crooks et al. 2004). The height of the 
letters in these graphics is proportional to its frequency at that position in the group of 
peptides being studied. These logos would obviously reveal the consensus sequence 
for a group of substrates, but it would also allow for the detection of subtle sequence 
patterns.  
For Figures 29 and 30, the peptide sequences identified in the no kinase 
reaction condition were removed from all conditions to try to truly detect patterns of 
substrate motifs for these different kinases.  
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Figure 29. Sequence Logos for Total Peptides Identified in Kinase Reactions in 
Human Hepatocyte Lysate.  
The total number of phosphopeptides identified in each condition were inputted into the 
sequence logo generator (Crooks et al. 2004) to yield these graphs: 1642 
phosphopeptides for PRKACA, 1688 phosphopeptides for DNAJB1-PRKACA, and 1183 
phosphopeptides for PRKACA (L206R).  
Figure 29 shows very similar sequence logos between the three kinases, but the 
-3 position for the peptides identified in the PRKACA (L206R) sample show a slight 
difference in preference compared to the DNAJB1-PRKACA and PRKACA which are 
very similar. It also looks like there may be subtle differences in the +2 and +3 positions 
between these three kinases. This matches what was seen in the heatmap and Venn 











































































Figure 30. Sequence Logos for Peptides Only Identified in One of the Kinase 
Reactions in Human Hepatocyte Lysate. 
The number of phosphopeptides that were only identified in each condition were 
inputted into the sequence logo generator (Crooks et al. 2004) to yield these graphs: 43 
phosphopeptides for PRKACA, 44 phosphopeptides for DNAJB1-PRKACA, and 20 
phosphopeptides for PRKACA (L206R).  
Figure 30 is looking at the sequence logos of peptides that were only identified in 
that particular kinase reaction. These sequence logos may provide more information 
about substrate preference or specificity of a kinase since it is looking at peptides that 
were uniquely enriched for phosphorylations in just those samples with that particular 
kinase. Interestingly, the negatively charged amino acids in the +3 and +4 positions of 
the peptides found in the PRKACA (L206R) sample match the recently published 
sequence logo of this kinase from a paper that suggests that this variant has substrate 












































































Peptides Only Identified in Each Condition
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may have more of a preference for hydrophobic peptides than DNAJB1-PRKACA. The 
peptides identified only in the DNAJB1-PRKACA sample also seem to have a 
preference for a positively charged amino acid in the -6 position and a negatively 
charged amino acid in the +7. Our lab is following up on these potential differences with 
computational modeling. 
Conclusions 
Knocking down the endogenous kinase activity in human hepatocyte lysate with 
FSBA provides a diverse substrate pool for in vitro kinase reactions. Phosphopeptide 
enrichment from these kinase reactions is sufficient and robust enough to detect 
hundreds of phosphorylation events above the background phosphorylation detected in 
the no kinase added control. This method is highly suitable for comparing the potential 
substrates of multiple kinases on the same lysate. 
Since the experiment done in this part of the study was in triplicate, statistical 
analysis was possible using the Perseus software. A PCA plot and heatmap that was 
generated using an FDR-corrected ANOVA test (FDR-0.01) show that each of these 
kinases has a distinct phosphorylation pattern when compared to each other. 
Interestingly, there is a group of potential substrates of DNAJB1-PRKACA and PRKACA 
(L206R) that are not enriched from the PRKACA samples. Since both of these PRKACA 
variants are found in tumors, this may be a key group of proteins to focus on for further 
studies of tumorigenesis.  
STRING analysis based on this interesting list of potential substrates suggests 
that DNAJB1-PRKACA and PRKACA (L206R) could phosphorylate many human 
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hepatocyte proteins involved in mRNA regulation or various catabolic processes, both of 
which could contribute to tumor growth. 
 A comparison of proteins identified with phosphosites in the mouse liver in vitro 
assay with the proteins identified with phosphosites in the human hepatocyte in vitro 
assay revealed that there are more differences between the two than similarities. A 
comparison of these same proteins to the proteins identified by the other PKA substrate 
identification methods in Chapter I also reinforced that the ability to detect certain 
substrates is affected by the methodology and source material.  
Lastly, sequence logo analysis allows for the detection of subtle differences in 
preference of certain amino acids in particular positions in a peptide favored by a certain 
kinase. Subtle differences in preference for a particular amino acid can inform a lot 
about the structure of a kinase.  
Discussion 
The data from this triplicate experiment is very dense and can continue to be 
mined for more information. It is an interesting question to consider how to sift through 
and analyze this data. Just because a potential substrate is highly phosphorylated by 
DNAJB1-PRKACA in this assay does not necessarily mean it is being phosphorylated in 
FLC, or even if it is being phosphorylated, it may not be crucially relevant to the 
pathogenesis of FLC. However, a highly phosphorylated substrate from this in vitro 
assay could provide structural insight into how this kinase favors certain substrates over 
another. Understanding more about the structure and substrate preference of this 
kinase could also direct paths to therapeutic discoveries.  
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It is also interesting that there is a defined overlap between PRKACA (L206R) 
and DNAJB1-PRKACA phosphorylation targets that is detected in the in vitro screen. It 
is even more interesting that this group of proteins seem to be implicated in mRNA 
regulation and various catabolic processes. Transcriptional and metabolic changes are 
crucial to tumor growth and development and both of these kinases were identified in 
tumors. It is possible that they both have some substrates in common that are crucial to 
beginning the kinase cascades to trigger tumorigenesis.  
I am not surprised that the phosphorylation targets change considerably between 
mouse liver lysate and human hepatocyte lysate. Having access to human hepatocytes 
to lyse for this assay is a crucial component for how useful this data set will be in 
comparing phosphosites of proteins found in FLC tumors to phosphosites of proteins 
identified in this assay in the condition with DNAJB1-PRKACA.   
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CHAPTER IV: Comparing Phosphosites of Proteins Enriched in FLC Patient 
Samples to Phosphosites Enriched in the Presence of DNAJB1-PRKACA in 
Human Hepatocyte Lysate 
Background and Rationale 
The data set from the triplicate in vitro assay using FSBA-treated human 
hepatocyte lysate contains a lot of interesting information in its own right as has been 
discussed, but it cannot tell me which substrates are phosphorylated in an FLC tumor. 
The total phosphome of a normal and tumor sample from an FLC patient can tell me 
what is differentially phosphorylated in the tumor and normal tissues and perhaps what 
pathways are largely being affected, but it cannot tell me what a particular kinase could 
phosphorylate. However, combining these two data sets can narrow down a list of 
candidate substrates for DNAJB1-PRKACA that may be relevant to the development or 
growth of FLC.  
FLC is a rare cancer so tissue samples can be hard to come by, but as I 
mentioned in Chapter I, our lab has a tissue repository of over a hundred patient 
samples. However, for phosphoproteomics studies, the quality of the sample matters 
considerably, as does the size. Luckily, members of our lab are very involved in 
retrieving these samples, so we have some amount of confidence about the time the 
samples have been outside of the patient until they can be frozen to be preserved.  
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For this next experiment I designed, I collaborated with Solomon Levin, now an 
MD/PhD in our lab, to lyse three normal patient liver samples and their corresponding 
FLC tumors for phosphopeptide enrichment with Soren Heissel in the Proteomics 
Resource Center.   
Phosphopeptides Enriched from FLC Patient Tumor and Normal Liver Samples 
The PCA plot generated using Perseus in Figure 31A shows that all of the 
normal patient liver samples are grouping together and that each of the tumors is 
grouping on its own, meaning that the phosphorylation pattern of the tumor is 
significantly altered from the phosphorylation pattern of the normal liver tissue. In order 
to ease my search of comparable phosphosites, the phosphosite intensities were 
averaged among technical replicates. The PCA plot that resulted after this condensing 
of data looked very similar as before (Figure 31A-B) which was reassuring.  
The heatmap of this averaged data also shows a clear signature of 
phosphorylation for the tumor compared to normal in the same patient (Figure 32); all 
intensity values in the data set comprising the heatmap have a p-value > 0.05. Figure 
33B shows that of the 316 proteins that have phosphosites that are significantly 
changed (p-value>0.05) between the tumor and normal liver samples, 108 of these 
proteins also have phosphosites found enriched in the in vitro condition with DNAJB1-
PRKACA. Figure 33A shows that there is an overlap of 352 proteins that have 
phosphosites in the total tumor and normal patient data with the proteins that have 
phosphosites enriched in the DNAJB1-PRKACA added sample in the in vitro assay. 
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This does not mean that they are the same phosphosites, just that they are the same 
protein that also has phosphosites. We are currently working on a way to be able to 
quickly identify whether or not a phosphosite matches from the patient data to the in 
vitro data, but for now this is done manually.  
Figure 31. FLC Tumors Have a Distinct Phosphorylation Pattern Compared to 
Normal Liver Tissue in the Same Patient. 
(A) PCA plot generated with Perseus of normal liver tissue compared to FLC tumor 
tissue from the same patient based on the phosphopeptides enriched from these 
samples. (B) PCA plot, also generated with Perseus, of averaged phophosite intensities 
among technical replicates of the FLC tumor and normal liver samples. 
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Figure 32. FLC Tumors Have Distinct Phosphorylation Pattern from Normal. 
Heatmap of the averaged phosphopeptide intensities that significantly change (p<0.05) 
from normal tissue to tumor tissue generated with Perseus.  
Using phosphopeptide data exported from Perseus for the patient samples and 
the in vitro kinase reaction for the DNAJB1-PRKACA condition, I manually generated 
the list of phosphosites that were in common with each other in Excel. I then used this 
list to manually highlight these points on the plots seen in Figures 34-36 in red, which 
are also listed in Table 17. Points in orange represent phosphorylation sites present in 
the patient data and in the in vitro data in the DNAJB1-PRAKCA and PRKACA samples; 
these proteins are also listed in Table 18. It is of note that Figure 36B, which is a 
magnified shot of Figure 34B, features heat shock proteins, a proteasome subunit, a 
PKA regulatory subunit, cofilin, and (in red) a 3-keto-steroid reductase as being more 
phosphorylated in the tumor than the normal patient liver and also being phosphorylated 
by DNAJB1-PRAKCA in the in vitro data. 
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Figure 33. Venn Diagram Comparing Proteins with Phosphosites Found Enriched 
from the DNAJB1-PRKACA Sample in vitro to Patient Data. 
(A) Potential DNAJB1-PRKACA targets identified from the in vitro assay using FSBA-
treated human hepatocyte lysate (in green) overlapped with all of the phoshpoproteins 
identified in the normal and tumor tissues (in blue). (B) Potential DNAJB1-PRKACA 
targets identified from the in vitro assay using FSBA-treated human hepatocyte lysate 
(in green) overlapped with the phosphoproteins that show a significant change in 
phosphorylation between normal and tumor (p<0.05) (in purple).  
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Figure 34. Phosphosites Found in Normal FLC Patient Liver versus FLC Tumor. 
Intensity values were log2 transformed and normalized by subtraction of the median 
intensity values in each experiment. Teal represents all phosphosites that are more 
present in the tumor than the normal and purple represents all phosphosites that are 
more present in the normal than the tumor. (A) The phosphosites labeled in red are all 
phosphosites that show up as only phosphorylated in the in vitro assay in the DNAJB1-
PRKACA condition. (B) Orange represents phosphosites that are also enriched in the 
samples with DNAJB1-PRKACA and PRKACA in the in vitro assay; this list did not take 
into account if more phosphopeptides with that site were identified in the DNAJB1-




Table 17. Phosphosites Found in Patient Tumor or Normal Liver and Only 
Identified in DNAJB1-PRKACA Sample in Human in vitro Assay. 
Phosphosite 
Uniprot 
Number Gene Name Protein 
500 A0A2R8Y420 EPB41 Protein 4.1 
872 Q96RT1 ERBB2IP Protein LAP2 




166 O43399 TPD52L2 Tumor protein D54 
353 Q96Q42 ALS2 Alsin 
177 P56937 HSD17B7 3-keto-steroid reductase 
452 P08238 HSP90AB1 Heat shock protein HSP 90-beta 
1100 P35568 IRS1 Insulin receptor substrate 1 
293 P08559 PDHA1;PDHA2 
Pyruvate dehydrogenase E1 component subunit 
alpha, somatic form, mitochondrial;Pyruvate 
dehydrogenase E1 component subunit alpha, 
testis-specific form, mitochondrial 
113 P06702 S100A9 Protein S100-A9 
81 O43765 SGTA 
Small glutamine-rich tetratricopeptide repeat-
containing protein alpha 
712 E9PCT1 SRRM1 Serine/arginine repetitive matrix protein 1 
637 E9PCT1 SRRM1 Serine/arginine repetitive matrix protein 1 
10 F8VSL7 STOM Erythrocyte band 7 integral membrane protein 
450 E7EX17 EIF4B Eukaryotic translation initiation factor 4B 
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Figure 35. Phosphosites Found More in Normal Patient Liver versus FLC Tumor. 
(A) is a magnification of the right side of Figure 34B. (B) is a magnification of (35A).  
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Figure 36. Phosphosites Found More in FLC Tumor versus Normal Patient Liver. 
(A) is a magnification of the left side of Figure 34B. (B) is a magnification of (36A). 
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Table 18. Total Phosphosites Found in FLC Tumor & Normal Patient Samples 






527 F8W8M4 ABLIM1 Actin-binding LIM protein 1 
767 S4R3H4 ACIN1 Apoptotic chromatin condensation inducer in the nucleus 
503 S4R3H4 ACIN1 Apoptotic chromatin condensation inducer in the nucleus 
455 P53396 ACLY ATP-citrate synthase 
9 Q99424 ACOX2 
Peroxisomal acyl-coenzyme A oxidase 2;Acyl-coenzyme 
A oxidase 
342 P00325 ADH1B Alcohol dehydrogenase 1B;Alcohol dehydrogenase 1A 
5448 Q09666 AHNAK Neuroblast differentiation-associated protein AHNAK 
135 Q09666 AHNAK Neuroblast differentiation-associated protein AHNAK 
84 
A0A1B0G
TG2 ALDH7A1 Alpha-aminoadipic semialdehyde dehydrogenase 
353 Q96Q42 ALS2 Alsin 
139 H0Y360 AMPD2 AMP deaminase 2 
125 P09525 ANXA4 Annexin A4;Annexin 
400 
A0A2R8Y
611 AP3D1 AP-3 complex subunit delta-1 
410 Q9UKG1 APPL1 DCC-interacting protein 13-alpha 
240 Q8N6H7 ARFGAP2 ADP-ribosylation factor GTPase-activating protein 2 
34 P52565 ARHGDIA Rho GDP-dissociation inhibitor 1 
141 H7C113 ATP11C Phospholipid-transporting ATPase IG 
68 O75348 ATP6V1G1 V-type proton ATPase subunit G 1 
123 I3L0Y9 BAIAP2 
Brain-specific angiogenesis inhibitor 1-associated protein 
2 
331 Q9UHR4 BAIAP2L1 
Brain-specific angiogenesis inhibitor 1-associated protein 
2-like protein 1 
151 P00918 CA2 Carbonic anhydrase 2 
283 E7EX44 CALD1 Caldesmon 
308 Q01518 CAP1 Adenylyl cyclase-associated protein 1 
52 Q9Y2V2 CARHSP1 Calcium-regulated heat stable protein 1 
27 P0DN79 CBS Cystathionine beta-synthase 
93 Q13185 CBX3 Chromobox protein homolog 3 
95 Q13185 CBX3 Chromobox protein homolog 3 
248 J3KNF4 CCS Copper chaperone for superoxide dismutase 
24 P23528 CFL1 Cofilin-1 
24 Q9Y281 CFL2 Cofilin-2 
933 P53618 COPB1 Coatomer subunit beta 
312 P31327 CPS1 
Carbamoyl-phosphate synthase [ammonia], 
mitochondrial 
404 P31327 CPS1 
Carbamoyl-phosphate synthase [ammonia], 
mitochondrial 
654 P35221 CTNNA2 Catenin alpha-2;Catenin alpha-1 
552 
A0A2R8Y
804 CTNNB1 Catenin beta-1 
127 P11712 CYP2C9 Cytochrome P450 2C9;Cytochrome P450 2C19 
113 E7ENE7 CYP2D6 Cytochrome P450 2D6;Putative cytochrome P450 2D7 
158 
350 Q3LXA3 DAK 
Bifunctional ATP-dependent dihydroxyacetone 
kinase/FAD-AMP lyase (cyclizing);ATP-dependent 
dihydroxyacetone kinase;FAD-AMP lyase (cyclizing) 
51 P51397 DAP Death-associated protein 1 
245 Q9UJU6 DBNL Drebrin-like protein 
251 Q9UJU6 DBNL Drebrin-like protein 
267 Q9UJU6 DBNL Drebrin-like protein 
372 Q08495 DMTN Dematin 
35 O75937 DNAJC8 DnaJ homolog subfamily C member 8 
24 P60981 DSTN Destrin 
298 P26641 EEF1G Elongation factor 1-gamma 
450; E7EX17 EIF4B Eukaryotic translation initiation factor 4B 
1053 E7EUU4 EIF4G1 Eukaryotic translation initiation factor 4 gamma 1 
164 
A0A087W
UT6 EIF5B Eukaryotic translation initiation factor 5B 
649 
A0A2U3T
ZH6 EPB41 Protein 4.1 
674 
A0A2U3T




Band 4.1-like protein 3;Band 4.1-like protein 3, N-
terminally processed 
872 Q96RT1 ERBB2IP Protein LAP2 
701 H7BXI1 ESYT2 Extended synaptotagmin-2 
56 P07148 FABP1 Fatty acid-binding protein, liver 
2236 P49327 FASN 







39 M0R299 FBL rRNA 2'-O-methyltransferase fibrillarin 
2107 O75369 FLNB Filamin-B 
280 P49326 FMO5 Dimethylaniline monooxygenase [N-oxide-forming] 5 
99 Q96AE4 FUBP1 Far upstream element-binding protein 1 
881 F8W9S7 GAPVD1 
GTPase-activating protein and VPS9 domain-containing 
protein 1 
89 A2A2G5 GGT7 
Gamma-glutamyltransferase 7;Gamma-
glutamyltransferase 7 heavy chain;Gamma-
glutamyltransferase 7 light chain 
83 C9JFE4 GPS1 COP9 signalosome complex subunit 1 
229 Q9UJM8 HAO1 Hydroxyacid oxidase 1 
7 P05114 HMGN1 Non-histone chromosomal protein HMG-14 
95 P09651 HNRNPA1 
Heterogeneous nuclear ribonucleoprotein 
A1;Heterogeneous nuclear ribonucleoprotein A1, N-
terminally processed;Heterogeneous nuclear 
ribonucleoprotein A1-like 2 
432 
A0A087X
0X3 HNRNPM Heterogeneous nuclear ribonucleoprotein M 
318 P51659 HSD17B4 
Peroxisomal multifunctional enzyme type 2;(3R)-
hydroxyacyl-CoA dehydrogenase;Enoyl-CoA hydratase 2 
177 P56937 HSD17B7 3-keto-steroid reductase 





Heat shock 70 kDa protein 1B;Heat shock 70 kDa protein 
1A 
76 P34932 HSPA4 Heat shock 70 kDa protein 4 
82 P04792 HSPB1 Heat shock protein beta-1 
56 Q9BUP3 HTATIP2 Oxidoreductase HTATIP2 
403 O43719 HTATSF1 HIV Tat-specific factor 1 
387 O43719 HTATSF1 HIV Tat-specific factor 1 
38 Q9NX55 HYPK Huntingtin-interacting protein K 
685 Q13576 IQGAP2 Ras GTPase-activating-like protein IQGAP2 
16 Q13576 IQGAP2 Ras GTPase-activating-like protein IQGAP2 
1100 P35568 IRS1 Insulin receptor substrate 1 
540 Q63ZY3 KANK2 KN motif and ankyrin repeat domain-containing protein 2 
1701 Q9BY89 KIAA1671 Uncharacterized protein KIAA1671 
566 Q9NSK0 KLC4 Kinesin light chain 4 
18 P05783 KRT18 Keratin, type I cytoskeletal 18 
408 E9PDI4 LAD1 Ladinin-1 
1040 Q6PKG0 LARP1 La-related protein 1 
369 Q9UHB6 LIMA1 LIM domain and actin-binding protein 1 
423 P02545 LMNA Prelamin-A/C;Lamin-A/C 
429 P02545 LMNA Prelamin-A/C;Lamin-A/C 
431 Q8N1G4 LRRC47 Leucine-rich repeat-containing protein 47 
3922 H3BPE1 MACF1 Microtubule-actin cross-linking factor 1, isoforms 1/2/3/5 
31 P33908 MAN1A1 Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA 
2145 E7EVA0 MAP4 
Microtubule-associated protein;Microtubule-associated 
protein 4 
188 D6REM6 MATR3 Matrin-3 
747 Q96PC5 MIA2 
Melanoma inhibitory activity protein 2;cTAGE family 
member 6;cTAGE family member 15;cTAGE family 
member 4;cTAGE family member 8;cTAGE family 
member 9 
1773 Q15746 MYLK 
Myosin light chain kinase, smooth muscle;Myosin light 
chain kinase, smooth muscle, deglutamylated form 
1354 M0R300 MYO9B Unconventional myosin-IXb 
330 Q92597 NDRG1 Protein NDRG1 
243 P06748 NPM1 Nucleophosmin 
148 Q02818 NUCB1 Nucleobindin-1 
214 Q9H1E3 NUCKS1 
Nuclear ubiquitous casein and cyclin-dependent kinase 
substrate 1 
198 Q9H1E3 NUCKS1 
Nuclear ubiquitous casein and cyclin-dependent kinase 
substrate 1 
342 Q96CV9 OPTN Optineurin 
9 P61457 PCBD1 Pterin-4-alpha-carbinolamine dehydratase 
457 Q53EL6 PDCD4 Programmed cell death protein 4 
293 P08559 PDHA1 
Pyruvate dehydrogenase E1 component subunit alpha, 
somatic form, mitochondrial;Pyruvate dehydrogenase E1 
component subunit alpha, testis-specific form, 
mitochondrial 
293 P08559 PDHA2 
Pyruvate dehydrogenase E1 component subunit alpha, 
somatic form, mitochondrial;Pyruvate dehydrogenase E1 
component subunit alpha, testis-specific form, 
mitochondrial 
483 O60825 PFKFB2 
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 
2;6-phosphofructo-2-kinase;Fructose-2,6-bisphosphatase 
2039 Q15149 PLEC Plectin 
160 
66 Q9H307 PNN Pinin 
667 P48147 PREP Prolyl endopeptidase 
204 P17612 PRKACB 
cAMP-dependent protein kinase catalytic subunit 
beta;cAMP-dependent protein kinase catalytic subunit 
gamma;cAMP-dependent protein kinase catalytic subunit 
alpha 
58 P13861 PRKAR2A 
cAMP-dependent protein kinase type II-alpha regulatory 
subunit 
198 O60256 PRPSAP2 




2I1 PSMC6 26S protease regulatory subunit 10B 
14 O00231 PSMD11 26S proteasome non-ATPase regulatory subunit 11 
269 Q5VWC4 PSMD4 26S proteasome non-ATPase regulatory subunit 4 
1509 P49792 RANBP2 E3 SUMO-protein ligase RanBP2 
46 Q96TC7 RMDN3 Regulator of microtubule dynamics protein 3 
115 P46779 RPL28 60S ribosomal protein L28 
10 P62888 RPL30 60S ribosomal protein L30 
23 P62857 RPS28 40S ribosomal protein S28 
236 P62753 RPS6 40S ribosomal protein S6 
32 Q99584 S100A13 Protein S100-A13 
113 P06702 S100A9 Protein S100-A9 
221 M0QWZ7 SARS2 Serine--tRNA ligase, mitochondrial 
316 Q8WVM8 SCFD1 Sec1 family domain-containing protein 1 
681 
A0A0U1R
QQ9 SCYL2 SCY1-like protein 2 
151 E7ESK6 SDC2 Syndecan;Syndecan-2 
137 O75396 SEC22B Vesicle-trafficking protein SEC22b 
559 F5H365 SEC23A Protein transport protein Sec23A 
158 Q99442 SEC62 Translocation protein SEC62 
85 Q9UHD8 SEPT9 Septin-9 
203 Q8NC51 SERBP1 Plasminogen activator inhibitor 1 RNA-binding protein 
81 O43765 SGTA 
Small glutamine-rich tetratricopeptide repeat-containing 
protein alpha 
188 Q13596 SNX1 Sorting nexin-1 
185 O60749 SNX2 Sorting nexin-2 
72 O60493 SNX3 Sorting nexin-3 
13 C9JI79 SORBS2 Sorbin and SH3 domain-containing protein 2 
377 H7BXR3 SORBS2 Sorbin and SH3 domain-containing protein 2 
306 H7BXR3 SORBS2 Sorbin and SH3 domain-containing protein 2 
832 Q69YQ0 SPECC1L Cytospin-A 
2358 Q01082 SPTBN1 Spectrin beta chain, non-erythrocytic 1 
722 A9Z1X7 SRRM1 Serine/arginine repetitive matrix protein 1 
647 A9Z1X7 SRRM1 Serine/arginine repetitive matrix protein 1 
734 A9Z1X7 SRRM1 Serine/arginine repetitive matrix protein 1 
722 A9Z1X7 SRRM1 Serine/arginine repetitive matrix protein 1 
645 A9Z1X7 SRRM1 Serine/arginine repetitive matrix protein 1 
647 A9Z1X7 SRRM1 Serine/arginine repetitive matrix protein 1 
734 A9Z1X7 SRRM1 Serine/arginine repetitive matrix protein 1 
5 P84103 SRSF3 Serine/arginine-rich splicing factor 3 
105 C9JA28 SSR3 Translocon-associated protein subunit gamma 
138 O95210 STBD1 Starch-binding domain-containing protein 1 
10 P27105 STOM Erythrocyte band 7 integral membrane protein 
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281 P26639 TARS Threonine--tRNA ligase, cytoplasmic 
216 P21980 TGM2 Protein-glutamine gamma-glutamyltransferase 2 
928 Q9Y2W1 THRAP3 Thyroid hormone receptor-associated protein 3 
444 Q9Y2W1 THRAP3 Thyroid hormone receptor-associated protein 3 
605 G3V1L9 TJP1 Tight junction protein ZO-1 
163 G3V1L9 TJP1 Tight junction protein ZO-1 
245 
A0A3B3IT
E1 TJP2 Tight junction protein ZO-2 
175 
A0A3B3IT
E1 TJP2 Tight junction protein ZO-2 
203 O95049 TJP3 Tight junction protein ZO-3 
104 P29401 TKT Transketolase 
376 O60784 TOM1 Target of Myb protein 1 
93 Q15785 TOMM34 Mitochondrial import receptor subunit TOM34 
14 E9PN66 TP53I11 Tumor protein p53-inducible protein 11 
166 O43399 TPD52L2 Tumor protein D54 
79 P26368 U2AF2 Splicing factor U2AF 65 kDa subunit 
266 Q9Y385 UBE2J1 Ubiquitin-conjugating enzyme E2 J1 
28 P61081 UBE2M NEDD8-conjugating enzyme Ubc12 
303 P22695 UQCRC2 Cytochrome b-c1 complex subunit 2, mitochondrial 
783 P45974 USP5 Ubiquitin carboxyl-terminal hydrolase 5 
164 Q9P0L0 VAPA 
Vesicle-associated membrane protein-associated protein 
A 
239 P50552 VASP Vasodilator-stimulated phosphoprotein 
5 Q9BQA1 WDR77 Methylosome protein 50 
109 P46937 YAP1 Transcriptional coactivator YAP1 
515 Q6PJT7 ZC3H14 Zinc finger CCCH domain-containing protein 14 
A Few Proteins of Interest as Potential DNAJB1-PRKACA Targets Relevant to FLC 
I was intrigued by the suggestion of RNA regulation from Chapter III and saw the 
SRRM1 protein in Table 17 and 18. SRRM1 is a serine and arginine repetitive matrix 1 
protein that is part of the pre- and post-splicing mRNP complexes. In a collaboration 
with David Requena in our lab, a pilot test was conducted to see if the amount of 
alternative splicing events were the same in tumor and normal samples from the same 
patient using previously obtained RNA data from a patient. This analysis was done with 
SplAdder (Kahles et al. 2016). Nothing seemed significant from this pilot, though that 
does not mean SRRM1 or RNA splicing is not significant in FLC.  
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Table 19. SplAdder Analysis. 
Alternative_Splicing_Events 59N7 59T5 59T6 
Alt_3prime 1439 1481 952 
Alt_5prime 1041 1065 621 
Exon_skip 2599 2630 1650 
Intron_Retention 1885 3313 1653 
Multi_Exon_Skip 271 273 163 
Mutex_Exons 71 81 60 
Total number of reads 32710485 44563838 29536248 
PDHA1 also has a phosphosite identified only when DNAJB1-PRKACA or 
PRKACA-L206R is present; this particular phosphosite has previously been identified to 
inhibit the function of Pdha1 which can induce cell growth by enhancing glycolysis (Liu 
et al. 2018). This could be particularly interesting to follow up on since PRKACA-L206R 
was found in adrenal adenomas in Cushing’s syndrome and the DNAJB1-PRKACA 
results in cancerous tumors in FLC.   
Another protein of potential interest to FLC is HSD17B7 which was identified as 
being highly and significantly phosphorylated in the tumor more than the normal in the 
patient data. It was also only identified in the DNAJB1-PRKACA condition in the in vitro 
assay. This 3-keto-steroid reductase is involved in the biosynthesis of sex hormones. 
The role of estrogens in FLC is still unclear, but some male patients present with 
gynecomastia, or breast growth. This phosphorylated protein could be a contributing 
factor.  
Before getting any results, I was hopeful about seeing phosphorylation of heat 
shock proteins in the tumor and the in vitro assay because of the presence of the J-
domain on the fusion kinase.  I thought the J-domain of DNAJB1-PRKACA could be 
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attracting heat shock proteins, like Hsp70 or Hsp90 family members, which would then 
be phosphorylated. Indeed, Hsp90ab1 was one of the proteins detected with a 
phosphosite in common between the patient data and the in vitro data in the conditions 
with DNAJB1-PRKACA and PRKACA (L206R). The involvement of heat shock proteins, 
and also the implication of DNAJB1-PRKACA interaction with proteins involved with 
catabolism made earlier in Chapter III, prompted me to want to see how much 
phosphorylation would change when cells were starved in the presence and absence of 
DNAJB1-PRKACA.  
The experiment I designed required the use of two cell lines: Huh7 and Huh7 
cells with a plasmid that expresses DNAJB1-PRKACA from the DNAJB1 promoter. In 
collaboration with a technician in our lab, Harriet Prior, cells from each cell line were 
either grown as normal or starved for 16 hours. Cells were then harvested and lysed to 
run on a gel. Western blots were visualized using an antibody against the 
phosphorylated consensus sequence for PKA (100G7E, Cell Signaling Technology) or 
an antibody against PRKACA (sc-28315, Santa Cruz Biotechnology). I was expecting to 
see the change in phosphorylation seen in Figure 37A, but I was surprised to see that 
DNAJB1-PRKACA was not detected in the cell line expressing it under starved 
conditions. From a literature search, I found a paper that claimed when cells are 
deprived of amino acids, HSF1, a heat shock transcription factor, loses its DNA binding 
activity and, as a consequence, DNAJB1 transcript levels sharply decreased (Hensen et 
al. 2012). If this is what happened in these cell lines, then obtaining an HSF1 inhibitor or 
using siRNA to knock down HSF1 could be an effective strategy to knockdown 
DNAJB1-expression, at least experimentally, if not therapeutically.  
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Figure 37. Starved Huh-7 Cells Expressing DNAJB1-PRKACA.  
(A) Western blot with an anti-phospho-PKA Substrate antibody (100G7E, CST) and 
actin control. (B) Western blot with an anti-PKA antibody (sc-28315) and actin control. 
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Conclusions 
The results of the phosphopeptide enrichment from the three patient tumor and 
normal liver samples showed that the phosphopeptide signature of the tumor is 
distinctly different from the patient’s normal liver. 178 phosphosites were identified in the 
tumor and normal that were also matched to phosphosites that were increased in the 
presence of DNAJB1-PRKACA in vitro.  
Four of these phosphosites belonged to four different heat shock proteins: 
HSP90AB1, HSP1A1B, HSPA4, and HSPB1. As established in the introduction, heat 
shock proteins have been implicated to play a role in cancer and disease so these 
proteins may warrant a further look.  
Another three of these phosphosites were found in HSD17B7, PDHA1, and 
SRRM1. HSD17B7’s role in estrogen synthesis, PDHA1’s role in cell growth, and 
SRRM1’s role in RNA splicing make them all interesting potential targets to continue to 
study.  
One surprising protein that warrants follow up studies is the heat shock 
transcription factor, HSF1. This protein was not identified as phosphorylated by either 
screen, rather it was found as a potential protein of interest to FLC as a consequence of 
these phosphorylation studies. The implication of DNAJB1-PRKACA’s interaction with 
many metabolic proteins from the phosphorylation studies prompted me to just want to 
see what changes in phosphorylation could be seen in starvation or normal conditions in 
the presence or absence of this oncogenic kinase via a western blot with a PKA 
substrate motif antibody. Under starvation conditions, DNAJB1-PRKACA was no longer 
detected by western blot. A literature search provided a possible explanation that HSF1 
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cannot bind DNA in an amino acid depleted environment and thus the transcription of 
DNAJB1 sharply decreases. It is possible that something else was happening here, but 
this could be an alternative method to knockdown the oncogenic fusion kinase 
experimentally, or perhaps therapeutically.  
Discussion 
It can be enticing to only go after the phosphorylation targets that present as 
extremely high in the tumor, but perhaps a true and relevant direct target of DNAJB1-
PRKACA would only be phosphorylated at low levels due to a regulatory feedback loop, 
but the activity conferred by the low-level phosphorylation triggers a cascade of events 
necessary for tumorigenesis or growth. I think it is easy to imagine ways for any protein 
to be involved with cancer development or progression. So, in that regard, I think a fair 
argument could be made to follow up with any of the proteins that have phosphosites in 
common between the two sets of data.  
However, this would still be a fairly large endeavor. One way to focus the list 
even more though would be to only look at phosphosites that are significantly and highly 
detected in just the tumor samples. You can then compare that list to the phosphosites 
found in the DNAJB1-PRKACA condition of the in vitro assay; you could even make this 
a more stringent comparison by only considering a match with DNAJB1-PRKACA valid 
if DNAJB1-PRKACA is the only one detected of the four conditions in vitro or if 
DNAJB1-PRKACA’s intensity value is twice that of PRKACA’s when they are both 
detected in vitro.  
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Focusing on proteins that are part of a pathway that seems over-represented 
among the potential substrates would be another way to let this data guide you to a next 
step. For instance, probing further at specific catabolic processes that DNAJB1-
PRKACA could affect or delving deeper into RNA splicing mechanisms that may be 
important to FLC.  
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Chapter V:  Concluding Remarks 
The work presented in this thesis focused on addressing the open question of 
whether or not the oncogenic kinase DNAJB1-PRKACA has different substrates than 
PRKACA that are relevant in FLC. Establishing a known substrate-kinase interaction 
with pathological effects that is specific to DNAJB1-PRKACA would provide a different 
avenue for therapeutic development. There is no current way to inhibit the activity of 
DNAJB1-PRKACA without inhibiting the activity of the crucial native PRKACA. 
Understanding more about the structure of this oncogenic kinase and the biochemical 
functions of any slight structural differences would create avenues to exploit for 
therapeutic options.  
My studies show that when PRKACA, DNAJB1-PRKACA, and PRKACA (L206R) 
have the same pool of substrates for the same amount of time at the same temperature, 
these kinases exhibit reproducible preferences for certain substrates over others. It is 
still possible that inside the cell the crucial component to differential phosphorylation is 
differential subcellular localization of DNAJB1-PRKACA and PRKACA. However, after 
seeing these results, I would be surprised if the pathology was only due to a difference 
in localization. I think it is likely a synergistic effect of intrinsic specificity and subcellular 
localization. It is also possible that the J-domain on the kinase is acting as a scaffold 
and this scaffold is providing a platform for carcinogenesis.  Again, I am not ruling this 
out. However, I do feel confident that my data, which eliminates any localization 
variations, rules out the hypothesis that there are no differences in substrate specificity 
between PRKACA and DNAJB1-PRKACA intrinsic to their structure. 
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It is also possible that part of the reason this cancer is slow growing is that 
maybe the kinase isn’t initially expressed at a level to be harmful because the DNAJB1 
promoter is tightly regulated. It may remain this way until a physical stressor or even a 
normal change in development hyperactives the DNAJB1 promoter. This 
hyperactivation would then release this oncogenic kinase to wreak havoc on the cell. Or 
maybe this PRKACA variant is the cell stressor that overtime activates the heat shock 
response due to some action it has that causes protein aggregates to form, but by 
activating the heat shock response, the consequence is actually upregulation of this 
kinase. Maybe part of the oncogenic nature of this kinase is dose dependent in some 
way that is specific to DNAJB1-PRKACA since overexpression of PRKACA did not 
result in FLC like tumors in our collaboration with the Lowe lab. Maybe the upregulation 
of multiple heat shock proteins we see in the transcriptomic data of FLC tumors is a clue 
that heat shock factors in general are getting elevated and increasing the levels of 
DNAJB1-PRKACA as an unintended consequence.  
While there is plenty to still analyze and mine from the data I already have, I am 
keen to get back to some experiments. In the immediate future, I would like to repeat 
this triplicate in vitro FSBA-treated human hepatocyte assay with an additional kinase: a 
kinase-dead version of DNAJB1-PRKACA. This condition should yield the same results 
as the no kinase condition, but it would be surprising and interesting if it was 
significantly different.  I also would like to try this assay using what we are calling normal 
liver from an FLC patient that we receive with their tumor samples. It is possible that 
there is something different about the normal livers of FLC patients that is shown on a 
protein level that is not detected by genomic analysis. Total MS analysis of this liver 
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sample may bury the key protein difference, but if a key difference is a certain substrate 
population present in normal FLC patient livers not found in the livers of non-FLC 
patients, then lysing the FLC patient’s normal liver and subjecting it to this assay could 
reveal a new substrate population. Now that our lab has FLC cells robustly growing in a 
dish, it is also possible to consider doing this assay with the lysate of FLC cells.  
The substrate specificity of DNAJB1-PRAKCA and PRKACA seen in the 
sequence logos of my data has already informed computational biology projects in the 
lab that will continue to investigate the subtle changes in the active pocket that could 
confer substrate specificity.  
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Appendix I: Materials and Methods 
Mouse Liver Lysate  
Livers were harvested from mice and homogenized in Lysis Buffer (150mM NaCl, 0.5% 
Triton X-100, 10% glycerol, 50mM Tris HCl pH 8.0, 1x Protease inhibitor) until sample 
mixture was consistent. These mixtures were then sonicated five times with brief one 
second pulses on ice followed by incubation on ice for 15-30 minutes. Then the 
mixtures were centrifuged at max speed for 20-30 minutes and supernatants were 
collected in a manner to avoid the fatty layer; this step may need to be repeated to 
sufficiently remove the fatty layer. The protein amount was then measured by Bradford 
(ThermoFisher). The samples were flash frozen or immediately treated with FSBA.  
FSBA Treatment 
As published for HeLa cells (Embogama and Pflum 2017). 
Kinase Reactions with FSBA-Treated Lysates 
Thoroughly exchange buffer of at least 100ug of FSBA-treated lysate to wash out any 
residual FSBA using 3kDa Ultracel Concentrators (Amicon) using a buffer optimal for 
the kinase to be optimally active. Reactions carried out with 1mM ATP of choice and 
1ug of purified kinase for every 100ug of FSBA-treated lysate. Make sure to add 
PhosSTOP to desired concentration to maximize phosphorylation signal. Incubate at 
30°C for 30min-2hr. Quench with 20mM EDTA.  
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In Vitro Assay with Mouse Liver Lysate 
Digestion 
Proteins were precipitated by ice-cold acetone (HPLC-grade, Sigma) overnight at 
-20C. Pellets were dissolved in 8M urea (GE Healthcare), 50 mM ammonium 
bicarbonate (AMBIC. Fluka Chemicals), 10mM dithiothreitol (EMD Chemicals) in 
water, and disulfide bonds were reduced for 1 hour at room temperature with 
vigorous shaking. Iodoaceamide (Sigma) was added to 20mM and alkylation 
proceeded for 1 hour at room temperature in the dark. Samples were diluted with 
50 mM AMBIC and digested with lysyl endopeptidase (Wako) overnight at room 
temperature. The concentration of urea was adjusted to 1.5M using 50mM 
AMBIC, and the samples were further digested for six hours at room 
temperature, using sequencing grade modified trypsin (Promega). Digestion was 
stopped by acidification using either formic acid (FA, Fluka) or trifluoroacetic acid 
(TFA, Thermo), and peptides were purified using high-capacity 30 mg Oasis HLB 
cartridges (Waters), according to manufactorer specifications.  
Phosphopeptide Enrichment 
Peptides were subjected to a two-step phosphopeptide enrichment, first by in-
house constructed titanium dioxide microtips as described by Larsen et al in 
20051 with minor modifications followed by High-Select Fe-NTA Phosphopeptide 
Enrichment Kit (Thermo Scientific), according to manufacturer specifications. 
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LC-MS/MS 
Solvent A was 0.1% formic acid in water and solvent B was 0.1% formic acid, 80 
% acetonitrile (ACN) in water. All LC-MS solvents are of HPLC grade and 
purchased from Sigma. 
Enriched phosphopeptides were separated using a Dionex 3000 Ultimate HPLC 
equipped with a NCS3500RS nano- and microflow pump (Dionex). Peptides 
were loaded onto a 100 µm*20mm Acclaim PepMap C18 trap column (Thermo 
Scientific) at 3µL/min. Separation was achieved using a 75µm*120mm pulled-
emitter nanocolumn (Nikkyo Technos). Solvent B went from 1% to 5 % over 6 
minutes, increased to 40% over 80 minutes followed by a sharp 1-minute 
increase to 90% where it was kept for 22 minutes. Peptides were analyzed using 
a Q-Exactive HF mass spectrometer (Thermo Scientific). Data was recorded in 
positive mode with Top 20 DDA acquisition. MS1 resolution was set to 60 000 
and an MS2 resolution of 30 000. AGC targets of 3e6 (MS1) and 2e5 (MS2) were 
applied.  
Database searching 
RAW files were searched using MASCOT (Mass Matrix) through Proteome 
Discoverer v. 1.4 (Thermo Scientific) with the Percolator function enabled. The 
False Discovery Rate (FDR) was set to 1%. Data was queried against the Mus 
musculus proteome, concatenated with common contaminants. Oxidation of M, 
acetylation of protein N-terminus and phosphorylation of S and T were allowed 
as dynamic modifications. Carbamidomethylation of C was set as static 
modification. A maximum of 3 missed cleavages was allowed. 
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Thiophosphopeptides from Gel Bands 
In-gel digestion 
Bands were excised from the gel using a scalpel, cut into small pieces (roughly 
2*2mm) and destained using a solution of 40% ACN, 100mM AMBIC in water. In-
gel digestion was performed as described by Shevchenko et. al5 using the same 
chemical suppliers as described in the section In Vitro Assay with Mouse Liver 
Lysate. 
LC-MS/MS 
The same solvents were used as described in the section In Vitro Assay with 
Mouse Liver Lysate. 
Peptides were separated using a Dionex 3000 Ultimate HPLC equipped with a 
NCS3500RS nano- and microflow pump. Peptides were loaded onto a 100 
µm*20mm Acclaim PepMap C18 trap column  at 3µL/min. Separation was 
achieved using a 75µm*120mm pulled-emitter nanocolumn. Solvent B went from 
1% to 5 % over 1 minute, increased to 38% over 20 minutes followed by a sharp 
1-minute increase to 90% where it was kept for 15 minutes. Peptides were 
analyzed using a Q-Exactive HF mass spectrometer. Data was recorded in 
positive mode with Top 15 DDA acquisition. MS1 resolution was set to 60 000 




RAW files were searched using MASCOT through Proteome Discoverer v. 1.4 
with the Percolator function enabled. The False Discovery Rate (FDR) was set to 
1%. Data was queried against the Mus musculus proteome, concatenated with 
common contaminants. Oxidation of M, acetylation of protein N-terminus, 
phosphorylation of S and T and thiophospho esterification of S and T were 
allowed as dynamic modifications. Carbamidomethylation of C was set as static 
modification. A maximum of 3 missed cleavages was allowed. 
Human Hepatocyte Lysate  
Hepatocytes were isolated from chimeric livers as described (de Jong et al. 2014; 
Vercauteren et al. 2016). Briefly, mice were anesthetized with ketamine/xylazine and a 
24G angiocath was inserted into the inferior vena cava. Then the portal vein was cut, 
and the mouse liver was perfused sequentially with PBS-/- supplemented with heparin, 
Hanks buffered saline solution (HBSS) supplemented with 5mM EDTA and 50mM 
HEPES, and finally HBSS supplemented with 0.05% Type IV collagenase (Sigma 
Aldrich) and 1U/ml DNAse (Thermo Fisher, Waltham, MA). After perfusion, the liver was 
disrupted over a 70mm cell strainer, washed in PBS-/- and live hepatocytes enriched by 
Percoll density centrifugation. Hepatocytes were resuspended in 54% Percoll (GE 
Healthcare, Chicago, IL) and centrifuged at 100g for 5 minutes. After washing with PBS, 
cells were pelleted and kept at -20oC until ready for lysis. Lysis requires the use of 1mL 
The mixtures were incubated with Lysis Buffer (150 mM NaCl, 0.5% Triton X-100, 10% 
glycerol, 50mM Tris HCl pH 8.0, 1x protease inhibitor) on ice for 15 minutes (1 mL Lysis 
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Buffer for every 20x10^6 cells) After incubation, the samples were centrifuged for 10 
min at 4°C at 13.5 rpm and supernatant was collected. The protein amount was 
measured by Bradford (ThermoFisher), and the samples were flash frozen or 
immediately treated with FSBA. 
In Vitro Assay with Human Hepatocyte Lysate 
Digestion 
Samples were digested and purified as described in the section In Vitro Assay 
with Mouse Liver Lysate. 
Phosphopeptide Enrichment 
Phosphopeptides were enriched as described in the section In Vitro Assay with 
Mouse Liver Lysate. 
LC-MS/MS 
Solvent A was 0.1% formic acid in water and solvent B was 0.1% formic acid, 80 
% acetonitrile (ACN) in water. All LC-MS solvents are of HPLC grade and 
purchased from Sigma. 
Enriched phosphopeptides were separated using a Dionex 3000 Ultimate HPLC 
equipped with a NCS3500RS nano- and microflow pump. Peptides were loaded 
onto a 100 µm*20mm Acclaim PepMap C18 trap column at 3µL/min. Separation 
was achieved using a 75µm*120mm pulled-emitter nanocolumn. Solvent B went 
from 1% to 4 % over 1 minute, increased to 38% over 60 minutes followed by a 
sharp 1-minute increase to 90% where it was kept for 15 minutes. Peptides were 
analyzed using a Q-Exactive HF mass spectrometer. Data was recorded in 
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positive mode with Top 20 DDA acquisition. MS1 resolution was set to 60 000 
and an MS2 resolution of 30 000. AGC targets of 3e6 (MS1) and 2e5 (MS2) were 
applied.  
Database Searching 
Acquired RAW files were analyzed in the MaxQuant3 framework (v. 1.6.0.13). 
Spectra were queried against the human proteome and searched with a 1% false 
discovery rate on both PSM and protein level. Carbamidomethylation of C was 
applied as a static modification and oxidation (M), acetylation (Protein N-
terminus) and phosphorylation (S, T or Y) were applied as variable modifications. 
A maximum of 5 modifications was allowed on each peptide. Matching between 
runs was enabled.  
Data analysis 
Statistical analysis of the phosphosites was performed within the Perseus4 
framework (v. 1.6.1.3).  
Intensities were log2 transformed and normalized by subtraction of the median in 
each experiment. Observed values in at least 2/3 replicates in at least one 
condition was required. Missing values were imputed by low-abundant random 
signals. Significant differences in phosphosite abundances were determined by 
Student’s t-tests (p=0.05) and a permutation FDR truncated ANOVA test 
(FDR=0.01). Heatmaps were generated by performing hierarchical clustering with 
Euclidian distances of z-scored ANOVA-significant phosphosites. 
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FLC Patient Tumor and Normal Liver Tissue Processing 
Liver samples were placed on dry ice immediately after resection and stored at -80 C. 
For tissue lysis, small pieces (2-5 mm in diameter) were cut from the specimen and 
placed in ice cold lysis buffer (5mM EGTA, 1mM EDTA, 1% Triton X-100, 150 mM 
NaCl, 50mM Tris pH 7.5) supplemented with cOmplete EDTA-free protease inhibitor 
(Roche), and PhosSTOP phosphatase inhibitor (Roche) tablets. Samples were 
sonicated on ice for 20-30 seconds and spun at 1,100 x RCF for 10 minutes. The 
supernatant was transferred to another tube and spun at 30,000 x RCF for 30 minutes. 
To avoid the lipid layer, the Eppendorf tube was punctured near the bottom (above the 
pellet) and the supernatant flowed into another tube until the lipid layer reached the 
level of the hole. Spins were performed at 4 C. The lysate was assayed for protein 
concentration using the BCA assay (Pierce).  
Total Phosphoproteomics of FLC Patient Tumor versus Normal Liver Tissue 
Digestion 
Based on optical concentration measurements, 390 µg protein was withdrawn 
from all samples which were precipitated by acetone. Proteins were digested and 
peptides were purified as described in the section In Vitro Assay with Mouse 
Liver Lysate. 
Phosphopeptide Enrichment 
Peptides were again subjected to a two-step phosphopeptide enrichment, first by 
titanium dioxide batch enrichment as described by Thingholm and Larsen in 
20162 The flow through was enriched by High-Select Fe-NTA Phosphopeptide 
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Enrichment Kit, according to manufacturer specifications and the two fractions 
were combined. 
LC-MS/MS Analysis 
Solvent A was 0.1% formic acid in water and solvent B was 0.1% formic acid, 80 
% acetonitrile (ACN)  in water. All LC-MS solvents are of LC/MS purity and 
purchased from Fisher Chemical. 
Enriched phosphopeptides were separated using an Easy 1200 nLC (Thermo 
Scientific). Separation was achieved directly using a 75µm*120mm pulled-emitter 
nanocolumn without trap column loading. Solvent B went from 0% to 30% over 
70 minutes and to 60 % over 10 minutes followed by a sharp 5-minute increase 
to 90% where it was kept for 15 minutes. Peptides were analyzed using a 
Orbitrap Fusion Lumos mass spectrometer (Thermo Scientific). Data was 
recorded in positive mode with Top 20 DDA acquisition and quadrupole isolation 
and HCD fragmentation (30% CE). MS1 resolution was set to 60 000 and an 
MS2 resolution of 30 000. AGC targets of 1e6 (MS1) and 8e4 (MS2) were 
applied.  
Database searching 
Acquired RAW files were analyzed as described in the section In Vitro Assay with 
Human Hepatocyte Lysate 
Data Analysis 
All phosphosite intensities were averaged among technical replicates. It was 
required that a site must be observed in at least 50% of technical replicates 
within each biological replicate, or the average would be replaced by “NaN”. 
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Statistical analysis of the average intensity values for the 3 patients was 
performed within the Perseus framework. Intensities were log2 transformed and 
normalized by subtraction of the median in each experiment. Observed values in 
at least 2/3 replicates in at least one condition was required. Missing values were 
imputed by low-abundant random signals. Significant differences in phosphosite 
abundances were determined by Student’s t-tests (p=0.05). 
Splicing with SplAdder 
RNA was extracted from OCT embedded frozen tissue using the miRNeasy Mini Kit 
(Qiagen). Two samples from the primay tumor and 1 sample from the adjacent normal 
liver tissue. Paired-end RNA sequencing libraries (2x150 bp) were generated using the 
TruSeq Stranded Total RNA Sample Prep Kit, including ribosomal RNA depletion using 
Ribo-Zero (Illumina). These libraries were sequenced in an Illumina MiSeq system.  
Quality control of the resulting sequencing files was performed using FastQC and 
MultiQC  (Ewels et al. 2016), followed by adapter trimming using BBDuk (included in 
BBMap v37.47). The trimmed reads were mapped to the annotated Human Genome 
GRCh38.92 using STAR v2.6.1 (Dobin et al. 2013). Alternative splicing events were 
quantified on the alignment files using splAdder (Raetsch & Kahles, version March-
2019), including exon skip, intron retention, alternative 3'/5' splice site, multiple exon 
skip and mutually exclusive exons. 
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Huh7 Starvation Experiment 
Huh7 and Huh7-chimera cell lines were grown in Dulbecco’s Modified Eagle’s medium 
(DMEM, Gibco) supplemented with 1X non-essential amino acids (NEAA, Gibco) and 
10% fetal bovine serum (FBS, Sigma). ~16 hours prior to harvesting, one dish for each 
cell line was then starved in media containing only DMEM and 1X NEAA. Cells were 
then harvested by trypsinization, and samples were subjected to total protein 
concentration normalization using a DC Assay (Bio-Rad). Samples were then lysed in a 
solution containing RIPA (Alfa Aesar) with cOmplete protease inhibitors (Sigma) and 
phosSTOP (Sigma), run on a NuPAGE 4-12% Bis-Tris protein gel, transferred to a 
membrane, blocked in 5% milk in TBS-T, and incubated with the relevant primary 
antibodies. Each blot was incubated with either PKAa cat Antibody (sc-28315, Santa 
Cruz Biotechnology) or phospho-PKA substrate (100G7E, Cell Signaling Technology) at 
a 1:1000 dilution. Secondary antibodies were then added at a 1:50,000 dilution, 
developed with Amersham ECL Prime (GE Life Sciences), and imaged using a LI-COR 
chemiluminescent gel imager. All blots were then stripped and incubated with an 
antibody against actin at a dilution of 1:5000 as a control to ensure equal loading. Blots 
were then developed and visualized using the same Amersham ECL developing 
solution and LI-COR system.  
Antibodies and Proteins and Constructs 
pET151DNAJB1-PRAKCA-GST with thrombin cut site gift from Sergio Botero 
pET151PRAKCA-GST with thrombin cut site gift from Sergio Botero 
pET151DNAJB1-PRKACA tagless gift from Sergio Botero 
pET151PRKACA tagless gift from Sergio Botero 
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PKAa cat antibody (sc-28315, Santa Cruz Biotechnology) 
GST antibody (GE 27457701)  
Thrombin (GE 27084601) 
AcTEV (ThermoFisher 12575015) 
Thiophosphate ester antibody for WB (ab92570, abcam) 
Thiophosphate ester antibody for IP (ab133473, abcam) 
Kinase Purifications and Assays 
GST-tagged protein purification using Glutathione Sepharose 4B beads (GE), per 
manufacturer’s protocol.  
Kinase-Glo (Promega) per the manufacturer’s protocol 
Tycho for protein quality per the manufacturer’s protocol 
ADP-Glo (Promega): 
Customized Assay Buffer not included in kit: (40 mM Tris (pH 7.5); 20 mM MgCl2; 
0.1% Tween 20; 2mM TCEP).  Compounds are dispensed in 384-well plate with 
10 μL/well Assay Buffer with ATP (final concentration of 10, 50, or 100 μM) The 
following reagents are added: 3 μL/well kemptide (final concentration of 50 or 
250 μM depending on ATP concentration) and 2 μL/well DNAJB1-PRKACA (final 
concentration of 1 nM). The plates were sealed, centrifuged, and incubated at 
room temperature for 10 min when the kinase reactions had 10 μM ATP and for 
15 minutes when the reactions had 50 μM or higher ATP.  After incubation, 5 μL 
of ADP-Glo reagent were added to each well. These plates were centrifuged, 
sealed, shaken, and incubated for 60 min at room temperature. Then 10 μL of 
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kinase detection reagent were added to each well. Then the plates were again 
centrifuged, sealed, shaken, and incubated for 60 min at room temperature. The 
plates were then read, and luminescence was measured.  
Kinase reactions with ATP-γ-S and subsequent alkylation and immunoprecipitation were 
conducted per the manufacturer’s protocol (abcam). 
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Appendix II:  Rights and Permissions 
Figure 6. Reprinted by permission from Elsevier: Cell. Hanahan D, Weinberg RA. 
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